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The growing emergence of resistance to anti-infective drugs has 
become a global problem, threatening to derail infection control efforts. 
Malaria drug resistance is no exception as reports of artemisinin resistance 
becomes ever more prevalent. As new classes of drugs are poised to enter the 
global antimalarial pipeline, understanding the mechanisms of resistance 
(MoR) becomes paramount for disease control in the broader context of proper 
drug combinations, phenotypic and/or genotypic diagnostics, and targeted 
treatment in the clinic. An early understanding of MoR is equally crucial in 
drug discovery, where new antimalarials are often identified from phenotypic 
screening. This thesis reports the establishment of a platform for the in vitro 
selection of Plasmodium falciparum drug-resistant mutants. This in vitro 
approach has demonstrated some unique advantages over existing 
conventional methods; such as (a) accelerated rate of resistance selection to 
minimize genetic drift, (b) simultaneous selection of multiple mutants, (c) 
discovery of novel target(s) or genes associated with resistance and (d) 
identification of resistance-associated fitness costs.  
As an example of this approach, a forward chemical genetics was used 
to select for in vitro spontaneous mutants resistant to KAF179, an 
imidazolopiperazine class of saturated cyclic amines with activity in both 
liver- and blood-stage parasites. Previously, resistance to this class of 
compounds had only been correlated with mutations in the P. falciparum 
cyclic amine resistance locus (PfCARL), an uncharacterized protein with 
seven predicted transmembrane domains. Using this in vitro approach, two 
previously unreported mechanisms of resistance to imidazolopiperazines were 
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identified. In this study, it was found that only three out of twelve clones 
encoded mutations in PfCARL while another eight out of twelve SNPs (single 
nucleotide polymorphisms) were found in two alternative genes, namely P. 
falciparum UDP-galactose transporter (PfUGT) and acetyl-CoA transporter 
(PfACT). All three are proteins that are likely localized within the 
endoplasmic reticulum. The novel discovery of PfUGT and PfACT as putative 
targets or resistance genes provided additional information in deciphering the 
mechanism of resistance of imidazolopiperazines. Analysis of growth kinetics 
revealed that mutation in either of these genes resulted in elevated levels of 
resistance (as high as 600 fold), extensive morphological changes and a 
noticeable loss of fitness. In contrast, PfCARL mutants derived from 
conventional in vitro evolution methods displayed minimal fitness loss during 
cell culture.  
Cross-resistance screening with KAF179-resistant mutants has 
suggested the likelihood of a new global mechanism of resistance involved.  
The mechanism of resistance of imidazolopiperazines is likely associated with 
the parasite secretory pathway. In addition, the elucidation of the 
intraerythrocytic stage of action of the imidazolopiperazines, would aid in the 
selection of a combinatorial partner drug for KAF156, a Phase IIb clinical 
drug candidate in the future.  
The tools developed and presented for genotypic and phenotypic 
characterization of the mutants in this thesis can be applied to assess the risk 
of resistance for preclinical antimalarial compounds in development. Finally, 
molecular information obtained from this project will aid in monitoring of 
clinical drug resistance of KAF156 in the future. 
 x 
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1.1 Malaria  
Malaria is one of the most widespread infectious diseases with 
devastating global impact. There are approximately 3.2 billion people, 
equivalent to half of the world’s population, at risk of contracting malaria (1). 
The latest estimates by World Health Organization (WHO) revealed 198 
million malaria cases in 2013, of which approximately 90% occur in sub-
Saharan Africa (1). Malaria remains inextricably linked with poverty. 
Mortality rates are highest in countries with lower gross national income 
(GNI) per capita (1). There was an estimated 584 000 malaria deaths in 2013, 
with a vast majority (78%) being children under 5 years of age (1). It is 
estimated that one child dies of malaria every minute. The disease is caused by 
the protozoan parasite of genus Plasmodium, and is transmitted by an 
Anopheles mosquito vector (2). The five Plasmodium species that affect 
humans are Plasmodium falciparum, Plasmodium vivax, Plasmodium ovale, 
Plasmodium malariae, and Plasmodium knowlesi. (1, 3). Of the five species, 
P. falciparum and P. vivax are the most important. P. falciparum is the most 
virulent and deadly species, accounting for more than 90% of all deaths (1). 
Unlike P. falciparum that has a dominant presence in Africa, P. vivax has a 
wider distribution worldwide, attributed to its ability to develop in harsh 
conditions such as lower temperatures and higher altitudes in the Anopheles 
mosquito vector. The lesser presence of P. vivax in Africa is also due to the 
prevalence of the Duffy negative trait among most African populations (1). Of 
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the five species, only P. vivax and P. ovale are able to develop dormant liver 
stage form, known as the hypnozoite, that causes the relapsing form of malaria 
(2, 4). This dormant form allows the parasite to survive winter months when 
female Anopheles mosquitoes are not present for malaria transmission. Of the 
400 Anopheles species worldwide, only 30 of them are vectors of importance 
(1). 
The greatest part of the global malaria burden has always been in Asia 
and Africa. The WHO has committed the past 66 years to fighting malaria 
with the aim of eradicating this century old health menace. In the nascent 
years of WHO, regional malaria elimination campaigns were carried out in 
Asia, Western Pacific region and Africa before the eventual instatement of the 
Global Malaria Eradication Campaigns in 1955 (5). The simultaneous 
deployment of antimalarial drug, chloroquine and employment of residual 
insecticide DDT to spray homes were crucial for the success in reducing 
incidences of malaria in parts of Asia, especially in India and Sri Lanka (5). 
However, the malaria problems of Africa were on a different level altogether 
as the campaign efforts had minimal success in the continent except in the 
southern and marginal zones of transmission (5).  Many were concerned about 
the effectiveness of DDT as tool in a high intensity transmission region such 
as Africa. Despite the poor distribution and access to treatment, Africa did 
benefit from the use of chloroquine as malaria-related mortality declined from 
the 1950s to early 1980s (5). In the early 1970s, the emergence of drug 
resistance to chloroquine and insecticide DDT, coupled with political 
instability and inadequate health systems, hindered the WHO Global Malaria 
Eradication Campaign. This resulted in the resurgence of malaria transmission 
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across Asia and Western Pacific and into Africa (6, 7). The turning point in 
the war against chloroquine-resistant P. falciparum was the development of 
the synthetic derivatives of artemisinin, also known as Qinghaosu, a Chinese 
herbal medicine in the 1990s (7). The use of the artemisinin derivatives 
contributed significantly to the reversal of the renewed rise in mortality rates 
in the Southeast Asia region (7). Up to date, artemisinin-based combination 
therapies (ACTs) remain the first-line treatment for uncomplicated malaria.  
In a bid to tackle the malaria problem with a coordinated global 
response, the WHO, United Nations Children’s Fund (UNICEF), United 
Nations Development Programme (UNDP) and the World Bank launched the 
Roll Back Malaria (RBM) Partnership in 1998 (8). The partnerships forged 
between international organizations, governments, academic institutions, 
private companies and non-governmental organizations in both endemic and 
non-endemic countries have helped to drive and scale up malaria-control 
efforts at both global and national levels. Their effective coordination have 
prevented duplication and fragmentation, thereby ensuring optimal use of 
resources (8). Some of their efforts were focused on developing new tools for 
malaria research by engaging experts in the field and advocating new drug 
candidates to encourage international financial investment for these projects 
(7, 8). Building on a decade of good work by the RBM Partnership, world 
leaders and the global malaria community gathered at the United Nations 
Millennium Development Goals (MDG) Malaria Summit in 2008 to endorse 
RBM’s ambitious Global Malaria Action Plan (GMAP) (8, 9). The GMAP 
was developed in collaboration with more than 250 malaria experts and 
included a detailed blueprint with short- and medium-term goals to be met at a 
 5 
specific timeline with the eventual goal of malaria eradication in the long 
term. The short term goal of the GMAP is to achieve universal coverage of 
malaria prevention and treatment tools by 2010 (8, 9). The medium term goals 
of the GMAP are to 1) reduce global malaria cases from 2000 levels by 50% 
in 2010 and by 75% in 2015, 2) to reduce global malaria deaths from 2000 
levels by 50% in 2010 and to near zero preventable deaths in 2015 and 3) 
eliminate malaria in 8-10 countries by 2015 (8, 9). Of the 106 countries with 
ongoing malaria transmission in 2000, only 66 countries have reported data 
which are consistent and reliable to assess their trends between 2000 to 2013 
(1). Of these, 55 countries are on track to meet the GMAP targets of reducing 
malaria incidence rates by 75% by 2015 (1). The latest estimates by WHO, 
after taking population growth into account, revealed a 30% reduction in 
global malaria incidence rates between 2000 – 2013 and 34% reduction in the 
WHO Africa Region (1). Consequently, malaria mortality rates have also 
decreased by 47% worldwide and by 54% in the WHO Africa Region since 
year 2000 (1).  
These successes brought about by the concerted effort of the malaria 
community over the past decade may be short-lived as the artemisinin 
derivatives encounter the same drug resistance conundrum faced by all anti-
infectives from time immemorial, undermining efforts for malaria elimination 
and eradication. Drug efficacy studies have detected resistance of P. 
falciparum to artemisinin in 5 countries in the Greater Mekong region, 
namely, Cambodia, Thailand, Vietnam, Laos and Myanmar (1). ACTs remain 
largely clinically efficacious, provided that the partner drug remains 
efficacious (1). The key activities of the Worldwide Antimalarial Resistance 
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Network (WWARN) serve as an extension of WHO’s Global Plan for 
Artemisinin Resistance Containment (GPARC), launched in 2011, to monitor, 
identify and provide quality-assured evidence of drug resistance as well as 
develop research tools, which will aid in understanding malaria drug 
resistance (10).  
The path to malaria eradication is fraught with challenges; the absence 
of an effective vaccine coupled with increasing resistance to insecticides and 
antimalarial drugs. To this end, discovery and development of new chemical 
entities to combat the rising drug resistance to artemisinin could be the best 
bet to safeguard a cure against malaria.  
In this thesis, we will discuss in detail the peril of drug resistance, the 
resistance profile of KAF179, a compound of the imidazolopiperazine scaffold 
with a different mode of action from the current arsenal of antimalarial drugs, 
identification and validation of genes associated with KAF179 resistance and 









1.2 Characteristics of malaria  
1.2.1 Lifecycle of the malaria parasite  
The century old discovery of the malaria parasite and the vector-borne 
nature of the disease by Ronald Ross and Alfonso Laveran advanced the 
understanding of the malaria disease biology (11). The lifecycle of the malaria 
parasite involves development in both mosquito and vertebrate hosts (Fig. 1). 
In humans, the cycle begins with the release of infectious Plasmodium 
sporozoites from the bite of an infected female Anopheles mosquito into the 
mammalian bloodstream. The sporozoites invade the mammalian liver cells or 
hepatocytes, where they either remain dormant or develop over the next few 
days, forming schizonts which comprises 10,000 – 40,000 liver merozoites 
(12). Dormancy is only present in P. vivax, P. ovale and P. cynomolgi, the 
simian equivalent of P. vivax in humans. The infected liver cells rupture and 
release the merozoites into the bloodstream and they invade red blood cells to 
begin the asexual erythrocytic stage cycle. This asexual blood stage is a 48-
hour cycle comprising three main asexual stages - ring, trophozoite and 
schizont. Similar to the liver stage, the schizonts lyse the infected red blood 
cell and release blood-form merozoites, which reinvade a fresh red blood cell, 
and the cycle repeats (12). At each round of schizogony, approximately 1% of 
merozoites differentiates into male and female gametocytes (13). These 
developmentally arrested gametocytes taken up during a mosquito blood meal 
undergoes maturation and fusion to form a zygote in the mosquito midgut. The 
zygote differentiates into an ookinete, containing thousands of sporozoites 
which reside in the salivary glands of the mosquito until the next bite that 
initiates the lifecycle again.  
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1.2.2 Pre-patent and incubation period  
In P. falciparum infection naïve patients, the median pre-patent period 
(time from sporozoite inoculation to detectable parasitemia) is 10 days (range 
5 – 10 days) (14). The incubation period from the time of sporozoite 
inoculation to the development of symptoms is 11 days (range 6 – 14 days) 
(14).  However, the incubation period may be extended in P. falciparum naïve 
patients with acquired immunity through either previous exposures or 
antimalarial prophylaxis; these patients may exhibit symptoms of malaria 
infection within a month of departing the malaria-endemic region (14). The 
incubation period is also longer (median 15-16 days) for P. vivax and P. ovale 
infections, these 2 species may result in relapse months or years after exposure 
due to their ability to form the dormant hypnozoite in the liver (14).  
 
1.2.3 Clinical symptoms of malaria  
Patients infected with malaria typically exhibit a cyclical display of 
clinical symptoms that coincide with the schizont rupture and destruction of 
erythrocytes. The majority of patients experience fever, chills, headaches, 
increased perspiration and non-specific symptoms which include dizziness, 
muscle weakness, vomiting and mild diarrhoea (14).  P. falciparum is the 
main culprit responsible for almost all severe malaria cases and deaths 
although there were recent reports which mentioned P. vivax as an accomplice 
(1, 14, 15). It is estimated that severe malaria account for 5% of all P. 
falciparum cases. Young children (< 5 years old), pregnant women, the 
immunosuppressed and elderly are at higher risk of developing severe malaria 
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(1). The major complications of severe malaria include cerebral malaria, 
pulmonary edema, acute renal failure, severe anemia, bleeding, acidosis and 
hypoglycemia. Many patients experience a combination of complications that 
could evolve rapidly in a short time, eventually leading to coma and death (1). 
Although severe malaria caused by P. vivax cover a similar spectrum of 
complications as P. falciparum, there are notable differences in the clinical 
manifestations of the severe disease. Coma, metabolic acidosis and mortality 
due to severe anemia and acute lung injury are less frequent in P. vivax cases 
compared to P. falciparum cases (15).     
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1.3 Advances in vector control for malaria 
Malaria transmission is seasonal and the peak occurs during or just 
after a rainy season. Malaria outbreaks could take place in an area where 
individuals have little or no immunity when the temperature and humidity 
conditions are favourable for malaria transmission (1). Current vector control 
methods such as indoor residual spray (IRS) and distribution of long-lasting 
insecticide treated nets (LLINs) have substantially reduced the risk of malaria 
infection in high transmission areas (1).  However, extensive usage of a single 
class of insecticides, the pyrethroids, in IRS and in particular, LLINs has 
resulted in the development of insecticide resistance in the Anopheles 
mosquito vector. To circumvent this issue, many countries have switched to 
other non-pyrethroid insecticides such as carbamates, organochlorine or 
organophosphates (1). Despite the gains in malaria control over the past 
decade, current vector control methods such as IRS and LLINs are inadequate 
in managing outdoor malaria transmission. Recent studies have proposed the 
use of ivermectin, an endectocide, as a potential tool in reducing outdoor 
malaria transmission (16, 17). It was found that vectors that ingest a blood 
meal from a person who has recently been treated with ivermectin have a 
higher rate of mortality with possible reductions in sporogony and delayed 
feeding frequency (17-19). Ivermectin has been used in human mass drug 
administration (MDA) campaigns over 25 years for controlling onchocerciasis 
and lymphatic filariasis (16). The good safety profile and the distinct 
mechanism of action from current insecticides make ivermectin an attractive 
additive drug with ACTs in areas where residual transmission potential is a 
major concern. ACTs are highly efficacious in clearing asexual blood stage 
 12 
parasites but it does not prevent malaria transmission. The use of ivermectin in 
combination with ACTs can reduce onward transmission of malaria as it 
prevents development and sporogony of ingested gametocytes in the mosquito 
vector (16, 17). A recent randomized controlled trial (RCT) has shown that 
ivermectin can be safely given in combination with artemether-lumefantrine 
and will reduce the likelihood of malaria transmission as ivermectin shortens 
the lifespan of the mosquito vectors (20). However, given the paramount 
importance of ivermectin in the control of chocerciasis, lymphatic filariasis 
and helminthes, early research should be done to study the possibility of 
resistance mechanisms in Anopheles and intensive research should be carried 
out before ivermectin is rolled out as a complementary strategy in malaria 











1.4 Challenges in antimalarial vaccine development 
Vaccines have achieved remarkable success in disease prevention and 
eradication in many infectious diseases such as polio, measles, diphtheria, 
tetanus, rabies and smallpox (21). In spite of the successes in antimalarial 
chemotherapy and vector control strategies, the development of an 
antimalarial vaccine has been lackluster. The protection against malaria 
through acquired immunity from repeated mosquito bites was demonstrated 
more than 30 years ago (22), yet there is still no licensed antimalarial vaccine 
today. The plethora of antigens expressed during the 10 morphological 
changes throughout the two-host lifecycle of the Plasmodium parasite posed a 
major challenge in the identification of a promising antigen for vaccine 
development, not withholding antigenic polymorphisms and variations across 
parasite strains and species (22, 23). The antigenic variations during 
morphological transitions allow the parasite to escape the protective immune 
responses of the host. The elusiveness of the key stage-specific antigens 
responsible for protection against malaria has spurred on research and 
development of stage-specific vaccines. The three main types of vaccine in 
development are (i) transmission-blocking vaccines (TBVs), (ii) pre-
erythrocytic vaccines and (iii) blood-stage vaccines.  
 
1.4.1 Transmission-blocking vaccines 
Transmission-blocking vaccines (TBVs) target antigens on gametes, 
zygotes and ookinetes to inhibit the development of the parasite in the 
mosquito midgut. The leading TBV candidates include the P. falciparum 
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ookinete surface antigens Pfs25 and Pfs28 and their corresponding P. vivax 
homologues Pvs25 and Pvs28 (22). While TBVs do not protect individuals 
from contracting malaria, they are potentially effective for malaria elimination 
and eradication programmes when deployed into a community.   
 
1.4.2 Pre-erythrocytic vaccines  
Pre-erythrocytic vaccines target antigens that are expressed in liver-stage 
malaria and to date, the vaccine candidates in this group has shown the most 
promise for an approved vaccine (22, 23). The most clinically advanced 
candidate, currently in Phase III trials, is GlaxoSmithKline’s RTS, S vaccine 
(Mosquirix™) (24, 25). The ‘R’ stands for the central repeat region of 
Plasmodium falciparum circumsporozoite protein (CSP); the ‘T’ for the T-cell 
epitopes of the CSP; and the ‘S’ for hepatitis B surface antigen (HBsAg). 
These are combined in a single fusion protein (‘RTS’) and co-expressed in 
yeast cells with free HBsAg (24, 25). The ‘RTS’ fusion protein and free ‘S’ 
protein spontaneously assemble in ‘RTS, S’ particles. The vaccine has been 
shown to confer a ~50% protection against malaria in children aged 5-17 
months (24, 25). Although the mechanism by which the vaccine confers 
protection in blood-stage malaria is unclear, it is postulated that RTS, S 
vaccine reduces the emergence of merozoites from the liver, thereby resulting 
in individuals acquiring immunity from the subclinical exposure of asexual 
parasites (26). However, a recent study may have proven this hypothesis 
otherwise; showing that RTS, S vaccine confers protection by blocking 
sporozoite invasion of hepatocytes (27). The recent success achieved by 
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Sanaria’s PfSPZ in a clinical trial using experimental sporozoite inoculation 
under chloroquine prophylaxis has also rekindled interest in a whole-organism 
vaccine (28). Irradiated sporozoites are currently being used in the clinical 
trials but there are ongoing efforts to genetically attenuate the sporozoites by 
disrupting genes involved in liver-stage infection. This could circumvent the 
irradiation step during the manufacturing process but other challenges such as 
the delivery of a viable cryopreserved whole-parasite vaccine remain (22).  
 
1.4.3 Blood-stage vaccines  
Blood-stage vaccines are designed to inhibit parasitic invasion of the 
erythrocytes that in turn, prevents clinical manifestation of malaria symptoms. 
The antigens that are highly expressed on merozoites are currently being 
investigated for their efficacy in the patients include: apical membrane antigen 
1 (AMA1), erythrocyte-binding antigen-175 (EBA-175), glutamate-rich 
protein (GLURP), merozoite surface protein (MSP) 1, MSP2 and MSP3, 
serine repeat antigen 5 (SERA5), P. falciparum reticulocyte-binding protein 
homologue 5 (PfRH5) and rhoptry-associated leucine zipper-like protein 1 
(RALP1) (22). While antigens such as PfRH5 and RALP1 have shown 
potential to be blood-stage vaccine candidates (29-31), there are also reports 
of inefficacy of AMA1 and MSP1 in African children (32, 33). The failure of 
the antigens was probably due to a summation of host and parasite factors. 
The genetic polymorphisms present in the parasite and the immune responses 
of the host are major issues, which need to be resolved for the development of 
this class of vaccines. 
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1.5 Antimalarial agents and their drug targets  
In the absence of an effective vaccine, which holds promise for radical 
malarial control, antimalarial agents and insecticides remain the cornerstones 
for disease control, prevention and treatment (1). With the emergence of drug 
resistant parasites, almost all antimalarials are administered as part of a 
combination therapy, with each drug targeting distinct mechanism and target 
within the parasite (Table 1) (34-37). 
 
Table 1 Common antimalarial agents and their drug targets 
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Food vacuole Free-radical 
generation 
Unknown  
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1.6 Drug resistance in malaria 
Resistance is a common phenomenon to all anti-infective agents. It 
poses a constant challenge for drug development and this conundrum is not 
unique to malaria, as seen in other endemic diseases such as tuberculosis (TB) 
and human immunodeficiency virus (HIV). Antimalarial drug resistance is a 
major public health problem that hinders the control and eradication of 
malaria. Drug resistance has resulted in the successive demise of first line 
treatments such as chloroquine, sulfadoxine-pyrimethamine (Fansidar®), 
proguanil, mefloquine, which were unable to produce a 90% clinical response 
in areas which they have been deployed intensively (38, 39). With the 
exception of quinine, chloroquine and artemisinin, the rest of the antimalarials 
developed clinical resistance within 5 years of their introduction (Table 2) 
(40).  
At present, artemisinin and its derivatives (e.g. artemether, artesunate, 
and dihydroartemisinin), are central to ACTs. ACTs combine a semi-synthetic 
derivative of artemisinin, a natural product isolated from Chinese wormwood 
(Artemisia annua) with a drug of a distinct chemical class with a different 
mode of action (41). ACTs are the current recommended first line treatment 
for both complicated and uncomplicated P. falciparum malaria (39). The five 
ACTs recommended for use by WHO are artemether plus lumefantrine, 
artesunate plus amodiaquine, artesunate plus mefloquine, artesunate plus 
sulfadoxine-pyrimethamine, and dihydroartemisinin plus piperaquine (1). In 
spite of the desirable pharmacological properties such as rapid onset of action, 
short half-life, broad spectrum activity against stages of the malaria life cycle 
and excellent safety profile possessed by the artemisinin derivatives (42), the 
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demise of artemisinins seems imminent with recent reports of delayed parasite 
clearance time (43-49) with the drug and the discovery of a Kelch-13 
molecular marker (50-52).  
 










Quinine 1632 1910 278 (53) 
Chloroquine 1945 1957 12 (54) 
Proguanil 1948 1949 1 (53, 55) 
Sulfadoxine-
pyrimethemine 
1967 1967 0 (53, 55) 
Mefloquine 1977 1982 5 (56) 
Atovaquone 1996 1996 0 (57) 
Artemisinin 1971 2006 27 (43, 58)  
Adapted with modifications from (40) 
 
1.6.1 Drug resistance assessment tools  
The rapid spread of antimalarial drug resistance prompted the need for 
regular monitoring of antimalarial susceptibility. The three main tools used to 
assess antimalarial susceptibility include: (i) therapeutic efficacy test (in vivo 
test), (ii) in vitro sensitivity assay and (iii) molecular markers. P. falciparum 
susceptibility to antimalarial drugs is commonly assessed by therapeutic 
response of the patients to the drug using the therapeutic efficacy test (59). 
This in vivo test is the gold standard for monitoring antimalarial drug efficacy 
and for guiding drug policies. In brief, symptomatic patients infected with P. 
falciparum were given a standard dose of an antimalarial drug and 
subsequently followed up for clinical signs and symptoms and parasitemia 
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over 28 days (59). The outcomes of the therapeutic efficacy test are classified 
into the following four categories: early treatment failure, late clinical failure, 
late parasitological failure and adequate clinical and parasitological response 
(60). The therapeutic response is classified as an early treatment failure or late 
clinical failure if the patient develops clinical or parasitological symptoms 
during the first 3 days of follow-up for the former and during the follow-up 
period (from day 4 to day 28) for the latter. A late parasitological failure is 
defined as the appearance of parasitemia without any clinical symptoms 
between days 7 to 28 of the follow-up period. The absence of clinical and 
parasitological symptoms on day 28 is believed to be an adequate therapeutic 
response. The in vitro sensitivity assay serves as an adjunct to the therapeutic 
efficacy test to monitor antimalarial drug susceptibility. The virtue of the in 
vitro test lies in the ability to assay multiple antimalarials using one clinical 
isolate. However, there is neither a standardized in vitro protocol nor validated 
resistance threshold (59). The WWARN has developed the In Vitro Analysis 
and Reporting Tool (IVART) platform with the aim of standardizing and 
automating data processing and analysis to deliver reproducible IC50 
estimations (61). The IVART platform is able to analyze growth inhibition 
results from different assays such as the enzyme-linked immunosorbent assays 
(ELISA) histidine-rich II protein (HRP2) (62) or lactate dehydrogenase (63), 
SYBR®Green (64, 65), hypoxanthine isotope uptake inhibition (66), 
polymerase chain reaction (PCR) (67), flow cytometry (68, 69) and WHO 
micro-test (mark III) (70). It is notable that in vitro results may not necessarily 
correlate with in vivo results due to presence of host immunity or need for 
metabolism of pro-drugs. With the elucidation of P. falciparum genome in 
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early 2000s (71) and the advent of whole genomic sequencing techniques, 
molecular markers are increasingly being used to assess antimalarial 
susceptibility. The key mutations responsible for resistance to common 
antimalarials will be discussed in detail in the subsequent sections.  
 
1.6.2 Resistance associated factors  
Antimalarial drug resistance is defined as therapeutic failure or 
recrudescence of the original infecting strain(s) within 28 days of adequate 
treatment, when expected blood drug level has been reached (39). 
Recrudescence refers to the reappearance of parasites or symptoms, in the case 
of parasitological or clinical recrudescence, in the days following drug 
treatment (35). It is due to incomplete clearance of the infection. Multidrug 
resistance of P. falciparum is defined as resistance to more than two 
antimalarial compounds of different chemical classes (72).  
There are a myriad of factors associated with antimalarial drug 
resistance; ranging from drug properties, human host immunity, parasite 
















Table 3 Factors associated with antimalarial drug resistance   
Factor Variables  
Drug Clinical parasite reduction ratio 
Drug half-life 
Drug dosage  
Drug pressure 
Drug combination  
Cross-resistance 
Mode-of-action (MOA) / molecular targets  
Human Host immunity 
Growth rate of resistant parasite (fitness cost) 
Parasite Nature of mutation required for resistance  
• Single nucleotide polymorphism (SNP) 
• Copy number variation (CNV) 
Number of mutations required for resistance (causal and 
compensating) 
Target mutation frequency 
Fitness cost  
Vector and 
environment  
Parasite transmission intensity 
Insecticide resistance  
 
1.6.3 Mechanisms of resistance to common antimalarials 
In the past two decades, many researchers around the world have 
invested a great amount of time and effort in elucidating the molecular 
mechanisms underlying resistance for various common antimalarials. The 
cumulative research has identified the key mutations responsible for drug 
resistance that in turn, allowed us to use these as molecular markers to assess 
drug susceptibility. In this section, we will discuss the mechanisms of 
resistance of common antimalarials such as chloroquine, sulfadoxine-




1.6.3.1 Chloroquine resistance  
Introduced in 1945, chloroquine is a 4-aminoquinoline that has been 
used extensively for the treatment of malaria (54). It has a long elimination 
half-life of one to two months (75). P. falciparum parasites obtain their 
exogenous supply of amino acids through ingestion of hemoglobin from their 
host erythrocytes. The parasite detoxifies the by-product of hemoglobin, heme 
in its food vacuole through polymerization to form a non-toxic hemazoin (76, 
77). Chloroquine enters the food vacuole as a weak base and becomes 
diprotonated in the acidic environment (pH 5.7) within the food vacuole (78). 
This diprotonated chloroquine prevents detoxification of heme when it binds 
to heme molecules in the food vacuole (78). It is widely accepted that the 
concentration of chloroquine within the food vacuole is of paramount 
importance for its activity (79, 80). Chloroquine resistance was found to be 
associated with lower concentrations of chloroquine within the food vacuole 
(80). An analysis of a genetic cross between a chloroquine-sensitive (CQS) 
and a chloroquine-resistant (CQR) clone mapped resistance to P. falciparum 
chloroquine resistance transporter (PfCRT) (81, 82). Localized to the 
membrane of the food vacuole, PfCRT is predicted to have 10 transmembrane 
domains (83, 84). Fidock et al has identified ten point mutations in PfCRT 
from CQS and CQR isolates from Asia, Africa, Papua New Guinea and South 
America (82). The lysine to threonine substitution on codon position 76 of 
PfCRT (K76T) was present in all the CQR isolates from various regions (82). 
The removal of the ubiquitous K76T mutation in CQR isolates in in vitro 
studies rendered them fully sensitive to chloroquine (85). Consistent in vitro 
and in vivo findings support the strong association of PfCRT mutation at 
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K76T with chloroquine resistance and treatment failure, leading to its 
widespread use as a predictive molecular marker for chloroquine resistance 
(40, 60, 86). Many different models have been proposed for the mechanism of 
chloroquine resistance. The 3 models that were widely accepted were 
discussed in detail in a review (78). These models attempted to reconcile the 
decrease in chloroquine concentration with one of the following mechanisms: 
(i) active efflux of chloroquine out of the food vacuole, (ii) leakage of charged 
chloroquine out of the food vacuole and (iii) pH-dependent reductions in 
chloroquine accumulation (78). Both mechanisms (i) and (ii) showed the 
involvement of PfCRT in chloroquine movement but with a key difference; 
the protein actively effluxes the drug while in the latter, the diprotonated 
chloroquine passively leaks out of the food vacuole through mutant PfCRT 
(77, 87). 
An orthologous gene of the mammalian P-glycoproteins that mediate 
multidrug resistance in cancer cells (80), P. falciparum multidrug resistance-1 
(PfMDR1) transporter, has also been implicated in chloroquine resistance (40, 
78, 88). The PfMDR1 is also localized to the membrane of the food vacuole 
and could play a role in the transportation of chloroquine in and out of the cell; 
however the exact mechanism is unclear (83). Five SNPs have been identified 
among isolates from Asia, South America, Papua New Guinea and Africa 
(89). Amongst the five, a tyrosine for asparagine substitution at codon position 
86 (N86Y) of PfMDR1 showed a partial association (70%) to chloroquine 
resistance (82, 90). Evidence has also shown that mutations in PfCRT alone 
are sufficient to cause clinical chloroquine resistance and the mutations in 
PfMDR1 play a secondary role in modulating chloroquine resistance (82, 86). 
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In summary, parasites that are highly resistant to chloroquine often harbour 



















1.6.3.2  Sulfadoxine-pyrimethamine resistance  
Sulfadoxine and pyrimethamine were introduced as an antifolate 
combination therapy in 1967. Both drugs have relatively long half-lives: 
approximately 200 hours for sulfadoxine and 100 hours for pyrimethamine 
(91). Sulfadoxine and pyrimethamine act synergistically to inhibit two 
important enzymes in the folate pathway, resulting in folate depletion that in 
turn, inhibit DNA synthesis and some amino acid synthesis (92). 
Pyrimethamine competes with dihydrofolate for binding with P. falciparum 
dihydrofolate reductase (PfDHFR). Sulfadoxine, being structurally similar to 
p-aminobenzoic acid (PABA), competitively inhibits P. falciparum 
dihydropteroate synthase (PfDHPS). It was unfortunate that resistance to this 
effective and affordable drug combination was reported soon after it was 
introduced (40). The molecular basis of resistance to sulfadoxine-
pyrimethamine is the best characterized of all antimalarial resistance (40). It 
has been shown that both PfDHFR and PfDHPS acquired mutations 
sequentially, almost invariably beginning with an initial mutation at a 
particular codon (84). The extent of resistance to either sulfadoxine or 
pyrimethamine is correlated with the number of point mutations with each 
mutation conferring a stepwise reduction in susceptibility (60). The specific 
point mutations in these two genes will be discussed in detail in the following 
paragraphs.  
Five single nucleotide polymorphisms in the PfDHFR gene that are 
associated with pyrimethamine resistance include: C50R, N51I, C59R, 
S108N/T and I164L (93-96). The initial mutation for pyrimethamine 
resistance is a serine to asparagine substation at position 108 of the PfDHFR 
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gene. This amino acid change has been confirmed in all pyrimethamine-
resistant isolates (92). This crucial S108N/T confers only a ten-fold reduction 
in drug susceptibility and should not pose as a major concern clinically (60). 
However, subsequent acquisition of mutations at position 50, 51 or 59 resulted 
in triple mutants with a high level of resistance (93-96). Lastly, the final 
acquisition of the devastating mutation at position 164 to form a quadruple 
mutant rendered pyrimethamine completely ineffective (97). Point mutations 
in 5 codons in PfDHPS that confer resistance to sulfadoxine have been 
identified to include: S436A/F, A437G, K540E, A581G and A613S/T (98-
100). The first step to sulfadoxine resistance is the alanine to glycine 
substitution at codon 437 of the PfDHPS gene (101, 102). Similar to PfDHFR, 
resultant triple mutants from subsequent acquisition of mutations at position 
436, 540 and 581 demonstrated the highest levels of sulfadoxine resistance 
(101, 102). Some studies have suggested that mutations in PfDHPS alone is 
insufficient to confer resistance in presence of folate and mutant selection on 
PfDHPS only takes place in parasites with a background of multiple mutations 
in PfDHFR (103-105).  
Clinical evidence has shown that parasites with 3 mutations in 
PfDHFR and 2 mutations in PfDHPS were strongly associated with 
sulfadoxine-pyrimethamine treatment failure (106). The elevated production 
of gametocytes after treatment with sulfadoxine-pyrimethamine could be 




1.6.3.3 Mefloquine resistance  
Mefloquine is a 4-methanolquinoline with a long half-life of 14-18 
days and was first introduced in 1977 (56, 108). It is structurally related to 
quinine and halofantrine (60). Mefloquine is used for both malaria prophylaxis 
as well as treatment. Mefloquine resistance is a major problem in Southeast 
Asia; with a failure rate of >60% in Thailand and >40% in Cambodia, 
Vietnam and Myanmar (59). Clinical resistance to mefloquine emerged within 
a short span of 5 years and monotherapy is no longer effective since 1980s 
(59). There are two possible explanations for this rapid emergence of 
resistance; the presence of strains with reduced susceptibility to quinine and 
the long half-life of mefloquine (40, 59). Mefloquine resistance has been 
associated with an amplification of PfMDR1 (109, 110). Increased copy 
numbers of PfMDR1 were highly predictive of recrudescence in patients 
treated with mefloquine monotherapy or ART combination therapy of 
artesunate with mefloquine (111). Stepwise induction of mefloquine resistance 
in vitro by Preechapornkul et al has shown amplification in PfMDR1 gene, 
thereby correlating PfMDR1 copy number with in vitro susceptibility to 
mefloquine (111). The increase in copy number of PfMDR1 was also 
associated with an increase in IC50 values for structurally similar drugs, 
halofantrine and quinine (109). Preechapornkul et al has investigated the in 
vitro frequency of PfMDR1 amplification (one to two copies) to be 10-8 and 
coupled with the estimation that 108 to 1012 parasites are circulating in a 
symptomatic malaria patient, PfMDR1 gene amplification is likely to occur in 
most clinical cases (111). Their statistical model also estimated the in vitro 
frequency of PfMDR1 amplification from two to three copies to be 10-3. While 
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the high rate of amplification frequency may seem inaccurate, it is biologically 
plausible because the initial rate-limiting duplication step may create regions 
of homology in the genome that facilitates further amplification (112). 
Although the mutation frequency (10-14) in PfMDR1 gene is low, an 
asparagine to tyrosine substitution at position 86 (N86Y) was observed in the 
Gambia and Thailand isolates (40). Isolates that harbour this mutation were 
found to be more sensitive to mefloquine, which suggests a possible inverse 
relation between sensitivity to mefloquine and to chloroquine (113). Despite 
the high amplification frequency of PfMDR1 gene, not all hope is lost for 
mefloquine treatment, as parasites with multiple copies of the gene possess a 
high fitness cost (114). In the absence of mefloquine as a selection pressure, 
parasites with a single copy of PfMDR1 will outcompete those with multiple 
copies of the gene (111). The deamplification of PfMDR1 gene over time has 











1.6.3.4 Atovaquone resistance  
Atovaquone is a hydroxynaphthoquinone that is currently used for both 
malaria prophylaxis and treatment in a fixed-dose combination drug 
(Malarone®) with the antifolate, proguanil. It was first introduced in 1996 and 
it has half-life of 66-70 hours (60). Due to the high cost and propensity to 
develop resistance, malarone is used mainly as a prophylactic medication for 
tourists (116). Atovaquone mimics ubiquinone, the natural substrate of 
malarial mitochondria cytochrome bc1 complex (117). Atovaquone binds to 
cytochrome bc1 complex and hinders the translocation of protons across the 
inner mitochondrial membrane, resulting in a collapse of the mitochondrial 
membrane potential and inhibition of the electron transport chain (118). It was 
also shown that atovaquone indirectly inhibits the regeneration of oxidized 
dihydroorotate dehydrogenase (DHOHD), a critical enzyme required for the 
catalysis of dihydroorotate to orotate during early steps of the pyrimidine 
biosynthesis pathway (119). The exact mechanism for the synergy with 
proguanil remains unclear, but it was observed that proguanil alone does not 
have any effect on either electron transport or mitochondrion membrane 
potential. It was deduced that proguanil acts to lower the concentration of 
atovaquone required to abolish mitochondrial membrane potential, which is 
critical for various metabolic processes (120). Studies have shown that clinical 
and in vitro point mutations in P. falciparum cytochrome b gene (PfCYTB) 
are in discordance. Clinical isolates have revealed that a serine, cysteine or 
asparagine substitution for tyrosine located on codon 268 of PfCYTB (Y268S, 
Y268C or Y268N) confer clinical resistance with increase in IC50 values over 
a 1000-fold (57, 121-123). However, point mutations on codon 268 of 
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PfCYTB were never found when resistance was selected in vitro. In vitro 
stepwise induction of resistance with low concentrations of atovaquone 
yielded an initial point mutation of isoleucine for methionine substitution at 
codon 133 of PfCYTB and subsequent mutations at positions 272, 275 and 
280 (121, 124). In vitro single-step selection with continuous atovaquone 
pressure resulted in fewer mutants with mutations only at position 283 and 
284 (121). Rathod et al has found the in vitro frequency of mutation of 
parasites to 100 nM of atovaquone to be 10-5 (125). The high propensity of 
atovaquone to develop resistance could be due to its slow rate of absorption 
and high lipophilicity that exposes the parasite to relatively low levels of the 













1.6.3.5 Artemisinin resistance  
Artemisinin, a sesquiterpene lactone with an endoperoxide, was first 
discovered by Chinese scientists in 1971 and introduced to the world in 1979 
(58). The leading Chinese scientist, Professor Tu Youyou at the China 
Academy of Traditional Chinese Medicine in Beijing, was recently awarded 
the prestigious Nobel Prize in Physiology or Medicine 2015 for her discovery 
of artemisinin (qinghaosu) (126).  
The rapid onset of action, broad-spectrum anti-parasitic activity and 
novel mechanism of action of artemisinin resulted in the widespread 
monotherapeutic use of the drug to combat chloroquine resistance in the 1980s 
(42, 127). However, high rates of recrudescence were soon observed due to 
patient non-compliance with the 7-day artemisinin monotherapy and the 
inadequate parasite clearance owing to the short half-life (~ 1 hr) of its most 
potent metabolite, dihydroartemisinin (128). In the 1990s, artemisinin was no 
longer recommended as a monotherapy and ACTs were introduced (84). 
Artemisinin derivatives are combined with partner drugs (lumefantrine, 
amodiaquine, mefloquine, piperaquine and sulfadoxine-pyrimethamine) with 
long half-lives in order to ensure complete clearance of the parasites (1, 128).   
  In the climate of rampant antimalarial drug resistance (chloroquine, 
mefloquine, sulfadoxine-pyrimethamine, atovaquone), artemisinin derivatives 
remained the most effective class of antimalarials. In spite of the continuous 
efforts to decipher the mechanism of action of artemisinin, the targets and 
pathways remained elusive. Although 4 different models have been proposed 
to explain the mode of action of artemisinin, none has been unequivocally 
proven. The 4 different models proposed include: (i) interference with the 
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heme detoxification pathway; (ii) induction of alkylation of the translationally 
controlled tumour protein; (iii) inhibition of the sarco/endoplasmic reticulum 
membrane calcium ATPase 6 (PfATPase6); or (iv) interference with 
mitochondrial function (129). The details of each proposed model for the 
mode of action of artemisinin can be found in some excellent reviews (129-
134).  
Artemisinin resistance has been spreading rapidly since it was first 
detected seven years ago in western Cambodia (43, 44). The proximity of the 
countries in the Greater Mekong region has facilitated the spread of 
artemisinin resistance. The prevalence of artemisinin resistance was observed 
in other Cambodian provinces (48, 52), Thailand-Myanmar border areas (47, 
50), and Southern Vietnam (49, 50). Drug resistance continues to undermine 
the global efforts in malaria elimination and eradication. The artemisinin 
resistance phenomenon in the Greater Mekong region seemed to parallel what 
was observed with chloroquine in the past. If artemisinin resistance progresses 
at the same rate as its predecessor, the world may cease to have an effective 
treatment for malaria.  
The search for a molecular marker for artemisinin resistance is in the 
nascent stage but the recent discovery of an association between 
polymorphisms in the kelch propeller domain K13 and artemisinin resistance 
have demonstrated promising use of K13-propeller mutations as a potential 
molecular marker for resistance (51, 52, 135). Prior to the discovery of this 
potential molecular marker, clinical artemisinin resistance was defined by a 
reduction in parasite clearance rate, expressed as an increase in parasite 
clearance half-life or the presence of microscopically detectable parasites on 
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the third day of ACT (136, 137). A patient with a parasite clearance half-life 
of > 5 hours is deemed to be resistant to artemisnin treatment (50). “K13-
propeller” polymorphisms are predictive of artemisnin resistance in Southeast 
Asia and the extensive work put into the discovery of this molecular marker is 
remarkable (52). Ariey et al devised an alternative strategy to guide the 
analysis of polymorphisms in clinical isolates from areas where artemisinin 
resistance is prevalent. Their alternative strategy was the in vitro selection of 
artemisinin-resistant parasite clones by exposing an artemisinin-sensitive 
African clone to stepwise, incremental doses of artemisinin over 125 cycles. 
The strong correlation between the in vivo parasite clearance half-life and in 
vitro ring-stage survival assay (RSA0-3h), which measures the survival rate of 
young rings after exposure to 700 nM of dihydroartemisinin (138) led the 
team to focus their efforts on mutations with a significant association with 
RSA0-3h survival rates. Interestingly, 4 non-synonymous SNPs (Y493H, 
R539T, I543T and C580Y) within a kelch repeat of the C-terminal K13-
propeller domain were found to have significantly higher RSA0-3h survival 
rates than wild-type parasites (52). It was also found that the cysteine to 
tyrosine substitution at codon 580 (C580Y) mutant allele was the most 
frequently observed mutation (approx. 85%) and incidentally, clinical isolates 
that carried this mutation also possessed the longest parasite clearance half-life 
(52). The in vitro selection did not observe any mutation with genes or targets 
that were putatively associated with artemisnin resistance (PfCRT, PfCTP, 
PfMDR1, PfMRP1, PfATPase6 and PfUBP1) (52).  
The discovery of the promising “K13-propeller” molecular marker also 
sparked the interest in deciphering the mechanism underlying artemisinin 
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resistance. Recent evidence seems to indicate that artemisinin resistance could 
affect the early ring stage of the intraerythrocytic cycle (138, 139). 
Transcriptomics analyses of artemisinin-resistant clinical isolates by Mok et al 
revealed a delayed development from ring to trophozoite stage in the first 32 
hours of the parasite’s intraerythrocytic cycle and an upregulation of proteins 
involved in the unfolded protein response (UPR). Mok et al postulated the 
involvement of two chaperonin complexes, the Plasmodium reactive oxidative 
stress complex (PROSC) and TCP-1 ring complex (TRiC) as part of the UPR 
in the repair of proteins damaged by alkylation and oxidation by Fe2+-
activated artemisinin (51). The decelerated progression of ring-stage 
development struck a chord with P. falciparum dormancy, in which ring-stage 
parasites adopt a quiescence state that enable them to withstand drug pressure 
(140, 141).  
Mbengue et al has elucidated the molecular mechanism of artemisinin 
resistance in the most recent study published in Nature (142). The study 
presented biochemical and cellular evidence that P. falciparum 
phosphatidylinositol-3-kinase (PfPI3K) and its lipid product 
phosphatidylinositol-3-phosphate (PI3P) are key mediators of artemisinin 
resistance. Mbengue et al postulated the possible interaction between PfPI3K 
and PfKelch13, of which the mammalian orthologue of the latter functions as 
a substrate adaptor for an E3 ubiquitin ligase. They hypothesized that the 
mutations located in the putative substrate-binding domain of PfKelch13 may 
decrease affinity for PfPI3K, thereby increasing its steady state levels by 
reducing ubiquitination and proteosomal degradation. Briefly, the group first 
demonstrated by biochemical analyses that the active form of artemisinin, 
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dihydroartemisinin in low nanomolar concentrations, is a selective inhibitor of 
PfPI3k and blocks production of PI3P. They also showed the linear correlation 
between the levels of PI3P and resistance in both clinical and genetically 
engineered laboratory strains. Evidence suggested that elevated PI3P levels 
confer artemisinin resistance. Transgenic mutant lines with C580Y mutation 
inserted into PfKelch13 (PfKelch13C580Y) showed elevated levels of PfPI3K 
relative to their WT counterparts. Substrate-protein binding between 
immunopurified PfPI3K and PfKelch13WT was also reduced by the C580Y 
mutation, resulting in lesser ubiquitination and elevated levels of PI3K and 
PI3P, thereby conferring resistance to artemisinin. Mbengue et al has 
identified the ring-stage PfPI3K as a potential target for development of 
therapies to combat artemisinin resistance. However, downstream effectors 
and pathways of PfPI3K remain to be investigated. In addition, it is important 
to note that pools of available substrates (PI, ATP) and extent of ubiquitination 
of PfPI3K may be influenced by complex lipid, biosynthetic, transport and 
signaling networks that are varied across genetic backgrounds.  
In summary, the identification of the “K13-propeller” artemisinin 
resistance molecular marker would aid in the surveillance of emergence and 
spread of artemisinin resistance. Future studies should be done to explore the 
relationship between decelerated progression of ring-stage development and 
unfolded protein response as well as downstream effectors and pathways 




1.6.4 In vitro drug resistance and clinical therapeutic failure  
Resistance mechanisms are complex and varied across Plasmodium 
species and there is a poor correlation between in vitro drug susceptibility, 
molecular markers of resistance and therapeutic failure, except for 
antimalarials acting on well-defined molecular targets (73). Antimalarial drugs 
such as atovaquone and antifolates with a well-defined enzymatic target show 
good correlations between mutations at the drug’s active site, increased 50% 
inhibitory concentration (IC50) measured in vitro and frequency of therapeutic 
failure (143-148). Though in the case of atovaquone, the above holds true for 
only cytochrome b as dihydroorotate dehydrogenase (DHODH), a critical 
enzyme in electron transport was also proposed as a target of atovaquone 
(149). Recent discovery of the “K13-propeller” artemisinin resistance marker 
also demonstrated a strong correlation between the in vivo parasite clearance 
half-life and in vitro ring-stage survival assay (RSA0-3h) (52). However, drugs 
with more complex modes of action, i.e. involving more than one drug target 
exhibit more complex resistance mechanisms (150-152). In these cases, the 
connection between parasite drug susceptibility and in vitro measurements is 








1.7 The search for novel antimalarials  
In plight of the current situation where artemisinins are the only fully 
effective class of antimalarials left, many malarial-control strategies have been 
put in place to delay the development of resistance towards this class of drugs 
(1). Experience with drugs for treatment of tuberculosis (TB) and human 
immunodeficiency virus (HIV) pointed to the importance of using 
combination therapy in delaying the onset of resistance. Using a combination 
therapy, the parasite would have to mutate in several sites simultaneously to 
become resistant, an event that is less likely than a single mutation conferring 
resistance as in the case of monotherapy. The current 5 ACTs are 
combinations of fast, short-acting artemisinin derivatives with longer-acting 
partner drugs that act to eliminate residual parasite load to ensure complete 
clearance of parasites. With the exception of lumefantrine, all the partner 
drugs have been used prior as monotherapy (amodiaquine, mefloquine, 
sulfadoxine - pyrimethamine, piperaquine). Although lumefantrine was never 
used as a monotherapy, it was reported that the combination of artemether-
lumefantrine could select for in vivo PfMDR1 86N coding alleles that resulted 
in reduced sensitivity to the combination or essentially lumefantrine (153, 
154). In any ACT, the partner drug is known to have a longer half-life and in 
the case of lumefantrine, the short half-life of artemether may eventually result 
in lumefantrine acting as a monotherapy to eliminate the residual parasites not 
cleared by artemether, thereby exposing it to resistance selection. It was 
mentioned in the earlier section that the PfMDR1 N86Y mutation conferred 
chloroquine resistance but resulted in increased sensitivity to 
arylaminoalcohols such as mefloquine, halofantrine and lumefantrine (113). 
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This suggests that the PfMDR1 86N mutation might be a reversion selection 
by lumefantrine, which is consistent with in vitro data showing a significant 
increase in IC50 values of lumefantrine on laboratory clones that harbour this 
SNP (113). Therefore, the efficacy of combinations involving old drugs may 
be short-lived as resistance conferring mutations already exist (40). Hence, 
current ACTs offer a logical, albeit temporary solution (155).  
Our efforts in the development of novel antimalarials have not kept 
pace with the parasite’s ability to develop resistance. It is to our dismay that 
recent alarming reports observed the emergence of artemisinin resistance near 
the Thai-Cambodian border – the hotbed of multidrug resistance (1, 43-48, 50, 
52). Resistance to chloroquine, quinine, sulfadoxine – pyrimethamine and 
mefloquine were also first reported near this border (53-56). Therefore, there 
is a need to intensify efforts to discover new classes of antimalarial drugs to 
combat this war against malaria. With the ambitious aim of malaria 
eradication in mind, the ideal compound should be able to inhibit all stages of 
the parasite life cycle, including transmission and liver stages and be potent 
enough to be given as a single, curative dose – described as a single exposure, 
radical cure and prophylaxis (SERCaP) treatment (156, 157). New target 






1.7.1 The discovery of promising antimalarial compounds  
In order to speed up the drug discovery and development of new 
antimalarial compounds, the Medicines for Malaria Venture (MMV) was 
established in 1999. MMV is the first public-private product development 
partnership with the mission to discover, develop, and facilitate delivery of 
new, effective and affordable antimalarial drugs (74). A comprehensive list of 
the majority of antimalarials under development globally can be found on the 
MMV website, which is updated every quarter (Fig. 2).  
The different approaches (whole cell-based and target-based) and 
strategies (chemical modification of existing compounds) adopted for 
antimalarial compound screening and development were described in detail in 
these recent reviews (158-161). Whole-cell based screening has always been 
the approach to identify compounds with antimicrobial activity (162). The 
microorganism is incubated with the test compound (over a range of 
concentrations) for a period of time, which is dependent on the assay, and the 
activity of the test compound on the microorganisms is determined thereafter. 
Cellular screening has been largely successful in identifying not just 
compounds with antiparasitic activity but also compounds with novel 
mechanisms of action, an advantage but also a caveat with this approach (159, 
160). In contrast, target-based screening typically starts with the identification 
and validation of the target and proceeds with the production of the 
recombinant protein to screen compounds that inhibit its function. The targets 
are often vital for the survival of the parasite, for example, DHFR or 
cytochrome bc1 complex. Chemical modification of existing antimalarial drugs 
with the aim of improving the pharmacological properties such as half-life or 
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bioavailability is a reliable and relatively safer strategy in drug development. 
Although cross-resistance might remain a concern, the chemically modified 
molecule should possess similar pharmacokinetic and safety profiles to the 
original drug.  
Recent papers have described the identification and chemical 
structures of vast numbers of blood-stage compounds through whole-cell 
screening of extensive libraries (163, 164). The authors have identified at least 
100 promising compounds with novel chemical structures and at least 80% of 
them act on parasite targets distinct from those affected by the current drugs. 
Compounds that are active on the blood stages of the parasites should also be 
evaluated for activity in the sexual blood stage responsible for transmission to 
the mosquito vectors and the asymptomatic liver stage (165). These diverse 
novel chemical structures will hopefully be optimized and developed into 
potential antimalarial candidates with mechanisms of action unique from 












Figure 2 MMV Candidate Portfolio, 3rd quarter 2015 (www.mmv.org) 
Dotted lined boxes: Non-MMV compounds  
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1.7.2 Newly improved antimalarial drug candidates in clinical 
development 
The increase in malaria funding over the past decade and imminent 
failure of artemisinins and a possible resurgence of a malaria epidemic has 
propelled the research for new chemical entities in the malaria pipeline. 
Despite the good lineup of new chemical entities, most of the compounds are 
chemically modified from existing antimalarial drugs (chloroquine, 
primaquine and artemisinin) (160). Of the 16 antimalarial candidates in 
clinical development (Phase I, II and III) (Fig. 2), only 4 compounds 
(KAE609, KAF156, DSM265 and SAR97276) are novel chemical entities that 
truly have a shot at defeating the potential artemisinin-resistant malaria (Fig. 
3). In the following paragraphs, we will discuss in detail the compounds that 
possess novel chemical structures and those that are likely to bring us a step 
closer to the SERCaP therapy. 
The antimalarial drug candidates in Phase II clinical development 
showed good safety and pharmacokinetic profiles during Phase I. Compounds 
such as ferroquine (Sanofi-Aventis) and AQ-13 (Immtech) are chemically 
modified from chloroquine. Ferroquine is one of the few compounds in 
development with a long half-life of 16 days (31 days for its active metabolite, 
desmethylferroquine) (166). The long half-life of ferroquine makes it a 
potential candidate as a partner drug in combination therapy. New-generation 
endoperoxides such as OZ439 (Sanofi-Aventis) and artemisone (HKUST) 
could be answers to global demand for artemisinins, in light of the recent 
evidence of artemisinin resistance (50, 52). In spite OZ439 having a longer 
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half-life of 30 hours compared to its artemisnin counterparts, this relatively 
shorter half-life necessitates a partner drug with a longer half-life. Studies are 
ongoing to evaluate potential partner drugs, piperaquine phosphate or 
ferroquine in combination with OZ439 (160). In the past 60 years, primaquine 
was the only drug available for the radical cure of P.vivax and P. ovale 
infections. The unique ability of primaquine to eliminate hypnozoites has been 
unparalleled until tafenoquine (GSK), a chemically modified molecule from 
primaquine. Similar to primaquine, tafenoquine acts on liver stage schizonts 
and hypnozoites, blood stages and gametocytes (167). The advantages 
tafenoquine has over primaquine lies in its greater potency on blood stages 
and longer half-life, which allows it to be administered shorter than the current 
14-day regimen of primaquine, thereby aiding in patient compliance (168). 
Unfortunately, tafenoquine faces the same pharmacokinetic and 
pharmacodynamics challenges as with all 8-aminoquinolines; the need for 









1.7.3 Novel antimalarial drug candidates in clinical development 
A quarter of the 16 antimalarial candidates in clinical development are 
compounds (KAE609, KAF156, DSM265 and SAR97276) with novel 
chemical structures with unique mechanisms of action. Of the four novel 
compounds mentioned in earlier paragraphs, two compounds were discovered 
and developed by a consortium led by Novartis. The NGBS consortium 
comprising Novartis Institute for Tropical Diseases (NITD), Genomics 
Institute for Novartis Research Foundation (GNF), Biomedical Primate 
Research Centre (BPRC) and Swiss Tropical and Public Health Institute 
(Swiss TPH) were very successful in the discovery of two novel compounds, 
KAE609 and KAF156, using the whole cell-based screening approach (170, 
171).  
KAE609 or Cipargamin, belonging to the class of spiroindolones, 
showed a very promising profile in preclinical studies and Phase I and II 
clinical trials (171-174). In 2012, it was the first molecule of a new chemical 
class in the past 20 years that entered Phase IIa clinical trial. In vitro studies 
have shown that KAE609 inhibits growth of seven P. falciparum laboratory 
strains at sub-nanomolar potency as well as P. falciparum and P. vivax field 
isolates (171, 174). KAE609 is active on the intraerythrocytic cycle, in 
particular blood-stage schizonts and sexual gametocytes, making it attractive 
as a transmission-blocking drug (172). A single dose of KAE609 at 100 mg/kg 
was curative when administered to mice infected with P. berghei (171). 
KAE609 also demonstrated excellent bioavailability (100%), a half-life of 24 
hours and a rapid onset of action both in vitro and in vivo (173, 174). Target 
identification based on in vitro selection of drug-resistant clones has revealed 
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the putative target for spiroindolone to be P-type ATPase (PfATP4), an ATP-
dependent cationic transporter that participates in maintaining sodium 
homeostasis (175, 176). Another drug candidate in preclinical testing, SJ733, 
belonging to a class of dihydroisoquinolones also targets PfATP4. SJ733 
shares similar properties to KAE609; fast onset of action, novel mechanism of 
action, relatively long half-life and low propensity to develop resistance, all of 
which are in favour for development of a SERCaP therapy (177). The rapid 
progress of KAE609 from preclinical stage to current Phase II clinical trial has 
shown a lot of promise, the efficacy of KAE609 as a monotherapy will be 
evaluated in an ongoing clinical trial in Vietnam and Thailand 
(NCT01836458).  
KAF156 is a first-in-class antimalarial drug candidate of the 
imidazolopiperazine class that is active against P. falciparum asexual 
intraerythocytic forms, sexual gametocytes and liver stage schizonts (170, 
178, 179). This drug is pertinent to this thesis, which aims to deconvolute the 
target and mechanism of action and resistance of KAF156 using drug-resistant 
mutants to KAF179. KAF179 is structurally similar to KAF156, differing only 
by a –chloro to –fluoro substitution on the benzene ring. KAF156 has a good 
safety profile with minor adverse effects such as headache and gastrointestinal 
side effects and a relatively long half-life of 42.5 – 70.7 hours, which allow for 
once-daily dosing. A recent clinical study has evidence to suggest the potential 
application of KAF156 as a causal prophylactic and also a transmission-
blocking antimalarial (179). The putative target of KAF156 is the P. 
falciparum cyclic amine resistance locus (PfCARL) protein with seven 
transmembrane domains (170). However, little is known about the putative 
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target or the mechanisms of resistance of KAF156, a compound with both 
blood and liver-stage activity. However, a recent paper seemed to have cast 
doubts on PfCARL being the direct molecular target of KAF156 and they also 
did not rule out PfCARL as a transporter for imidazolopiperazines (178). 
Identifying the target(s) and deciphering the mechanism of resistance of 
KAF156 is of paramount importance, as the molecular target would provide 
opportunities to screen for compounds, which target both the blood and liver 
stages. This thesis will discuss the novel resistance selection strategy that 
selected for 12 KAF179 drug-resistant mutants, which aided in the 
identification of two other novel putative genes associated with KAF179 
resistance. Mutations were found in P. falciparum CARL, UDP-galactose 
transporter (PfUGT) and acetyl-CoA transporter (PfACT). The 12 mutants can 
be categorized into three clusters of mutants with different levels of resistance 
to the respective targets. Phenotypic characterization of the mutants also 
unraveled the cost of fitness of the SNPs associated with the newly identified 
resistance genes.  
DSM265 (MMV) belongs to the class of triazolopyrimidines, inhibits 
P. falciparum dihydroorotate dehydrogenase (DHODH), an essential enzyme 
involved in pyrimidine synthesis (180). Unlike humans, the inhibition of this 
enzyme is fatal for the parasite as it lacks the salvage pathway to obtain 
pyrimidines (180). DSM265 possesses favourable pharmacological properties: 
half-life of 10-13 hours in the mouse, good oral bioavailability and in vivo 
efficacy (181). DSM265 was discovered in a target-based screen for DHODH 
and preclinical data is hopeful for a radical cure or SERCaP therapy (182). 
Unfortunately, no clinical data is available as yet. DSM265 recently entered 
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Phase II clinical trial to evaluate its efficacy, safety and pharmacokinetics in 
uncomplicated P. falciparum and P. vivax (NCT02123290).  
SAR97276 (Sanofi) belongs to a novel class of choline analogs with 
two thiazolium cationic heads. SAR97276 inhibits enzymes responsible for 
phosphatidylcholine synthesis, thereby interfering with membrane synthesis of 
the membrane (183). It was also found to interact with ferriprotoporphyrin IX, 
interferring with heme detoxification (184). SAR97276 showed low 
nanomolar efficacy against P. falciparum in vitro and in vivo in mice and 
monkey malaria models (185, 186). However, two Phase II clinical trials 
(NCT01445938 and NCT00739206) designed to evaluate the safety and 
efficacy of SAR97276 were terminated by the data monitoring committee on 
the basis of the lack of efficacy. MMV has since withheld further clinical 
development of SAR97276.  
In summary, three compounds (KAE609, KAF156 and DSM265) are 
novel chemical entities with unique mechanisms of action that truly have a 
shot at defeating the potential artemisinin-resistant malaria. However, more 
clinical efficacy data is required before these compounds can be included into 
















Figure 3 Chemical structures of antimalarial drugs and candidates  
(a) Standard antimalarial drugs and antimalarial candidates that were 
identified with (b) whole-cell based screening, (c) target-based screening and 
(d) chemical modification of existing drugs. Adapted from Held et al (160) 
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1.7.4 Resistance assessment of antimalarials in development  
In face of drug-resistant malaria, the lifespan of the next generation of 
antimalarials is an important consideration for malaria control and eradication. 
Therefore, this increases the need to have an early assessment of the risk of 
developing resistance associated with hit and lead compounds during initial 
phases of drug discovery process (73, 74). In 2012, MMV proposed a 
framework for assessing the risk of resistance for antimalarials in development 
(74). This framework comprises three goals: (i) identify potential cross-
resistance to other antimalarial compounds, (ii) quantify the risk, or frequency, 
of de novo resistance selection in vitro and the associated fitness cost, (iii) 
characterize the molecular mode-of-action or resistance, including an 
understanding of its genetic basis. In most cases, the mutations are located 
within the target site of action, as in the cases of atovaquone and cytochrome b 
(121, 187), antifolates and their targets, DHFR and DHPS (188-191). 
However, some mutations reveal a mechanism of resistance rather than a 
specific target. For instance, the P. falciparum chloroquine resistance 
transporter (PfCRT) and the multidrug resistance-1 (PfMDR1) transporter 
mediates resistance to multiple drug classes (192). 
Hence, drug resistant mutants serve a dual function in target 
deconvolution as well as the elucidation of the mechanism of action or 
resistance. In addition, molecular information obtained during preclinical 




1.8 Key concepts pertinent to in vitro selection of resistance  
Trager and Jensen developed an in vitro system for continuous culture 
of P. falciparum in 1979 (193). Until today, only P. falciparum is amenable to 
long-term culture. In 1978, Nguyen-Dinh and Trager applied the Petri dish 
method to select P. falciparum resistant parasites in vitro (194). This work 
was perceived as a landmark as it was the first work that showed how 
resistance could be selected against antimalarials in vitro. The three key 
concepts pertinent to in vitro selection of resistance include, (i) resistance 
selection frequency, (ii) fitness cost of the parasite and (iii) accelerated 
resistance to multiple drugs (ARMD) phenomenon.  
 
1.8.1 Resistance selection frequency  
Resistance commonly develops within 10-15 years after an 
antimalarial is introduced (40). For instance, resistance to chloroquine was 
discovered 12 years after it was introduced (54). However, some antimalarials 
such as atovaquone and antifolates developed resistance in the same year that 
they were introduced into the clinic (53, 55, 57). This can be attributed to the 
difference in resistance selection frequencies of the antimalarials. Resistant 
parasites can be selected by applying drug pressure in vitro and in vivo (124). 
The appearance of naturally occurring resistance or spontaneous mutations 
depends solely on the background mutation rate of the parasite, independent of 
drug treatment. Spontaneous mutations occur at a relatively low rate of 10-7 to 
10-10 (125, 195, 196). Resistance may be manifested as amplifications of gene 
copy number, as in the case of PfMDR1. They are believed to occur at a rate 
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of 10-4 per nucleotide site per replication (197); however, there is insufficient 
published experimental confirmation. Among current antimalarials in use, 
atovaquone has the highest frequency of spontaneous resistance measured in 
vitro (125). It is frequently used as a benchmark to compare frequency of 
spontaneous resistance to new compounds in drug development (73). A simple 
approach is to expose independent cultures with parasite numbers ranging 
from 105 to 109 to fully inhibitory concentrations (> IC99) of the drug over a 
period of time. The culture with the lowest initial number of parasites able to 
sustain growth of the parasites is the frequency of spontaneous mutation 
termed minimum inoculum for resistance (MIR) (73, 74, 198). The MIR is an 
indirect measure of the likelihood of a resistant genotype to occur and to be 
selected in vitro (74). The limited data in the literature suggests a strain 
dependence of MIRs (121, 125). Experiments that measure the MIR should be 
performed for new antimalarial drug candidates to assist in decision making of 
pursuing or holding back on an antimalarial compound series (74, 199). The 
limited data in the literature suggests a strain dependence of MIRs (121, 125). 
Experiments that measure the MIR should be performed for new antimalarial 
drug candidates to assist in decision making of pursuing or holding back on an 
antimalarial series (74, 199). The existing literature data suggest that the 
frequency of mutation in P. falciparum is specific to the parasite strain, for 
instance, atovaquone has a mutation frequency of 10-5 in W2 but 6 x 10-8 in 
K1 (121, 125).  
In a combination therapy where two drugs have different modes of 
action, and therefore different resistance mechanisms, the mutation frequency 
or probability of developing resistance to both drugs is the product of their 
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individual mutation frequencies (200). Drug resistance is intricately linked to 
mutation frequencies. Malaria patients typically have 1010 – 1012 circulating 
parasites during the course of treatment, a drug or drug combination with a 
low mutation rate is expected to select for drug-resistant mutants even during 
a single infection (195). Despite the short course (usually 3 days) of 
antimalarial treatment, resistance will still develop due to the fact that 
passaging of a drug-resistant mutant through many patients will inevitably 
increase the mutant fraction of the parasitic population over time (201). 
Hence, mutation frequencies of antimalarials should not be disregarded as a 
mere in vitro parameter and it has potential implications on drug resistance 
and global health.  
 
1.8.1.1 Relationship between in vitro and clinical mutation frequencies  
The relationship between mutation frequencies derived from resistant 
mutants generated in vitro and clinical isolates is not clear. However, it has 
been shown that mutation frequencies derived from in vitro studies are often 
higher than those derived in vivo (195). Although both atovaquone and 
pyrimethamine have shown to have the highest propensity to mutate under 
drug pressure, their in-vitro and in-vivo mutation frequencies were dissimilar 
(200). The mutation frequency of atovaquone can be as low as 10-12 in vivo 
and as high as 10-5 in vitro (125, 200). However, it is often difficult to estimate 
in vivo mutation frequencies accurately. It takes many generations of growth 
under drug pressure for the manifestation of a resistant cell line. Resistance 
will first be displayed as delayed parasitic clearance times before development 
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into drug-resistant parasites that can be isolated and genotyped (202). In 
addition, an individual could be infected with many different parasite strains, 
ranging from 1 to 5 and up to 10 in high transmission areas (73). At best, 
molecular methods can only detect up to half of the infecting strains in an 
individual (203).  
 
1.8.2 Resistance associated fitness cost of the parasite  
Resistance to anti-infectives is generally achieved either by altered 
gene expression (often of a transporter) or by mutation(s) which alter protein 
structure to reduce drug-binding efficacy (204). In response to this 
physiological change, natural selection reduces the genetic ‘fitness’ of 
parasites carrying the mutation (204). The cost of fitness of a mutant parasite 
is expressed as a percentage reduction relative to the original non-mutated or 
wild-type (WT) parasite. For instance, a 5% cost of fitness indicates a 5% 
fewer offspring of the mutant strain as compared to the WT strain in the 
absence of the drug (204). However, the fitness cost involved in the evolution 
of antimalarial drug resistance is hardly a subject of discussion in most 
publications but it has gained traction in recent years. A majority of population 
genetics studies often used Drosophila, mice and humans as subjects, in these 
cases; fitness costs tend to be small due to the diploid genome. The haploid P. 
falciparum blood stage parasites are vulnerable to natural selection or 
antimalarial drugs; the effects of mutations cannot be obscured by the 
presence of another normal gene (204). Therefore, the impact of resistance on 
parasite fitness and vice versa is of great importance in malaria.  
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Fitness can be measured in vitro by comparing growth rates and in 
competitive growth experiments of resistant and sensitive strains at a given 
ratio (205, 206). The cost of fitness is linked to the spread of resistance of 
chloroquine, antifolates and other drugs from Asia to Africa. Antimalarial 
drug resistance tends to emerge in Southeast Asia, where the intensity of 
malaria transmission is low and the human population has low or no immunity 
to malaria (40). In areas with high transmission where people tend to be co-
infected with 3 to 7 genetically distinct parasite clones, a less fit parasite faces 
a greater natural selection pressure and a higher likelihood of being 
outcompeted by sensitive strains than it would in a low transmission area (73). 
The less fit parasite is allowed to thrive in a population with low immunity 
and over time, the parasite may evolve compensatory mutations that will 
restore its fitness. These secondary mutations do not affect drug resistance, as 
measured by in vitro IC50 values but they increase the replication rate in the 
absence or sub-inhibitory concentrations of the drug for the resistant mutants 
(73).  
Clinical chloroquine resistance provides an insight of the impact of 
fitness on resistance. The worldwide prevalence of chloroquine-resistant P. 
falciparum in the 1980s prompted the change of first-line therapy to 
sulfadoxine-pyrimethamine. In the years following the withdrawal of 
chloroquine from many countries, researchers screened the clinical isolates for 
the K76T mutation in PfCRT. The discontinuation of chloroquine as a 
selection pressure allowed the reemergence of chloroquine-sensitive parasites; 
demonstrating the fitness advantage of chloroquine-sensitive parasites (206). 
A higher level of resistance is usually associated with a higher fitness cost. For 
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instance, a double mutant (M133I and G280D) in PfCYTB decreased 
atovaquone sensitivity by 1000-fold compared to 25-fold conferred by a single 
mutant (M133I) (121). In an in vitro competitive growth experiment, the 
single mutant grew as well as the parent strain but the double mutant was 
outcompeted, with a 5-9% loss of fitness (207). In another similar example, a 
higher copy number of PfMDR1 was associated with a decreased 
susceptibility to mefloquine and a higher fitness cost. In the absence of 
mefloquine as a selection pressure, parasites with a single copy of PfMDR1 
outcompeted those with multiple copies (2 and 3) of the gene (111). The loss 
of fitness was estimated to be 6.3% and 8.7% for parasites with 2 and 3 copies 
of PfMDR1 respectively (111). The deamplification of PfMDR1 gene over 
time has also shown to increase susceptibility of P. falciparum to mefloquine 
(115). It is evident that fitness cost plays an important role in the spread of 
drug resistance; it is therefore important to investigate the fitness of mutations 
during drug development and preclinical testing.  
 
1.8.3 Accelerated Resistance to Multiple Drugs (ARMD) phenomenon 
Resistance to newly introduced antimalarial drugs has been repeatedly 
reported to occur along the Thai-Cambodian border. The accelerated 
resistance to multiple drugs (ARMD) phenomenon refers to the significantly 
higher ability of Asian parasite clones to develop resistance in vitro (125). 
ARMD strains are able to develop resistance to antimalarial drugs at an 
increased rate compared to other resistant strains. The exact molecular 
mechanisms has yet to be elucidated, however it is postulated that the genetic 
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basis for such phenotype is due to a defective DNA repair system (208, 209). 
Some strains suffered more extensive loss of repair mechanisms than others as 
in the case of Dd2, a clone line from the multidrug resistant (MDR) parent 
strain W2 (209). Spontaneous mutations occur at a rate of 10-6 in ARMD 
strains (209), meaning that a parasite population of 108 is almost assured of 
including resistant cells. Hence, Dd2 is an ideal strain to select for resistant 















1.9 Single-step versus stepwise selection of mutants 
The technique of evolving drug-resistant P. falciparum parasites in 
vitro has been relatively well established, but there is yet a standard protocol 
and it varies between laboratories (125, 210). However, most laboratories 
modify their resistance selection system based on the single-step or stepwise 
method. In single-step selection of mutants, a relatively large population of 
parasite population is exposed to greater than fully inhibitory concentrations 
(> IC99) of the drug. This method is thought to be better correlated with in vivo 
conditions than alternative methods (73). Resistant mutants generated by this 
single-step method provide useful genetic information for mechanism of 
resistance and drug target deconvolution studies. In stepwise selection of 
mutants, a comparatively smaller population of parasite population is exposed 
to sub-inhibitory concentrations (< IC50) of the drug initially. The 
concentration of the drug is increased to suppress the growth of the parasites 
and the cycle repeats until the parasites are unable to tolerate the concentration 
of the drug. Exposure to incremental concentrations of drug pressure may 
select for compensatory mutations that will relieve fitness cost associated with 
drug resistance (73).  
The process of evolving drug-resistant parasites in vitro generally 
begins with the simultaneous addition of the drug to the culture and the critical 
step of freezing down a stock for genomic DNA analysis post-selection of 
drug-resistant mutants. Drug resistance is then evolved using either the single-
step or stepwise method. After a few weeks to months of selection, the 
putative mutants are diluted out into smaller numbers, a step known as 
limiting dilution. The clones are then detected using SYBR® Green I, pLDH, 
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microscopy, or flow cytometry and proceeded to be scaled up for drug 
susceptibility testing to determine the level of resistance. There are a lot of 
variations between laboratories; these differences may include the method for 
selection (single-step or stepwise), concentration of drug, time taken for 
resistance selection, detection method and P. falciparum strain differences. 
The protocol may also be modified based on the pharmacokinetics of the drug.  
Prior to the advent of high-density microarrays and whole genome 
sequencing techniques that enabled the identification of SNPs and CNVs 
between a parental drug-sensitive clone and a drug-resistant clone, the 
technique of evolving drug-resistant parasites was not used to determine 
targets of unknown drugs (211, 212). P. falciparum often acquires mutations 
in the drug target and generation of mutants is an effective way to identify 
drug targets. Drug-resistant mutants are able to provide vast information about 
the target, the amino acids essential for drug activity and potentially shed light 




























2 OBJECTIVES AND HYPOTHESES 
2.1 Objectives  
The main objective of this project is target deconvolution and 
elucidation of mechanisms of resistance of imidazolopiperazine class of novel 
antimalarials through the use of drug-resistant mutants. The secondary 
objective is to utilize molecular genetic information to aid medicinal 
chemistry efforts to design and optimize novel compounds against the 
validated drug target(s) that have been elucidated in this project.  
 
There are five parts to this project specified as follows: 
1. Optimization of culture conditions  
 
2. Stage-specificity of Imidazolopiperazines (KAF156 and KAF179) 
 
3. Protocol development for selection of KAF179-resistant mutants 
 
4. Genotypic characterization of KAF179-resistant mutants 
a. Targeted gene sequencing  
b. Whole genome sequencing to identify genes associated with 
KAF179 resistance  
c. Validation of genes associated with KAF179 resistance  
 
5. Phenotypic characterization of KAF179-resistant mutants  
a. Level of resistance based on IC50 values 
b. Morphology 
c. Cross resistance with standard antimalarial drugs  
d. Cross resistance with imidazolopiperazine chemical analogs  
e. Cross resistance with compounds of different chemical classes 
f. Fitness cost  
g. Cellular localization  
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The materials and methods for all experiments can be found in chapter 3 of 
this thesis. The results and discussions of each part of the project will be 
discussed in five separate chapters.  
 
2.1.1       Optimization of culture conditions  
Chapter 4 will present the results and discussion for the optimization of 
culture conditions. In vitro cultivation of P. falciparum cultures under static 
conditions according to the method described by Trager and Jensen remains a 
common practice in most laboratories, despite previous work that have 
demonstrated the benefits of suspension cultures over static cultures (213-
216). The benefits associated with shaking or agitation of cultures include 
increased culture yield, prolonged culture synchrony and marked decreased in 
the prevalence of multiple infections (i.e. > 1 parasite per red blood cell) 
(216). Continuous agitation of cultures prevents multiple infections that could 
diminish the health of the parasites and reduce their multiplication rate. It also 
serves to speed up the rate of propagation in resistant mutant strains where 
there is a loss of fitness. More recently, large-scale production of P. 
falciparum cultures has also utilized the principle of shaking to increase the 
culture yield (217, 218).  Although the benefits of shaking have been shown in 
many studies, different laboratories adopt different culture conditions such as 
percentage of gas mixture, freshness of erythrocytes and media composition. 
Therefore, this section aims to optimize the conditions for cultivation of P. 
falciparum Dd2 WT cultures under suspension.  
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2.1.2       Stage-specificity of imidazolopiperazine compounds  
The novel antimalarial drug used for this project, KAF179 is a 
chemical analog of KAF156, a first-in-class antimalarial drug candidate of the 
imidazolopiperazine class that is active against P. falciparum asexual 
intraerythrocytic forms, sexual gametocytes and liver stage schizonts (170, 
178, 179). KAF179 is structurally similar to KAF156, differing only by a –
chloro to –fluoro substitution on the benzene ring. Despite a considerable 
amount of information about the in vitro, in vivo and clinical efficacy of 
KAF156, the intraerythrocytic stage (ring, trophozoite or schizont) at which it 
acts on is unknown (170, 178, 179).  
Chapter 5 will present the stage of action of KAF156 and KAF179 
within the intraerythrocytic cycle, together with standard antimalarials with 
known stage of action.  
 
2.1.3       Protocol development for selection of KAF179-resistant mutants 
In order to achieve both objectives of this project, tools have to be in 
place for the selection of drug-resistant mutants. A lot of effort has been put 
into the exploration and development of a novel protocol for the selection of 
drug-resistant mutants. The novel protocol differs from the current resistance 
selection methods, as it is able to (a) generate more resistant mutants in a 
shorter period of time, (b) select for mutants with variable fitness costs and (c) 
identify novel resistance-associated genes. KAF179 is pertinent to this thesis, 
which aims to deconvolute the target and mechanism of action of KAF156 
using drug-resistant mutants to KAF179.  
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Chapter 6 will present the novel protocol, which selected for 12 
KAF179-resistant mutants and optimization of detection platforms for higher 
throughput selection of drug-resistant mutants.  
 
2.1.4       Genotypic characterization of KAF179-resistant mutants  
Chapter 7 will present the single nucleotide polymorphisms of the 12 
KAF179 mutants through targeted sequencing of the putative target, P. 
falciparum cyclic amine resistance locus (PfCARL) (170) and whole genome 
sequencing. This chapter will also present and discuss the identification and 
validation of novel resistance genes with the SNPs derived from KAF179-
resistant mutants, which were selected using the novel protocol.  
    
2.1.5       Phenotypic characterization of KAF179-resistant mutants  
Chapter 8 will showcase the phenotypic characteristics of KAF179- 
resistant mutants in terms of their level of resistance, cross-resistance patterns, 
morphology, competitive growth kinetics and cellular localization. The cross-
resistance analysis with chemical analogues of imidazolopiperazine class and 
compounds of other chemical classes suggest a possible mechanism of 






The four hypotheses of this project are specified as follows: 
i. The development of a novel protocol that will result in the selection of 
more resistant mutants in a shorter period of time. 
ii. The use of a novel protocol for selection of drug-resistant mutants will 
potentially identify novel targets or mechanisms of resistance. 
iii. The use of a novel protocol for selection of drug-resistant mutants will 
allow the manifestation of resistant mutants with variable fitness costs.  
iv. Cross-resistance testing of KAF179 resistant mutants with compounds 
of novel chemical classes will aid in prioritization of compounds and 














3 MATERIALS AND METHODS 
 
This section comprises general cell culture techniques for malaria and 
experimental details for specific experiments in subsequent chapters of this 
thesis. The experimental details will be found under these sub-sections: 
3.1   General cell culture techniques  
3.2   Optimization of culture conditions  
3.3   Stage-specificity of imidazolopiperazine compounds  
3.4   Protocol development for selection of KAF179-resistant mutants 
3.5   Genotypic characterization of KAF179-resistant mutants 
3.6   Phenotypic characterization of KAF179-resistant mutants  
 
3.1 General cell culture techniques 
3.1.1 Parasitemia and hematocrit  
Parasitemia is a quantitative measure of the percentage of erythrocytes 
that are parasitized (35) and hematocrit is the proportion of red blood cells 
present in culture media. Parasitemia was determined by Giemsa-stained 
slides under the microscope (Nikon YS100) with 100× magnification. The 
number of red blood cells per milliliter (mL) was determined using a 
hemocytometer (inCYTO DHC-N01 Neubauer Improved) to be in the range 
of 9.8 × 106 – 1.0 × 107 RBCs/mL. The number of infected red blood cells 
(iRBCs)/μL can be calculated by this formula: (%Parasitemia)/100 × 1.0 × 107  
iRBC/μL.  
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3.1.2 Malaria culture media 
10.4 g/L of RPMI-1640 medium containing L-glutamine (Cat. No.  
6504, Sigma-Aldrich), 25 mM of 1.0 M HEPES solution (Cat. No.  H3537, 
Sigma-Aldrich), 50 mg/L gentamycin sulfate (Cat. No.  345815, Calbiochem), 
2.0 g/L sodium bicarbonate (Cat. No.  S5761, Sigma-Aldrich), 2 g/L D-
glucose (Cat. No.  G7021, Sigma-Aldrich), 27.2 mg/L hypoxanthine (Cat. No.  
4010CBC, Calbiochem) dissolved in a milliliter of 1.0 M sodium hydroxide 
(Cat. No.  S8045, Sigma-Aldrich) and 0.5% Albumax II (Cat. No.  11021045, 
Gibco). Medium was typically adjusted to a pH of 7.3 to 7.4.  
 
3.1.3 Parasite strain 
P. falciparum multidrug-resistant strain Dd2 was used for all the 
experiments except for stage-specificity experiments where P. falciparum 
drug-sensitive 3D7 strain was used. Dd2 is resistant to chloroquine, quinine, 
pyrimethamine and sulfadoxine and it multiples at a rate of 5-6 fold per 48-hr 
generation in vitro (35).  
 
3.1.4 Preparation of Giemsa-stained slides  
Giemsa is a nucleic acid stain used to visually distinguish Plasmodium 
parasites from surrounding cells. To visualize the parasites microscopically, 
0.5 mL of the culture was pipetted into an eppendorf tube and centrifuged 
using a benchtop centrifuge (Eppendorf 5415 R, Hamburg, Germany) at 13.2 
rpm for 1 min. The supernatant was then aspirated and 10.0 μL of the infected 
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red blood cells (iRBCs) was used to do a thin blood smear. The slide was 
fixed with 100% methanol (Cat. No.  A412-4, Fisher Scientific) for 1 min 
before staining in 10% Giemsa-stain (Cat. No. 48900, Sigma-Aldrich) in 
phosphate-buffered saline for 15 minutes.  
 
3.1.5 Preparation of host erythrocytes 
One bag of 450 mL single donor human whole blood (Cat. No.  IPLA-
WB2, Innovative Research) was aliquoted into tubes of 30 mL each. The 
human erythrocytes were washed at least 2 to 3 times in RPMI-1640 washing 
media to separate the erythrocytes from the plasma and buffy coat. RPMI-
1640 washing media consisted of 10.4 g/L of RPMI-1640 medium containing 
L-glutamine (Cat. No.  6504, Sigma-Aldrich), 10 mM of 1.0 M HEPES 
solution (Cat. No.  H3537, Sigma-Aldrich), 50 mg/L gentamycin sulfate (Cat. 
No.  345815, Calbiochem), 2.0 g/L sodium bicarbonate (Cat. No.  S5761, 
Sigma-Aldrich). Separation was achieved by centrifuging the whole blood at 
2000 rpm for 10 minutes using a benchtop centrifuge (Heraeus® Multifuge 
3SR, Thermo Scientific, Massachusetts, USA). Leukocyte-free erythrocytes 
were stored at 50% hematocrit in RPMI-1640 washing media.  
 
3.1.6 Culture conditions  
P. falciparum asexual blood stage parasites were routinely cultured at 
37oC in malaria culture media at 2-2.5% hematocrit in an incubator with 
reduced oxygen environment. Parasites were cultured in flasks that permit gas 
exchange. Culture media change coincided the 48-hr generation time of the 
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parasite. Dd2 multiples at a rate of 5-6 fold per 48-hr generation and care was 
taken to avoid parasite cultures from attaining too high a parasitemia (i.e. 
more than 10%).  
 
3.1.7 Thawing of infected red blood cells  
Cryovial containing infected red blood cells was removed from the 
liquid nitrogen storage tank. It was incubated in a beaker containing water at 
37oC for 30 seconds with gentle agitation. The infected red blood cells were 
transferred to a 15 mL falcon tube and centrifuged at 500 × g for 10 minutes 
(Heraeus® Multifuge 3SR, Thermo Scientific, Massachusetts, USA). After 
centrifugation, the supernatant containing glycerol was removed and an equal 
volume of 3.5% sodium chloride (Cat. No. S3014, Sigma-Aldrich) was added. 
The infected red blood cells were recovered by centrifugation at 2300 rpm for 
5 minutes and the saline supernatant was then removed and an equal volume 
of complete RPMI media is added. The previous washing step was repeated 
twice before placing the infected red blood cells in culture at 2% hematocrit.  
 
3.1.8 Cryopreservation of infected red blood cells  
The culture was transferred into a 50 mL falcon tube and the infected 
red blood cells are pelleted using a benchtop centrifuge (Heraeus® Multifuge 
3SR, Thermo Scientific, Massachusetts, USA) at 2300 rpm for 5 minutes. The 
supernatant was removed by aspiration and the volume of packed red blood 
cells was measured. An equal volume of cryoprotectant solution was added to 
the infected red blood cells. The cryoprotectant solution consisted of 4.2% D-
 72 
sorbitol (Cat. No. S1876, Sigma-Aldrich) and 38.9% glycerol (Cat. No.  
G5516, Sigma-Aldrich) in 0.9% sodium chloride (Cat. No. S3014, Sigma-
Aldrich) solution. The blood-cryoprotectant suspension was mixed until 
homogeneous before aliquoting into cryopreservation tubes. The 
cryopreservation tubes were placed immediately in the liquid nitrogen tank for 
storage.  
 
3.1.9 Saponin lysis of infected RBCs for parasite cell pellets  
Cultures were scaled up to at least 4-5% parasitemia in 100 mL of 
RPMI media at 2.5% hematocrit prior to parasite extraction from the red blood 
cells. The cultures were reconstituted to 10% hematocrit with fresh RPMI 
media and transferred to a 15 mL falcon tube. Lysis buffer (1.5% saponin and 
1.0% bovine serum albumin fraction V in phosphate buffered saline) was 
added on ice in 10 pellet volumes. Upon lysis of red blood cells, indicated by a 
clear red supernatant, the lysed cultures were centrifuged at 2700 × g for 5 
minutes at 4 oC (Heraeus® Multifuge 3SR, Thermo Scientific, Massachusetts, 
USA). The supernatant was removed by aspiration and the cells were washed 
twice using chilled PBS in microcentrifuge tubes. The cell pellets were then 






3.1.10 Synchronization of cultures  
3.1.10.1 Sorbitol synchronization 
The culture was transferred into a 50 mL falcon tube and the infected 
red blood cells were pelleted using a benchtop centrifuge (Heraeus® Multifuge 
3SR, Thermo Scientific, Massachusetts, USA) at 2300 rpm for 5 minutes. The 
supernatant was removed by aspiration and 4 volumes of 5% D-Sorbitol (Cat. 
No.  S1876, Sigma-Aldrich) in PBS was added to 1 volume of infected red 
blood cells. It was left to stand for 15 – 20 minutes at room temperature. After 
incubation with 5% sorbitol, the infected red blood cells were pelleted using a 
benchtop centrifuge at 2300 rpm for 5 minutes and the supernatant removed 
by aspiration. The infected red blood cells were then washed twice with PBS 
and once with complete RPMI media before being made up to 2 - 4% 
hematocrit and returned to culture.  
 
3.1.10.2 MACS purification 
The culture was transferred into a 50 mL falcon tube and the infected 
red blood cells are pelleted using a benchtop centrifuge (Heraeus® Multifuge 
3SR, Thermo Scientific, Massachusetts, USA) at 2300 rpm for 5 minutes. The 
purification column was first primed with 2 mL of albumax-free media. The 
infected red blood cells was suspended in 2 mL of albumax-free media and 
transferred into the MACS LD column (Cat No. 130042901, Miltenyi Biotec) 
that was fixed onto the MidiMACS Separator (Cat No. 130042302, Miltenyi 
Biotec) on the MACS MultiStand (Cat No. 130042303, Miltenyi Biotec). 
Uninfected red blood cells and ring stage parasites flow through the column 
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leaving schizonts which contain hemazoin magnetized to the LD column. The 
LD column was then washed twice with 2 mL of albumax-free media prior to 
removal from the MidiMACS Separator. The schizonts were then eluted with 
2 mL of albumax-free media from the LD column placed in a 15 mL falcon 
tube.  The pure schizonts, which appear dark brown, were then washed twice 
in complete RPMI media before being made up to 2 - 4% hematocrit and 
















3.2 Optimization of culture conditions 
A cryovial containing P. falciparum Dd2 infected red blood cells was 
thawed out and cultured at 2% parasitemia and 2.5% hematocrit for one cycle 
– 48 hours. Prior to splitting the cultures into different experimental arms – 
static and suspension cultures, the parasitemia of the culture was determined 
by Giemsa-stained slides under the microscope at 100× magnification. Static 
cultures were placed in the incubator at 37oC while suspension cultures were 
placed either on an orbital shaker (GFL 3017, Burgwedel, Germany) at a 
speed of 50 rpm or on a roller system in a 37oC warm room. At day 0 of the 
experiment, all flasks had an initial parasitemia of 0.2% in 50 mL RPMI-1640 
complete media at 2% hematocrit. All flasks were gassed with a mixture of 
gases (90% N2, 5% CO2, 5% O2) before placing them in their respective 
culturing conditions. The cultures were maintained for three cycles (6 days) in 
duplicates. At every 48 hours, 10% of the culture was propagated to the next 
with addition of fresh culture media and washed erythrocytes. At every cycle, 
cell counts were recorded from Giemsa-stained slides under the microscope. 
The parameters determined include: (a) parasite yield (1500 cells), (b) culture 
synchrony (1500 cells) and (c) prevalence of multiple infections (500 cells). 
The values in parentheses represent the minimum number of cells counted.  
Graphs for optimization of culture conditions were plotted using 
GraphPad Prism 5.02 (California, USA) and Microsoft Excel 2010 
(Washington, USA). Paired student’s t-tests were performed using GraphPad 
Prism 5.02 (California, USA) to discern the significance of parasite yield 
between static and suspension cultures.  
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3.3 Stage-specificity of imidazolopiperazine compounds 
A drug-sensitive P. falciparum 3D7 culture was synchronized for a 
week prior to the start of the experiments. The asynchronous 3D7 culture was 
first synchronized using MACS purification (Miltenyi Biotec) to obtain pure 
schizonts. The second synchronization with 5% sorbitol at the ring stage was 
carried out 12 hours preceding the next MACS purification. The alternating 
sorbitol and MACS purification was repeated for three lifecycles with a final 
purification using the MACS column for mature schizonts. To facilitate re-
invasion of merozoites into red blood cells, the culture was left in a shaking 
incubator at 40 RPM for 4 hours after MACS purification. The repeated 
synchronization of cultures gave a tight “4-6 hour window” of parasites. The 
aim of the experiment was to investigate the effect of KAF156 and KAF179, 
together with artemisinin, mefloquine and pyrimethamine, on early rings (0-6 
hr p.i.), rings (7-24 hr p.i), trophozoites (25-38 hr p.i) and schizonts (39-48 hr 
p.i).  
A master plate containing artemisinin, mefloquine, pyrimethamine, 
KAF156 and KAF179 was prepared in a 96-well plate, with a highest 
concentration at 10 μM and three-fold serial dilutions to yield 8 concentration 
points. A final working concentration of 0.1% DMSO was used as the 
negative control and 10 μM artemisinin was used as the positive control. Each 
well was spotted with 200 nL of compound using a Mosquito® nanoliter 
dispenser (Cambridge, UK). At different hours post-invasion (p.i) of the red 
blood cells; early rings (0 hr p.i), rings (6 hr p.i), trophozoites (24 hr p.i) and 
schizonts (36 hr p.i), 200 μL of P. falciparum 3D7 culture at the respective 
intraerythrocytic stage were seeded at 0.5% parasitemia and 4.0% hematocrit 
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manually into the compound-spotted plates. The plates were incubated in an 
incubator with reduced oxygen environment at 37oC. Giemsa-stained slides 
were prepared prior to seeding to ensure the culture is at the correct 
intraerythrocytic stage.   
The culture at the respective intraerythrocytic stage was incubated with 
the compounds for a respective number of hours before the compounds were 
being washed off extensively; twice with 1× PBS and once with complete 
RPMI media. The incubation times are as follows: early rings (6 and 24 
hours), rings (18 hours), trophozoites (12 hours) and schizonts (12 hours). 
Upon the removal of the compounds, the stage-specific parasites were cultured 
in complete RPMI media before being assessed with MitoTracker® Orange for 
their IC50 determinations at 24 hours and 72 hours. For detection with a final 
concentration of 250 nM MitoTracker® Orange, 170 μL of media was 
removed and to the remaining 30 μL of infected culture, an equal volume of 
mixture of MitoTracker® Orange in PBS was added. The plates were 
incubated for 24 hours at 370C before being read on the Opera® high content 
imaging system (PerkinElmer). Each well was imaged bottom-up for 25 fields 
using a 561 nm laser.   
The wells were imaged for live cells stained with MitoTracker® 
Orange. The number of live parasite counts was quantified using custom 
Acapalla script and algorithms for high content imaging. Quantitative data was 
normalized to the positive (Artemisinin) and negative control (DMSO) and 
IC50 graphs were plotted using a non-linear regression model. Bar graphs were 
plotted using TIBCO® Spotfire® 4.0.2 (Massachusetts, USA). The following 
formula was applied in the plot of the bar graphs: If (Ainf > -70, 10, AC50). 
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The formula sets a criterion of a minimum of 70% inhibition for the IC50 to be 



















3.4 Protocol development for selection of KAF179-resistant 
mutants  
 
3.4.1 Novel strategy for the selection of KAF179-resistant mutants  
A clonal P. falciparum Dd2 parasite line was cultured at 37oC in 
complete RPMI media at 4% hematocrit in an incubator with reduced oxygen 
environment(193). The half maximal inhibitory concentration (IC50) of 
KAF179 (6.0 nM) was determined using a 72-hour SYBR® Green I drug 
sensitivity assay (65, 203, 219). A single-step selection for pre-existing 
resistant mutants was employed by the addition of KAF179 at greater than 
fully inhibitory concentration (2 × IC99) to a large parasite population of 109 
(Fig. 12). Prior to the addition of KAF179, a stock vial of the culture was 
prepared for future whole genome sequencing. Excessive debris resulted by 
the death of drug sensitive parasites was removed using a 63% percoll 
purification step (220). Subsequently, the viable parasites were placed into 
four 96-well plates for continuous culturing in which each well contained 200 
μL of complete media at 2.5% hematocrit. Negative control wells that 
contained culture at 2.5% hematocrit without any parasite were also present in 
each plate. Parasites were kept under constant drug pressure with replacement 
of complete media, washed blood and drug every other day. After 25 days in 
culture, Giemsa-stained smears of every well were done in batches. Putative 
mutants were selected microscopically using Giemsa-stained slides and the 
corresponding positive wells were scaled up through stepwise transfer of 
culture from 96-well to 24 well to 12 well to 6 well and finally into a T-25 
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flask. The putative mutants were then subjected to drug sensitivity testing to 
be validated as resistant mutants.  
 
3.4.2 Limit of detection for platforms used for the selection of drug-
resistant mutants  
Experiments were designed to determine the limit of detection (LOD) 
for each detection method (Fig. 15): (1) high content imaging using SYBR® 
Green I nucleic acid stain (Cat No. S7567, Life Technologies) and 
MitoTracker® Orange stain (Cat No. M7511, Life Technologies), (2) SYBR® 
Green I nucleic acid stain and (3) quantitative PCR using 18s rRNA primers 
(Integrated DNA Technologies) and (4) fluorescence-activated cell sorting 
(FACS) using Hoechst and dihydroethidium (DHE).  
 
3.4.2.1 High Content Imaging platform using SYBR® Green I and 
MitoTracker® Orange stains  
(i) SYBR®Green I nucleic acid stain  
Prior to serial dilution, parasitemia of asynchronous P. falciparum 
culture Dd2 WT was determined as an average by microscopic counting of at 
least 1000 cells (10 fields of vision) on Giemsa-stained slides in triplicates. 
The number of parasites per μL was calculated based on the assumption that 
each red blood cell was infected with only one parasite. The culture was 
serially diluted to obtain parasites per well (p/well) in the range of 0, 200, 400, 
800, 1600, 3200, 6400 to 12800 p/well in the first experiment. In order to 
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determine the LOD, further two experiments with narrower ranges of parasites 
per well was carried out. The culture was serially diluted to obtain parasites 
per well (p/well) in the range of 0, 100, 200, 400, 800, 1600, 3200 to 6400 
p/well and 0, 25, 50, 100, 200, 400, 800, 1600 p/well in the second and third 
experiment respectively. Forty microliters of culture at the respective dilution 
with 0.025% hematocrit per well was manually dispensed using a 
multichannel pipette into a 384-well plate. The number of replicates (n) at 
each concentration dilution was 24, 27 and 42 for experiment 1, 2 and 3 
respectively. Negative control that comprised RPMI 1640-media with 2.5% 
hematocrit was dispensed into row A, column 1-24 and positive control that 
comprised approximately 20,000 p/well at 0.1% hematocrit was dispensed into 
row P, column 1-24. The cells were fixed with 14 μL of solution containing 
4% paraformaldehyde (PFA) (Cat. No. 15710, Electron Microscopy Sciences), 
1× SYBR® Green I nucleic acid gel stain (Cat. No. S7567, Invitrogen) and 
0.1% Triton X-100 (Cat. No. 0694, Amresco) per well. The plate was 
incubated overnight at 40C before being read on the Opera® high content 
confocal imaging system (PerkinElmer).  
 
(ii) MitoTracker® Orange viability stain  
Parasitemia of asynchronous P. falciparum cultures Dd2 WT and Dd2-
GFP were determined as an average by microscopic counting of at least 1000 
cells (10 fields of vision) on Giemsa-stained slides in triplicates. The 
parasitemia was approximately 3-5% for both strains in both experiments. The 
cultures were serially diluted to obtain parasites per well (p/well) in the range 
of 0, 80, 240, 400, 800, 2400, 4000, 8000, 24 000, 40 000, 80 000 to 240 000 
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p/well. There were 8 replicates for each parasite density for both P. falciparum 
Dd2 WT and Dd2-GFP strains and two independent experiments were carried 
out. Twenty microliters of culture at the respective parasite density with 4 % 
hematocrit per well was manually dispensed using a multichannel pipette into 
a 384-well plate. Negative control that comprised RPMI 1640-media with 4 % 
hematocrit was dispensed into column 1. Parasites of increasing parasite 
density were dispensed into columns 2 to 12. P. falciparum Dd2 culture was 
dispensed into rows A-H and Dd2-GFP culture was dispensed into rows I-P. 
Five μL of MitoTracker® Orange (Cat No. M7511, Life Technologies) at 1 
mM was added to 10 mL of pre-warmed PBS. 20 μL of the MitoTracker® 
Orange mixture was added manually into each well using a multichannel 
pipette. The plate was incubated for 24 hours at 37oC before being read on the 
Opera® high content confocal imaging system (PerkinElmer). Five fields were 
imaged for each well.  
The experiment was repeated to determine the LOD in 96-well plates. 
The cultures were serially diluted to obtain parasites per well (p/well) in the 
range of 0, 0.6, 6, 60, 600, 6000, 60 000, 600 000 p/well. There were 8 
replicates for each parasite density for P. falciparum Dd2 WT strain and two 
independent experiments were carried out. Eighty microliters of culture at the 
respective parasite density with 4% hematocrit per well was manually 
dispensed using a multichannel pipette into a 96-well plate. Negative control 
that comprised RPMI 1640-media with 4% hematocrit was dispensed into 
column 1. Five μL of MitoTracker® Orange (Cat No. M7511, Life 
Technologies) at 1 mM was added to 10 mL of pre-warmed PBS. 80 μL of the 
MitoTracker® Orange mixture was added manually into each well using a 
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multichannel pipette. The plate was incubated for 24 hours at 37 oC before 
being read on the Opera® high content confocal imaging system (PerkinElmer) 
with 16 fields imaged for each well.  
 
3.4.2.2 Total fluorescence using SYBR®  Green I nucleic acid stain  
Prior to serial dilution, parasitemia of asynchronous P. falciparum 
culture Dd2 WT was determined as an average by microscopic counting of at 
least 1000 cells (10 fields of vision) on Giemsa-stained slides in triplicates. 
The culture was serially diluted to obtain parasites per well (p/well) in the 
range of 0, 2344, 4688, 9375, 18750, 37500 and 75000. There were 12 
replicates in the negative control wells which contain 0 p/well and 14 at each 
parasite density. Thirty microliters of culture at the respective dilution with 
2.5% hematocrit per well was manually dispensed using a multichannel 
pipette into a 96-well plate. 4.8 μL of freshly prepared lysis buffer containing 
5 nM EDTA (1st Base), 1.6% Triton X-100 (Amresco), 20 mM Tris-HCl (1st 
Base), 0.16% Saponin (Sigma-Aldrich) and 0.1% SYBR® Green I nucleic acid 
gel stain (Invitrogen) was added into the each well. Upon the addition of lysis 
buffer, one plate was incubated at room temperature for 30 min and the other, 
incubated for 24 hours before fluorescence reading. The plate was read for 
fluorescence using BioTek Synergy™ 4 hybrid microplate reader (Vermont, 
USA) using a bottom read mode at excitation wavelength of 488 nm and 




3.4.2.3 Quantitative real time PCR (qPCR) platform with 18s rRNA 
primers  
Primers were designed on P. falciparum housekeeping gene, 18s 
ribosomal RNA (PF3D7_0112300), which has at least five copies dispersed on 
separate chromosomes. The forward primer sequence (5’ – 3’) is CTG GTT 
GAT CTT GCC AGT AGT CAT ATG C and the reverse primer sequence (5’- 
3’) is CAC AAG TAT TAG CTA CAG ATT TTC CGT AG. The forward and 
reverse primers sequence an amplicon of 172 base pairs. Four eppendorf tubes 
were filled with a microliter of P. falciparum Dd2 culture at 2% hematocrit 
and 5% parasitemia each. DNA was extracted from 3 eppendorf tubes using 
heat-kill method, which involved boiling the culture at 95oC for 5 minutes and 
the QIAamp DNA Blood Mini Kit (Cat. No. 51106, Qiagen) was used for 
DNA extraction of the last eppendorf tube. The heat-kill method will be used 
for DNA extraction for large-scale mutant screening if qPCR proved to be a 
reliable and efficient method. The pure DNA sample obtained using the 
QIAamp commercial kit will serve as a positive control in the qPCR setup. 
The supernatant removed from the heat-kill method contains DNA from an 
estimated 10 million parasites. The supernatant was serially diluted to yield 
DNA from a range of parasites: 4, 40, 400, 4000, 40 000, 400 000. Complete 
RPMI media containing 2% hematocrit was also subjected to heat-kill and the 
supernatant used as a negative control for the qPCR setup. A 50 μL reaction 
comprises 25 μL of 2× QuantiTect SYBR Green PCR Master Mix (Cat. No.  
204145, Qiagen), 1.5 μL (0.3 μM) of forward and reverse primers, 10.0 μL of 
DNA template and 12.0 μL of RNase-free water. Quantitative real time PCR 
was done using a real time PCR machine (iQ5 Real Time PCR, Bio-Rad) at 
 85 
the following cycling conditions: 95 oC for 15 minutes, 70 cycles of 10 
seconds at 95 oC, 30 seconds at 50 oC and 30 seconds at 72 oC (data 
acquisition step). Melting curve analysis was also done to ensure primer 
specificity at conditions: 95 oC for 2 minutes, 68 oC for 2 minutes with 
stepwise increase at 0.5 oC/s until 90 oC. The qPCR experiment was carried 
out twice with each parasite density being performed in triplicates.  
 
3.4.2.4 Flow cytometry platform with Hoechst and dihydroethidium 
stains  
Prior to serial dilution, parasitemia of asynchronous P. falciparum 
culture Dd2 WT was determined as an average by microscopic counting of at 
least 1000 cells (10 fields of vision) on Giemsa-stained slides in triplicates. 
The parasitemia was estimated to be 5%. The culture was serially diluted to 
obtain parasites per well (p/well) in the range of 0, 12, 49, 195, 782, 3125, 12 
500, 50 000, 200 000 and 800 000. There were 6 replicates in the negative 
control wells which contain 0 p/well and 3 at each parasite density. 40 μL of 
culture at the respective dilution with 4.0% hematocrit per well was manually 
dispensed using a multichannel pipette into a 96-well plate. 20 μL of the 
culture was mixed with 80 μl of PBS to carry out flow cytometry. For flow 
analysis, the mixture was stained with 8µm Hoechst 33342 (Sigma-Aldrich), 
5µg/µl dihydroethidium (Sigma-Aldrich) as described in (221). Diluted blood 
samples were incubated for 20 min at room temperature in the dark. After the 
incubation, 400 µl of cold PBS was added. 1×106 cells were acquired using 
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LSR II flow cytometer (Becton Dickinson) and the data was analyzed using 
FlowJo (Tree Star) software.  
 
3.4.3 Determination of time point for replica plating  
Prior to serial dilution, parasitemia of asynchronous P. falciparum 
culture Dd2 WT was determined as an average by microscopic counting of at 
least 1000 cells (10 fields of vision) on Giemsa-stained slides in triplicates. 
The number of parasites per μL was calculated based on the assumption that 
each red blood cell was infected with only one parasite. The culture was 
serially diluted to obtain parasites per well (p/well) in the range of 0, 0.1, 0.5, 
1, 2, 4, 8, 16 and 32 p/well. 200 microliters of culture at the respective dilution 
with 2% hematocrit per well was manually dispensed using a multichannel 
pipette into a 96-well plate. Complete RPMI media was also included for 
measurement of background signal. There were 6 replicates at each parasite 
density. A total of 4 plates were prepared for data sampling (Day 9, 13, 16 and 
19) over the course of 3 weeks. At each data sampling point, the plate is 
subjected to 3 detection methods – SYBR® Green I nucleic acid stain, c-
SNARF-1 dye and light microscopy. At each parasite density, three replicates 
will be detected with c-SNARF-1 and microscopy while the other three 
replicates will be detected with SYBR® Green I nucleic acid stain. As c-
SNARF-1 dye is a non-cytotoxic dye, which measures pH changes in the 
media, the dye was added into HEPES-free media before adding into the 
wells. Two days prior to data sampling point, complete RPMI media was 
removed from the wells for c-SNARF-1 detection and replaced with HEPES-
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free media containing a 1.0 μM final concentration of c-SNARF-1 dye in each 
well. On the day of data sampling, 20 μL of freshly prepared lysis buffer 
containing 5 nM EDTA (1st Base), 1.6% Triton X-100 (Amresco), 20 mM 
Tris-HCl (1st Base), 0.16% Saponin (Sigma-Aldrich) and 0.1% SYBR® Green 
I nucleic acid gel stain (Invitrogen) was added into the wells and incubated for 
an hour at room temperature prior to SYBR® Green I detection. Giemsa-
stained slides were also prepared from the wells detected with c-SNARF-1 
dye.  
The plate was read for fluorescence using BioTek Synergy™ 4 hybrid 
microplate reader (Vermont, USA) using a bottom read mode at excitation 
wavelength of 488 nm and emission wavelength of 528 nm for the SYBR® 
Green I nucleic acid stain detection. For c-SNARF-1 pH detection assay, the 
wells were measured with the same microplate reader using a bottom read 
mode at excitation wavelength of 488 nm and emission wavelength of 590 nm 
and 645 nm. The result of the c-SNARF-1 dye is a ratio of the signal readout 
at 590/645 nm. 
 
3.4.4 Statistical analysis 
Qualitative data (images) were analyzed and presented as quantitative 
data using custom Acapalla script and algorithms for high content imaging 
experiments. Quantitative data for high content imaging was analyzed and 
graphs were plotted using TIBCO® Spotfire® 4.0.2 (Massachusetts, USA). All 
other graphs were plotted with Microsoft Excel 2010 (Washington, USA).  
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3.5 Genotypic characterization of KAF179-resistant 
mutants 
3.5.1 Parasite extraction and genomic DNA isolation 
Cultures were scaled up to at least 4-5% parasitemia in 100 mL of 
RPMI media at 2.5% hematocrit prior to parasite extraction from the red blood 
cells. The cultures were reconstituted to 10% hematocrit with fresh RPMI 
media and transferred to a 15 mL falcon tube. Lysis buffer (1.5% saponin and 
1.0% bovine serum albumin fraction V in PBS) was added on ice in 10 pellet 
volumes. Upon lysis of red blood cells, indicated by a clear red supernatant, 
the lysed cultures were centrifuged at 2700 × g for 5 minutes at 4 oC. The 
supernatant was removed by aspiration and the cells were washed twice using 
chilled PBS in microcentrifuge tubes. The cell pellets were then stored in -
80oC until genomic DNA isolation with a Blood and Cell Culture DNA mini 
extraction kit (Cat. No. 13323, Qiagen).  
 
3.5.2 Targeted sequencing of P. falciparum Cyclic Amine Resistance 
Locus (PfCARL) gene  
P. falciparum Cyclic Amine Resistance Locus (PfCARL) 
(PF3D7_0321900) was previously reported to be the putative target of 
KAF179 and imidazolopiperazine class of compounds (170). PfCARL gene 
has seven transmembrane domains and 1283 amino acids (non-coding 
sequence: 4969 base pairs). In order to identify the mutations, the entire gene 
was divided into 8 smaller fragments with approximately a 1000 nucleotides 
each. 8 sets of forward and reverse primers were designed with an overlapping 
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region of 100 base pairs between the forward primer of the downstream 
fragment and the reverse primer of the upstream fragment (Table 4).  Melting 
gradient exercise was performed using standard Taq DNA polymerase for all 8 
primer sets using the following cycling conditions: 95 oC for 4 minutes, 95oC 
for 30 seconds, gradient annealing temperature sets (in oC): 42.0, 43.1, 45.0, 
48.1, 51.8, 54.7, 56.7 and 58.0 for 1 minute, 66oC for 1 minute and a final 
extension at 66 oC for 10 minutes. The PCR products were then loaded into a 
1% agarose gel for electrophoresis at 110V for 20 minutes. A thicker gel band 
would indicate a higher amount of PCR product that in turn, indicates an ideal 
annealing temperature. A high fidelity DNA polymerase, Elongase® enzyme 
mix (Cat. No. 10480-010, Invitrogen) was used to amplify the fragments prior 
to sequencing (First Base) for identification of SNPs. A 50 μL reaction 
consists of 200 μM dNTP, 200 nM forward and reverse primers, 2 μL of 
Elongase® enzyme mix, 10 μL of 5× Buffer B, 100ng of DNA template and 
RNase-free water. The cycling conditions were as follows: 95 oC for 4 
minutes, 95 oC for 30 seconds, 58.0  oC for 1 minute, 66 oC for 1 minute and a 
final extension at 66 oC for 10 minutes. Gel electrophoresis was performed on 
all PCR products to ensure that the correct fragment size was amplified prior 
to sequencing.  
Sequencing primers were checked for dimerization and melting 
temperatures using OligoAnalyzer tool (ver 3.1, Integrated DNA 
Technologies). Sequencing results were aligned and analyzed using Vector 
NTI® Advance Software (ver 11.0, Life Technologies).   
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Table 4 Sequencing primers for PfCARL gene 
Primer name Sequencing primers (5’ – 3”) No. of base pairs (bp) Tm (oC) Amplicon (bp) 
ssPfCarlF1 ATG AAC AGG ATT ACG CTT TAT GAT TTT ATA ATT G 34 55.1 
718 
ssPfCarlR1 GAA GAT TCA TCA AGG GAC TTC TCC 24 55.1 
ssPfCarlF2 CCA AAG AAG AAA TAT AAG GTG AGG G 25 53.4 
699 
ssPfCarlR2 CCA ATT TTC TTT TTC CAT ATC ATA AAT ATT ATC AC 35 53.1 
ssPfCarlF3 GTG TAA ATA ATA ATA ATG ATG ATG ATG AAG AAA AAG G 37 54.4 
798 
ssPfCarlR3 CTA CAA ATT CAT TAG AAT AAT TTT CGC CTT TG 32 54.3 
ssPfCarlF4 GGG AAA ATG TGT GAA TAT GTC TAA TAA GG 29 54.2 869 
 ssPfCarlR4 CAT ATA ATT TCA TAA AAG GCT GGG CTC 27 54.4 
ssPfCarlF5 GAA CGA AAA TAA TAA GAA GGA TTC AAA GAA TAT GAA G 37 55.6 880 
 ssPfCarlR5 GTA TGG TAA ATT TAA GTA CTA CAC TAT AGA AAG G 34 53.8 
ssPfCarlF6 GAC ATC ATG CAG ATT CAT TTT ATT ATC AG 29 53.2 888 
 ssPfCarlR6 GTA CTT TAA CAA ATA AGA ATG CTT ACA CC 29 53.1 
ssPfCarlF7 CAT TTT TTA GTA TTT CCA GTT GGC TGG 27 55.0 789 
 ssPfCarlR7 GGA ACA TAC TAT CAA GGT TAC GAC TG 26 54.9 
ssPfCarlF8 CAG TTC CGT GTA AAA ATA TTT TTT CCT TTT C 31 54.5 716 
 ssPfCarlR8 TTA TAA TGC ACT AAT GTC ATC ATA AGG TTT TTT C 34 55.0 
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3.5.3 Whole genome sequencing and identification of resistance genes 
DNA libraries for each gDNA sample were prepared for sequencing 
using the Nextera XT kit (Cat. No. FC-131-1024, Illumina), following 
standard dual index protocols. Libraries were clustered and ran on the Illumina 
HiSeq 2500 using the RapidRun mode, 100 base pairs sequenced in depth on 
either end.  Paired-end reads were aligned to the P. falciparum 3D7 reference 
genome (PlasmoDB v. 11.0) as previously described (222). To identify 
possible CNVs, interval depth for each gene was calculated using GATK 
diagnoseTargets. To reduce noise levels, interval depths were normalized 
across each sample, and then calibrated against four 3D7 parent samples 
sequenced previously at Winzeler’s laboratory at UCSD. Finally, samples 
were compared to their respective parents, and normalized intervals depth 
ratios ≥2 were flagged. All SNV and CNV mutations were visually confirmed 
using Integrative Genomics Viewer (IGV). 
 
3.5.4 Validation of genes associated with resistance  
The individual mutations identified from the in vitro selection, were 
confirmed by introducing those mutations into parent Dd2 parasites using the 
CRISPR/Cas9 system, similar to (223). Briefly, CRISPR in P. falciparum 
requires transfecting two constructs, one with Cas9 and the guideRNA, whose 
expression was driven by a T7 RNA polymerase promoter, the other with the 
modified template (with both the desired nucleotide replacement and the Cas9 
cut site mutated – the guideRNA site was changed to retain amino acid 
sequence), and T7 RNA polymerase itself, into Dd2 parasites which had been 
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synchronized to the ring-stage via sorbitol synchronization for electroporation 
(310kV, 950uF).  Parasites were then selected for 6 days with WR99210 and 
BSD (markers on the plasmids), and then with 5 × IC50 KAF179. The time to 
recover polyclonal strains was approximately 30 days from initial transfection. 
Once grown, parasitic lines were cloned by limiting dilution, then editing was 
validated by PCR and Sanger sequencing. Validated strains with the desired 
mutation were then assayed for resistance to KAF179 using the SYBR® Green 
I assay described previously. 
The guide RNA (listed as gRNA+PAM) used for PfUGT 
(PF3D7_1113300) was GAAGAGCTCAGGTATGTTTTGG, while the 
guideRNA sequence for PfACT (PF3D7_1036800) was 
GAAAAAGTTTTTAAAATTCTGG. Replacement templates were the full-
length coding region for the UDP-galactose transporter and 1kb in length 
(with ~500bp on either side of the mutation) for the acetyl-CoA transporter, 
and mutations in the replacement template, both for the gRNA target site and 
the desired SNV were introduced via the Quikchange II kit (Agilent 
Technologies). Primers for the replacement templates were as follows:  
UDP-Galactose F (NheI+Primer) 
GCGGTCAGCATGGTAAAAATACAGAAGAGCTCAGG,  
UDP-Galactose R (AAtII+Primer) 
CTTCTTGGCGGCTCATTTATTTTTACTTTGAACTTTTTTGGATTG,  
Acetyl-CoA F (NheI+Primer) 
GCGGTCAGCGGTGTACCAATTGGAGTTTCATCCG, and  
Acetyl-CoA R (AatII+Primer)   
GGGCCCGACGTCCTCTACAGAAGCAAATGGCAAACGG. 
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3.6 Phenotypic characterization of KAF179-resistant 
mutants   
3.6.1 Drug sensitivity assay using SYBR® Green I 
IC50 assay was carried out on a 384-well plate and each drug 
compound was tested in duplicates with 10 concentration points each. The 
highest concentration of the compound was 10 μM and three-fold serial 
dilutions were carried out to yield 10 concentration points. 0.1% working 
concentration of DMSO was used as the negative control and 10 μM 
artemisinin was used as the positive control. Each well was spotted with 50 nL 
of compound using a Mosquito® nanoliter dispenser (Cambridge, UK). 50 μL 
of culture (P. falciparum Dd2 or resistant mutants) at 0.3% parasitemia and 
2.5% hematocrit was dispensed manually into the wells. The plate was 
incubated in an incubator with reduced oxygen environment at 37 oC for 72 
hours. After incubation, 10 μL of freshly prepared lysis buffer (5 nM EDTA 
(1st Base), 1.6% Triton X-100 (Amresco), 20 mM Tris-HCl (1st Base), 0.16% 
Saponin (Sigma-Aldrich) and 0.1% SYBR® Green I nucleic acid gel stain 
(Invitrogen)) was added to each well. Upon addition of the lysis buffer, the 
plate was incubated for another 24 hours in the dark at room temperature. The 
plate was read for fluorescence using BioTek Synergy™ 4 hybrid microplate 
reader (Vermont, USA) using a bottom read mode at excitation wavelength of 
485 nm and emission wavelength of 528 nm. The level of resistance of 12 
KAF179 drug-resistant mutants as compared to the parental Dd2 WT strain 
was calculated based on 5 biological experiments (n=5) with 2 replicates at 
each concentration.   
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IC50 curves were plotted using a non-linear regression model: a four-parameter 
dose-response curve with a variable hillslope on GraphPad Prism 5.02 
(California, USA). IC50 values were obtained by curve fitting data points with 
a sigmoidal dose-response model: 
Response = bottom + (top-bottom)/(1 + (IC50/dose)slope) 
The drug concentrations were log-transformed (x-axis) and the response (y-
axis) was calculated from data normalized based on the following equation: 
100 – 100* (Max-value)/(Max – Min)  
Max value: Average absolute fluorescent signal of negative control (DMSO) 
Min value: Average absolute fluorescent signal of positive control (Artemisinin) 
Value: Average absolute fluorescent signal at a particular drug concentration 
 
3.6.2 Cross resistance studies  
P. falciparum Dd2 wild-type (WT) and 12 KAF-179 resistant mutants 
were tested for cross-resistance against 62 imidazolopiperazine chemical 
analogs and 67 compounds of various scaffolds, of which 10 compounds are 
standard antimalarial drugs using the SYBR® Green I drug sensitivity assay. 
The dose response was carried out in 10 concentrations for each chemical 
analog; with the top dose starting at 10 μM and three-fold serial dilutions to 
obtain 10 concentration points. In each plate, there were 32 wells that 
contained either 100% DMSO or 10 mM artemisinin, which served as 
negative controls and positive controls respectively. In addition, both 
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artemisinin and KAF179 were included as controls for dose-response in all 
plates.  
For the chemogenomics analysis for cross-resistance with 
imidazolopiperazine chemical analogs and non-imidazolopiperazine 
compounds, the mean IC50 value was used for mutants that share the same 
SNP. The biological activity data was converted to pIC50 values and fold-
shifts were calculated for the mutants relative to the wild type. The data is 
clustered using software R 3.2.0 using the following method: hclust(d, method 
= "complete", members = NULL). The complete linkage method finds similar 
clusters with Euclidean distance between activity profiles. All other graphs 
were plotted with Microsoft Excel 2010 (Washington, USA).  
 
3.6.3 Growth kinetics  
P. falciparum Dd2 WT culture and three mutants that target the UDP-
galactose transporter (Mutant A9), cyclic amine resistance locus (Mutant D6) 
and acetyl-CoA transporter (Mutant B3) were kept in continuous culture for at 
least a week prior to the start of the experiment. All cultures were 
synchronized with 5% sorbitol and MACS purification. The WT and mutant 
strains at ring stage were adjusted to an initial parasitemia of 0.1% and 3% 
hematocrit in 10 mL cultures on day 0. Two independent experiments were 
performed with each strain carried out in triplicates. Quadruplicates were 
performed for mutant lines in the absence of KAF179 and replicates for 
mutant lines in the presence of KAF179. Parental Dd2 strain was cultured in 
the absence of drug in six replicates. A 20 μL sample was taken daily for flow 
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cytometry analysis throughout the course of the experiment, namely at 0h, 
24h, 48h, 72h and 96h. Media changes were performed daily from 0h to 24h 
and twice daily on 48h to 96h. Each sample was stained with 5 mg/mL 
dihydroethidium (Sigma) and 8 nM of Hoechst 33342 (Sigma) as previously 
described by Malleret et al (221). Flow cytometry analyses were done using 
FlowJo software (Tree Star).  
 
3.6.4 Competitive growth kinetics  
P. falciparum Dd2 WT culture was mixed separately with three 
mutants that target the UDP-galactose transporter (Mutant A9), cyclic amine 
resistance locus (Mutant D6) and acetyl-CoA transporter (Mutant B3) in 
Mutant: WT ratios of 1:10, 1:1 and 10:1. The mutant and WT mixed cultures 
were adjusted to have an initial parasitemia of 1% in a 12 mL culture at 4% 
hematocrit. The parasites were passaged in a 1 in 6 dilution every other day 
for 10 generations. Genomic DNA was also harvested every other day using 
the QIAamp DNA Blood Mini Kit (Cat. No. 51106, Qiagen). The genomic 
DNA was subsequently used for digital PCR to amplify an amplicon between 
75-150 base pairs within the target of interest containing the mutation SNP. 
The droplet digital PCR data was used to analyze the frequencies of WT and 
mutant strain alleles, which in turn, reflects the growth kinetics of the WT and 
mutant strains.  
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3.6.4.1 Primers for competitive growth kinetics  
Specific sequencing primers for droplet digital PCR were designed to 
amplify an amplicon between 75-150 base pairs within the gene of interest 
containing the mutation SNP. The DNA sequence for the genes of interest 
were accessed from PlasmoDB based on their accession numbers (Table 5). 
The Taqman probes (Integrated DNA Technologies) used to measure the 
frequencies of WT and mutant strain alleles are found within the amplicon and 
differ only at the mutation SNP.  The probes are designed with the WT probe 
having a 5’ – HEX dye, the mutant probe having a 5’ – FAM dye and both 
probes end with a 3' Iowa Black Quencher.  
 
3.6.4.2 Droplet Digital PCR (DDPR) analysis 
20 μL DDPCR reactions were performed with 2 ng of genomic DNA 
as template with DDPCR supermix for probes (no dUTP).  Primer and probe 
concentrations were 900 and 250nM, respectively. Primers and probes were 
synthesized by Integrated DNA Technologies. WT probes were labelled with 
HEX dye and mutant probes labelled with FAM dye on 5’ end.  Emulsions 
were generated in the DDPCR droplet generator and then transferred to an 
Eppendorf TwinTec PCR plate. Emulsions underwent 40 cycles of 
amplification in a Bio-Rad C1000 under the following condition: 95ºC 10 
minutes, a two-step amplification at 94ºC 30 seconds and annealing 
temperature for 1 minute for 40 cycles, 98ºC for 10 minutes, and finally a 
12ºC hold. Optimal annealing temperatures were 57.6ºC for PfCARL and 
60ºC for PfACT as determined by a gradient PCR. Droplets were read on a 
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QX150 reader. Droplet populations were manually gated for double-negative, 




Table 5 Sequencing primers and probes for competitive growth experiment 
*stop gained mutation 
Gene of interest 


















































3.6.1 Morphology  
The morphology of the KAF179-resistant mutants was examined and 
imaged using Giemsa-stained slides under the light microscope (Nikon TS100 
and DS-Fi2 camera) with 100× magnification.  
 
3.6.2 Phenotypic reversion of mutations to wild-type 
All 12 KAF-179 resistant mutants were cultured without drug pressure 
for 4 months. Phenotypic reversion was defined by a change in IC50 values 
and morphology. IC50 assays using the SYBR® Green I drug sensitivity assay 
were carried out at 2nd, 3rd and 4th month to evaluate changes in IC50 values.  
 
3.6.3 Cellular localization 
3.6.3.1 Plasmids and transfections 
The full-length coding sequence for PfUGT (PF3D7_1113300) was 
amplified from genomic DNA using primers p4794 / p4795 and subcloned 
into a pDC2-based expression vector downstream of the P. berghei EF1alpha 
promoter and mRFP, yielding the expression plasmid pDC2-PbEF1alphapro-
mRFP-PfEGT-attP-BSD. This expression plasmid was transfected into the 
NF54-attB parasite line together with the pINT plasmid to use attP×attB 
integrase-mediated recombination (224). A plasmid (pDC2-GFP-Sec12-
hDHFR) expressing the ER marker, GFP-PfSec12 was co-transfected with 
mRFP-PfUGT, and the parasites selected with 2.5 nM WR99210 / 2 µg/ml 
Blasticidin / 250 µg/ml G418 (225). 
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3.6.3.2 Primers 




p4795 (UDP-galactose transporter (PF3D7_1113300) reverse, stop+XhoI) 
CCCTCGAGTCATTTATTTTTACTTTGAACTTTTTTGGATTG 
 
3.6.3.3 Fluorescence microscopy imaging  
Live cell imaging of parasites expressing GFP- and mRFP-tagged 
proteins was performed on a Nikon TiE PFS inverted microscope equipped 
with a CoolSNAP HQ2 monochrome camera. Aliquots (100 µL) of parasite 
culture were washed once with RPMI-1640 media lacking Albumax II, 
transferred to MatTek poly-L-lysine coated glass-bottom culture dishes, and 
overlaid with 1 ml of media containing 2 μg/ml Hoechst 33342 (Sigma) to 
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4 OPTIMIZATION OF CULTURE 
CONDITIONS  
 
4.1 Parasite yield  
P. falciparum Dd2 parasites were seeded at 0.2% parasitemia at 2% 
hematocrit in 50 mL of RPMI -1640 complete media. A pilot experiment was 
carried out to compare three different culturing conditions – static, roller bottle 
and orbital shaker. The results showed an increase in parasitemia in the first 48 
hours for all three experimental arms, and cultures kept in suspension by the 
orbital shaker showed the highest parasite yield (Fig. 4). The cultures were 
propagated by splitting them in 1:10 ratio at every cycle with the addition of fresh 
culture media and washed erythrocytes. Over the next 48 hours, it was observed 
that parasitemia continued to increase for cultures in static and shaker conditions 
while it decreased drastically for the cultures in the roller bottle system. At the 
end of the third cycle, it was found that cultures in the roller bottle system 
underwent lysis while the parasitemia of cultures in the orbital shaker showed a 
45.4% higher parasite yield than static cultures (Table 6). Some possible reasons 
for the lysis of red blood cells in the roller bottle system include the rapid rotating 
speed of the roller bottle and the plastic coating of the roller bottle, which may be 
unfavourable for culturing of parasites. The rapid rotating speed of the roller 
bottle potentially impeded the invasion of merozoites into red blood cells as well 
as caused the lysis of red blood cells. Based on the results of this pilot 
experiment, the roller bottle system was excluded from subsequent experiments. 
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As shown in Fig. 5, it was evident that cultures maintained in suspension 
by continuous orbital shaking showed significantly higher propagation rates 
compared to static cultures. The results in Table 7 have shown that cultures 
maintained on the orbital shaker achieved higher parasite yield compared to static 
cultures on day 2 (140.59%  ± 15.25%), day 4 (150.89% ± 37.74%) and day 6 
(165.19% ± 25.22%). Parasitemia of shaker cultures relative to that of static 
cultures (p = 0.0009, 0.0207 and 0.0043 for days 2, 4 and 6 respectively) were 
significantly different (p < 0.05). It was postulated that maintenance of cells in 
suspension resulted in uniform distribution of nutrients to all the parasites, 
maximized the probability of merozoites infecting uninfected erythrocytes, 
thereby increased growth and parasite yield (216).  
 
 
Figure 4 Comparison of parasitemia between static and suspension (roller 
bottle, shaker) cultures  
Cultures were observed for three lifecycles (6 days). Experiment was carried out 
in duplicates for each experimental arm.  
 
 
Parasitemia of static and suspension cultures





















Figure 5 Parasitemia of suspension (shaker) cultures expressed as a 
percentage of static cultures  
Experiments were carried in duplicates in both independent experiments (n=4). 
Error bars are expressed in standard error mean (SEM). 
 
Table 6 Comparison of parasitemia between static and suspension (roller 
bottle, shaker) cultures 
Cultures were observed for three cycles (6 days). Experiment was carried out in 
duplicates for each experimental arm. 
 
Table 7 Parasitemia of suspension (shaker) cultures expressed as a 
percentage of static cultures  
Experiments were carried in duplicates in both independent experiments (n=4). 
Data is expressed in mean ± s.d. *p = 0.0009, 0.0207 and 0.0043 for days 2, 4 and 
6 respectively. 
 Parasitemia (%) 
Time (Days) Static Roller bottle Shaker 
0 0.20 0.20 0.20 
2 2.82 1.19 3.66 
4 3.21 0.41 3.93 
6 2.91 0.0 4.23 
Time (Days) Parasitemia in shaker culture/ Parasitemia in static cultures (%)* 
0 100.00 
2 140.59 ± 15.25 
4 150.89 ± 37.74 
6 165.19 ± 25.22 
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4.2 Synchrony of cultures  
P. falciparum Dd2 WT parasites were freshly thawed and propagated in 
2% hematocrit in 50 mL of RPMI -1640 complete media for one cycle prior to 
seeding. Parasitemia and blood stages of original cultures were determined by 
microscopic counting of at least 1500 cells on Giemsa-stained slides prior to 
seeding of cultures in the respective culture conditions. At day 0, cultures were 
synchronous with all infected red blood cells at the ring stage in both static and 
suspension cultures. The results in Fig. 6 have shown that static cultures became 
asynchronous at an accelerated rate compared to shaker cultures. By the third 
cycle, it is evident that static cultures had lost synchrony as seen from the 
presence of all three blood stages in proportionate percentages (Ring: 22.6% ± 
5.63%. Trophozoites: 33.04% ± 13.22%, Schizonts: 44.36% ± 17.29%) (Table 8) 
while shaker cultures remained more synchronous with a higher proportion of 
ring-stage parasites (Ring: 80.69% ± 5.10%, Trophozoites: 15.09% ± 6.22%, 
Schizonts: 4.23% ± 1.53%) (Table 8). The uneven distribution of nutrients to 
parasites embedded in different layers of the static culture may have affected the 
development rate of the parasites. It is tempting to postulate that parasites that 
received sufficient nutrients develop to the next stage (e.g. from ring stage to 
trophozoites stage) at a rate that commensurates with the 18-hour window for 
each stage within the intraerythrocytic cycle of the parasite while those that did 
not receive adequate nutrients possibly took a longer time for development to the 
next stage. This could explain the asynchrony and potential reduction in growth 




Table 8 Synchronicity of static and suspension (shaker) cultures measured by  
the proportion (%) of blood stages (ring, trophozoites and schizonts)  
 
Experiments were carried in duplicates in both independent experiments (n=4). Data 





Figure 6 Synchronicity of static and suspension (shaker) cultures measured 
by the proportion of blood stages (ring, trophozoites and schizonts) 
Experiments were carried in duplicates in both independent experiments (n=4). 
 
 
 Static         Suspension (Shaker) Time  
(Days) 
  Ring 
 (%) 
    Troph 
  (%) 
  Schizont 
  (%) 
Ring 
(%) 
    Troph 
  (%) 
   Schizont 
  (%) 
  0 100 0 0 100 0 0 
  2    88.12 ± 8.71 
11.31 ± 
8.22 
  0.57 ± 
1.14 
  95.06 ±  
6.74 
  4.49 ±  
5.93 
   0.45 ±  
0.89 
  4   72.56 ± 9.29 
21.34 ± 
1.85 
  6.1 ± 
7.60 
  93.22 ±  
3.22 
   5.53 ±  
2.00 
    1.25 ± 
 1.56 
  6   22.6 ± 5.63 
33.04 ± 
13.22 
  44.36 ± 
17.29 
  80.69 ±  
5.10 
   15.09 ±  
6.22 
    4.23 ±  
1.53 
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4.3 Prevalence of multiple infections  
The results in Fig. 7(a) showed the effect of stasis on the prevalence of 
multiple infections (i.e. more than one parasite in one red blood cell). Singlet 
refers to the presence of one parasite per red blood cell, doublets refer to two 
parasites per red blood cell, triplets refer to three parasites per red blood cell and 
quadruplets refer to four parasites per red blood cell. The drastic decrease in 
proportion of singlets caused by stasis was observed in the first cycle (69.8% ± 
2.0%) whereas a large proportion of red blood cells remained singly infected 
(96.8% ± 1.2%) in the shaker culture carried out in parallel to the static culture 
(Table 9). Although results in Fig. 7(a) showed a slight increase in proportion of 
singlets in the subsequent two cycles for the static cultures, the proportion of 
singlets remained consistent around 70.0% (Table 9(a)). As seen from Fig. 7(b), 
the prevalence of multiple infections remained consistently less than 3% of the 
total infected erythrocytes over three cycles. It was clear that maintenance of 
cultures in suspension reduced the prevalence of multiply infected erythrocytes. A 
likely reason for the higher occurrence of multiply infected erythrocytes in static 
cultures would be the proximity of red blood cells in the erythrocyte layer that 
resulted in multiple invasion of one red blood cell by multiple merozoites upon 












Figure 7 Distribution of singly- (singlet) and multiply- infected (doublets, 
triplets, quadruplets) expressed as a percentage of total infected cells (500 
cells)  
(a) static condition and (b) suspension (shaker) condition 
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Table 9 Distribution of singly- (singlet) and multiply- infected (doublets, 
triplets, quadruplets) red blood cells expressed as a percentage of total 
infected cells (500 cells)  
(a) static condition and (b) suspension (shaker) condition. Experiments were 
carried in duplicates in both independent experiments (n=4). Data is expressed in 
mean ± s.d. 
Paired two-tailed t-test comparisons of each category of multiply infected cells at 













0 100 0 0 0 
2 69.8 ± 2.0 21.1 ± 1.9 6.5 ± 0.7 2.6 ± 0.3 
4 70.4 ± 2.9 21.5 ± 1.7 6.4 ± 1.5 1.7 ± 0.3 












0 100 0 0 0 
2 96.8 ± 1.2 2.3 ± 0.7 0.7 ± 0.5 0.1 ± 0.1 
4 97.9 ± 0.8 1.9 ± 0.9 0.1 ± 0.1 0 




















5 STAGE-SPECIFICITY OF 
IMIDAZOLOPIPERAZINES 
 
Current development of clinical drug candidates often emphasizes the 
stage (liver, asexual or sexual blood stages) at which the compound acts 
within the Plasmodium parasite lifecycle. Details on stage-specificity within 
the asexual intraerythrocytic blood stage of preclinical drug candidates are 
usually under reported. The information on stage-specificity of antimalarial 
drugs would enhance understanding on how different drugs affect disease 
progression; be it a delay in progression to the next stage or inhibition of 
schizont rupture and reinvasion (226). This would aid in the rational design of 
combination therapies for maximum efficacy. In the case of artemisinin 
resistance, the discovery of the presence of  “dormant” parasites where ring-
stage parasites adopt a quiescence state that enable them to withstand drug 
pressure further highlights the importance of stage-specificity within the 
intraerythrocytic cycle (140, 141).  
It was reported that the clinical drug candidate, KAF156 belonging to 
the imidazolopiperazine class has activity against P. falciparum asexual 
intraerythrocytic forms, sexual gametocytes and liver stage schizonts (170, 
178, 179). However, the stage-specificity of KAF156 within the 
intraerythrocytic cycle (ring, trophozoite, schizont) remains unknown.  In this 
thesis, KAF179 was used to select for drug-resistant mutants. KAF179 is 
structurally similar to KAF156, differing only by a –chloro to –fluoro 
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substitution on the benzene ring (Fig. 8). Given the potential of KAF156 as a 
possible causal prophylactic and transmission-blocking drug, it is of interest to 
investigate the stage-specificity within the intraerythrocytic blood stage.  
Briefly, an asynchronous culture was subjected to alternate MACS 
purification and 5% sorbitol synchronization for three cycles prior to the start 
of the experiments. MACS purification allowed the separation of pure 
schizonts from a mixture of rings and trophozoites while 5% sorbitol 
synchronization yielded ring stage parasites with the other stages eliminated. 
Alternate synchronization with both methods resulted in a tight synchronous 
culture with a “4-6 hour window” (Fig. 9). Double synchronization with 5% 
sorbitol was not performed, as that would yield late rings instead of early 
rings. The parasites at the respective stages were exposed to artemisinin, 
pyrimethamine, mefloquine, KAF156 and KAF179. The incubation times 
were as follows: early rings (6 and 24 hours), rings (18 hours), trophozoites 
(12 hours) and schizonts (12 hours). The compounds were washed off after 
incubation. Upon the removal of the compounds, the stage-specific parasites 
were cultured in complete RPMI media before being assessed with 
MitoTracker® Orange for their IC50 determinations at 24 hours and 72 hours. 
A schematic representation of the experiment can be found on Fig. 10.  
The IC50 values presented on Fig. 11 and Table 10 were based on the 
criterion of a minimum of 70% inhibition for the IC50 to be plotted, otherwise 
the IC50 was assumed to be 10 μM. The readout time points (24 hr and 72 hr) 
allowed parasites to recover post-exposure to the drugs. The speed of action of 
the compounds could also be inferred from the difference in IC50 values 
between the two time points. The results have shown that artemisinin was fast-
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acting on all intraerythrocytic blood stages (early ring, ring, trophozoite and 
schizont). Artemisinin was highly efficacious with nanomolar potency (<100 
nM) for all stages, the difference in IC50 values were within three to five-fold. 
The results seemed to suggest that artemisinin was more active on rings and 
schizonts than trophozoites. This observation was in concordance with the 
findings by Skinner et al (227). Their stage-specific data also showed that 
artemisinin achieved 100% inhibition within 6-8 hours, which was consistent 
with our findings. Although a study by Klonis et al reported that artemisinins 
were more active on the trophozoite- than ring-stage parasites due to the 
absence of hemoglobin reuptake, they also showed that a subpopulation of 
early rings were hypersensitive to artemisinin (139). A closer look at the 
experimental protocol provided an insight to the possible difference in 
observations. Klonis et al exposed the cultures to short drug pulse (1-6 hr), 
which closely mimics clinical exposure. Their data demonstrated that 
artemisinin was inactive when exposure time was one hour but active on ring 
stage when parasites were exposed to the drug for 6 hours, which was similar 
to our observations. The longer exposure times used in our experiment could 
explain the difference in observation (139). A study by ter Kuile et al has also 
found that stage dependency of drug effects decreased with increasing 
concentrations and exposure times (228).  
Pyrimethamine and mefloquine were rapid acting on schizonts as 
shown in Fig. 11. The IC50 values of pyrimethamine and mefloquine on 
schizonts at 24-hr readout were 97.54 nM and 181.06 nM respectively (Table 
10). The stage specificity of these two compounds was in agreement with 
published work (227, 229, 230). These two compounds were slow acting on 
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other stages of the intraerythrocytic cycle. Pyrimethamine was relatively less 
efficacious (micromolar potency) compared to the other drugs. The 
imidazolopiperazine compounds (KAF156 and KAF179) were fast-acting on 
the trophozoites and in particular, the schizonts. The IC50 values of KAF179 
and KAF156 on schizonts at 24-hr readout were 59.04 nM and 57.64 nM 
respectively (Table 10).  They were the most effective against the schizonts as 
compared to the other standard antimalarial drugs tested. Similar to 
pyrimethamine and mefloquine, the imidazolopiperazine compounds have a 
delayed effect on the rings as seen by their activity at 72-hr (Fig. 11).  
The results at 72-hr demonstrated the slower rate of action on certain 
stages by the antimalarial compounds. However, the IC50 values presented at 
72-hr may not truly reflect the stage-specific effects of the drug. The parasites 
might have accumulated drug within itself that could have affected other 
stages when the parasites progressed to at least a full cycle within the 72 
hours. The parasites would likely start to develop asynchronously which could 
affect the accuracy of the IC50 values.  
To summarize, the imidazolopiperazine compounds (KAF156 and 
KAF179) were fast-acting on schizont stage of the intraerythrocytic cycle. 
This information echoed the extensive morphological changes in late 
trophozoite to schizont stages of the KAF179-resistant mutants. A shorter 










Figure 8 Chemical structures of imidazolopiperazine compounds  





Figure 9 Giemsa-stained thin smears under light microscopy 










Figure 11 Stage-specific IC50 values (µM) for standard antimalarials and 
imidazolopiperazine compounds  
Standard antimalarial drugs: Artemisinin, Pyrimethamine and Mefloquine 
Imidazolopiperazine compounds: KAF156 and KAF179
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Table 10 Stage-specific IC50 values (nM) for standard antimalarials and imidazolopiperazine compounds 
Standard antimalarial drugs: Artemisinin, Pyrimethamine and Mefloquine 
Imidazolopiperazine compounds: KAF156 and KAF179 
 
 IC50 in nM ± S.D. at 24-hr readout 
 Early Ring_6 hr Early Ring_24 hr Ring Troph Schizont 
Artemisinin  17.81 ± 7.99 14.07 ± 7.21 32.39 ± 1.22 90.02 ± 16.79 65.13 ± 10.96 
Pyrimethamine 10 000 ± 0.0 10 000 ± 0.0 10 000 ± 0.0 10 000 ± 0 97.54 ± 33.50 
Mefloquine 10 000 ± 0 10 000 ± 0 10 000 ± 0 10 000 ± 0 181.06 ± 60.96 
KAF179 10 000 ± 0 10 000 ± 0 10 000 ± 0 5018 ± 49.84 59.04 ± 40.06 
KAF156 10 000 ± 0 10 000 ± 0 10 000 ± 0 5006 ± 65.50 57.64 ± 18.99  
 
 IC50 values in nM ± S.D. at 72-hr readout 
 Early Ring_6 hr Early Ring_24 hr Ring Troph Schizont 
Artemisinin  29.99 ± 10.99 15.93 ± 1.45 35.57 ± 9.81 69.54 ± 21.38 118.58 ± 49.05 
Pyrimethamine 1839 ± 724.83 1409 ± 0.57 1479 ± 78.02 339.50 ± 13.20 1803 ± 1539 
Mefloquine 269.84 ± 100.06 151.45 ± 33.82 217.52 ± 13.83 134.91 ± 9.35 5153 ± 241.45 
KAF179 67.11 ± 17.93 29.07 ± 3.37 43.55 ± 3.55 30.87 ± 1.54 101.46 ± 42.85 









FOR SELECTION OF KAF179- 
RESISTANT MUTANTS
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6 PROTOCOL DEVELOPMENT FOR 
SELECTION OF KAF179 -
RESISTANT MUTANTS  
 
6.1 Novel strategy for selection of KAF179 resistant mutants  
A total of 12 putative drug-resistant mutants were selected with 
KAF179 using the novel strategy for selection of drug resistant mutants as 
described in Fig. 12. Briefly, a large inoculum of P. falciparum parasites (109) 
was exposed to KAF179 at 2 × IC99 for 2 lifecycles (96 hours). As a result of 
massive cell death, a large amount of cell debris remained present in the flask. 
A 63% Percoll purification step was performed on day 4 post-exposure to 
KAF179. New complete RPMI media and fresh blood were added to the 
purified infected red blood cells to make up to 2.5% hematocrit in the culture. 
The culture was placed into four 96-well plates and kept under constant drug 
pressure of KAF179 at 2 × IC99 for 25 days.  
After approximately 3 weeks in culture, a replica plate of plate 1 was 
prepared by transferring 100 μL of culture per well into a new 96-well plate. 
Optimization of detection methods (Fig. 15), which will be described in detail 
in the next section, has demonstrated the use of SYBR® Green I nucleic acid 
stain as a good method for higher throughput identification of parasites using 
fluorescence. A lysis buffer containing the SYBR® Green I nucleic acid stain 
was added into the replica plate for identification of wells which contained 
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parasites or possibly resistant parasites. However, it was difficult to discern 
which wells truly contain parasites as all wells were shown to have a positive 
signal. Cellular debris could have contributed to the false positive signals (Fig. 
14). The lack of sensitivity of the SYBR® Green I nucleic acid stain resulted in 
the use of Giemsa-stained smears as a method of detection (Fig. 14). Two 
plates out of four plates seeded with culture were found to be contaminated 
and were discarded. A total of 12 putative resistant mutants were found in the 
remaining two plates. Seven mutants (Mut A3, A9, B6, D6, E8, D2 and B3) 
were found on plate A and five mutants (Mut H5, H8, A2, B5 and D8) were 
found on plate B.  
The 12 putative mutants were scaled up and tested for drug sensitivity 
to KAF179. All 12 mutants exhibited a rightward shift of their IC50 curves as 
compared to that of the parental Dd2 strain, thereby confirming their drug 
resistance to KAF179. The data for their level of resistance will be presented 
later in chapter 8.1.  
The novel strategy presented in Fig. 12 demonstrates distinct 
differences from the conventional single-step and stepwise methods presented 
in Fig. 13. These distinct differences include the usage of Percoll purification 
to remove the bulk of the cellular debris and the immediate upfront dilution of 
the cultures into 96-well plates as opposed to conventional methods where 
limiting dilution is the final step. The novel strategy adopted an approach from 
bacteriology, where upfront dilution of the cultures would allow one resistant 
clone to reside in each well; which allow the selection of clones that is akin to 
picking colonies on an agar plate. From an evolutionary perspective, this 
approach is advantageous for resistant mutants that possess a high fitness cost. 
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The compartmentalized well enabled the less fit resistant mutant to growth and 
harness nutrients without the competition from the wild type or fitter resistant 
mutants. The competition between the wild type strain, fit and less fit resistant 
mutants could be intense if resistance was evolved in the flasks over 60-90 
days, which is approximately 30 to 45 lifecycles of the P. falciparum parasite 
(Fig. 13). This could be the explanation for discovery of the two novel genes 
associated with KAF179 resistance, PfUGT and PfACT with the novel 
strategy used for the resistance selection with KAF179 and the failure of the 
conventional methods to do so, as the less fit resistant mutants which harbour 
SNPs against these two targets were outcompeted.  
While this novel strategy has its advantages of (a) generating more 
resistant mutants in a shorter period of time, (b) selecting for mutants with 
variable fitness costs and (c) identifying novel resistance genes, it is not 
without limitations. The detection of putative resistant parasites residing in the 
wells is undoubtedly the most challenging part of the resistance selection 
process. Prior to the resistance selection with KAF179, it was determined that 
SYBR® Green I nucleic acid stain with high content imaging was an ideal for 
higher throughput detection of parasites as the LOD was 400 parasites per 
well. The data for the optimization of detection methods will be discussed in 
the next section. However, during the course of the resistance selection with 
KAF179, many false positives were detected with SYBR® Green I nucleic 
acid and light microscopy was used instead. Despite light microscopy being 
the gold standard for detection of parasites, the process was laborious and 
required a skilled person to accurately identify a true parasite from cellular 
debris. It is important to note that the time taken for resistance selection is 
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dependent on the drug and the concentration used. This is exemplified in the in 
vitro selection for artemisinin-resistant mutants that took 5 years and 
atovaquone mutations, which arose readily in vitro (52, 120). 
In summary, the novel strategy with the inclusion of a purification step 
and immediate plating of P. falciparum cultures into 96-well plates was highly 
successfully in selecting a large number (12) of KAF179 mutants compared to 
conventional methods. However, there is a need to identify a sensitive and 
efficient detection method. It would be ideal to have a non-toxic stain that 
enables the monitoring of parasite growth over time. The next section will 














Figure 14 Giemsa-stained slides of P. falciparum parasites exposed to 
KAF179 
DPI: Days Post-Infection.  





6.2 Limit of detection for platforms used for the selection of 
drug-resistant mutants  
P. falciparum cultivation is performed in suspension cultures; it is not 
possible to visualize parasites in culture as colonies or as plaques. 
Traditionally, parasite cloning involves diluting the parasitic cultures to below 
one parasite per well and allow them to grow for 2-4 weeks in a 96-well 
microtiter plate (231) before detecting parasite growth by microscopic 
examination of smears. However, detection of parasite growth by microscopic 
examination of Giemsa-stained smears is time consuming and laborious. In an 
attempt to establish a higher throughput protocol for the detection of drug-
resistant mutants in a 96-well format, high content imaging (HCI) imaging 
platform using SYBR® Green I nucleic acid stain and MitoTracker® Orange 
viability stain, quantitative PCR (qPCR), absolute fluorescence using SYBR® 
Green I nucleic acid stain and flow cytometry using Hoechst and 
dihydroethidium were explored for their limit of detection (Fig, 15). A lower 
LOD would allow an earlier detection of drug-resistant mutants in the 96-well 
plates, thereby reducing the time taken for resistance selection.  
An estimation of the time needed before replica plating can be done for 
detection of parasites is as follows: (x)n = LOD where x represents the number 
of merozoites and n represents the number of lifecycles. It is known that each 
schizont produces at least 16 to 32 merozoites per cycle. Taking into 
consideration the possible fitness cost of the mutants, the use of a conservative 
number of x=8 merozoites in the calculation, replica plating could be carried 




















6.2.1 High Content Imaging platform using SYBR® Green I and 
MitoTracker® Orange stains 
 
(i) SYBR® Green I nucleic acid stain  
In this experiment, the lower LOD for the number of parasites per well 
was explored using Opera® high content imaging system. The optimization of 
the LOD using high content imaging (HCI) was carried out based on the 
detection of parasite DNA using DNA-binding dyes such as SYBR® Green I 
nucleic acid stain by exploiting the absence of DNA in erythrocytes. A pilot 
experiment was performed to compare fluorescence readouts of serial 
dilutions (range: 0, 200, 400, 800, 1600, 3200, 6400 and 12800 parasites/well) 
of P. falciparum Dd2 WT parasites using BioTek Synergy™ 4 hybrid 
microplate reader (Vermont, USA) and Opera® high content imaging system 
(PerkinElmer). It was shown that HCI assay has greater sensitivity compared 
to total fluorescence assay (232) as it is able to detect very low numbers of 
parasites. In addition, quantitation of parasites is possible with the Opera® 
system but not with the BioTek microplate reader. Quantitation of parasites 
with the BioTek microplate reader is only possible with a standard curve of 
known varying concentrations of DNA and the corresponding fluorescence 
readouts. Preparation of the standard curve could be challenging, as there is a 
lack of a commercial equivalent of standard parasitic DNA product, hence 




Optimization of experimental plan 
In this experiment, the LOD is defined as mean greater than three 
times the standard deviation of the background signal (233), or signal 
corresponding to zero parasites per well. The mean corresponding to the 
number of parasites per well will be the LOD for that experiment. Table 11 
shows the average number of parasites detected per image field (Parasites_No. 
/Field_Mean) expressed in mean and standard deviation. The precision is 
expressed in terms of percentage coefficient of variation (% CV). Fig. 16 
shows the graph plots of log (Parasites_No. /Field_Mean) against number of 
parasites/well over three different ranges. Parasite_No. /Field_Mean refer to 
the number of parasites detected over the average number of image fields 
taken. The number of image fields taken was varied for the three experiments 
(n = 5, 9 and 15 for experiment 1, 2 and 3 respectively). The number of image 
fields was increased to accommodate the decrease in range of parasites per 
well. All three graphs showed a good correlation between signal readout 
(Parasites_No. /Field_Mean) and number of parasites/well. The coefficients of 
determination (r2) are 0.920, 0.926 and 0.858 for experiments 1, 2 and 3 
respectively. The graphs in Fig. 17 have shown a linear increase in signal 
readout with increasing concentrations of parasites per well. However, this 
linear increase was not observed for dilutions of parasites below 100 per well 
(Fig. 17 (c)). This linear increase suggests robustness in the technique of serial 
dilution across the three independent experiments.  
Table 11 (a) shows that the mean corresponding to 400 parasites/well 
(9.53 > 3 × 2.20) is greater than three times the standard deviation of the 
background signal. In Fig. 17 (a), it is clear that 400 parasites/well can be 
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detected with confidence as the signal readout was distinct from the 
background. The highest concentration of parasites (12800 parasites/well) in 
experiment resulted in a high signal readout (Fig. 17 (a)). Therefore, the range 
of parasite per well was narrowed to 0 – 6400 parasites per well in experiment 
2. The results in Fig. 17 (b) suggested the lower LOD to be 400 parasites per 
well as the signal readout was well above that of the background signal. This 
was also reflected in Fig. 17 (c) where 400 parasites per well can be 
confidently discerned from the background signal. These observations were 
also in agreement with the results in Table 11 where the mean corresponding 
to 400 parasites/well is greater than three times the standard deviation of the 
background signal for experiment 1, 2 and 3 was (9.53 > 3 × 2.20), (14.21 > 3 
× 0.32) and (21.01 > 3 × 1.21) respectively.  
 
Experimental discussion 
The initial approach to detect parasites using the fixative solution 
comprising 4% PFA and 1× SYBR® Green I nucleic acid gel stain was not 
successful. SYBR® Green I nucleic acid gel stain is a membrane impermeable 
dye which intercalates DNA. It is believed that the dye was unable to penetrate 
the cell membrane of the erythrocytes and a cell permeabilization agent was 
required. Hence, the fixative solution was optimized to include 0.1% Triton X-
100 to ensure permeabilization of the dye into the erythrocytes to facilitate 
intercalation of the parasites’ DNA.  
In the detection of parasites, the amount of hematocrit is of paramount 
importance. It has been shown that erythrocytes possess autofluorescence 
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properties attributed to the peroxidation of phospholipids and glycation of 
proteins, which increases with the age of the cells (234). As mentioned in 
section 3.1, whole blood is routinely washed to obtain erythrocytes for 
culturing. It is likely that the remnant white blood cells, which contain DNA, 
could also be responsible for the background signal detected. With this in 
mind, the experiments were designed and performed in low amounts of 
hematocrit (0.025%). The determination of the LOD has also facilitated the 
calculation of time required from time of inoculation (1 parasite per well) to 
detection (400 parasites per well), taking into account the doubling time of the 
parasite. 
However, despite having a LOD of 400 parasites per well, a few 
resistance selection experiments using SYBR® Green I nucleic acid stain on 
the Opera® high content imaging system as a detection method failed to select 
for mutants. The lack of selectivity of SYBR® Green I nucleic acid stain 
resulted in stained cell debris which could not be distinguished from live 
parasites, attributing to a large number of false positive wells. Also, the 
detection assay was optimized using a low percentage hematocrit of 0.025%, 
which on hindsight, may not be an accurate reflection of the hematocrit (2-
4%) used in culture. A higher hematocrit would mean the presence of more 
uninfected red blood cells; which would pack more densely within the same 
surface area of the well as compared to one with a lower hematocrit. This 
could suggest that the LOD is possibly higher than 400 parasites per well if 
hematocrit is increased. 
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Table 11 Determination of the limit of detection using Opera® high content imaging system with SYBR® Green I 
Average number of parasites detected per field (Parasite_No. /Field_Mean) expressed in mean ± s.d. and percentage coefficient of variation (% 






























% CV 163.91 24.66 39.81 80.41 27.82 14.86 11.43 15.11 
Parasites/
well 



















% CV 70.06 26.94 34.00 13.85 20.36 15.55 12.35 12.84 
Parasites/
well 
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Figure 16 Correlation coefficient of LOD using Opera® high content 
imaging system  
Parasite_No. /Field_Mean refer to the number of parasites detected over the 
average number of image fields taken. R2 = 0.920, 0.926 and 0.858 for 
experiment 1, 2 and 3 respectively. n = 24, 27 and 42 replicates per 
concentration dilution for experiment 1, 2 and 3 respectively. Number of 









Figure 17 Determination of the limit of 
detection for number of parasites per well 
using Opera® high content imaging system 
using SYBR® Green I 
Different ranges of parasites/well: (a) 0, 200, 
400, 800, 1600, 3200, 6400 and 12800 p/well; 
(b) 0, 100, 200, 400, 800, 1600, 3200, 6400 
p/well and (c) 0, 25, 50, 100, 200, 400, 800, 
1600 p/well.  n=24, 27 and 42 replicates per 
concentration dilution for experiment 1, 2 and 3 
respectively.  
Parasite_No. /Field_Mean refer to the number  
of parasites detected over the average number 
of image fields taken. Number of image fields 
= 5, 9 and 15 for experiment 1, 2 and 3 
respectively. Signal readouts of positive 
controls were excluded in these graphs.  
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(ii) MitoTracker® Orange viability stain 
Similar to SYBR® Green I nuclei acid experiment earlier, the lower 
LOD for the number of parasites per well was explored using Opera® high 
content imaging system. The optimization of the LOD using high content 
imaging (HCI) was carried out based on the detection of parasite’s viability 
using reduced, non-fluorescent version of MitoTracker® Orange (Life 
Technologies) which fluoresces upon oxidation. The dye also stains 
mitochondria in live cells.  In this experiment, the LOD is defined as mean 
greater than three times the standard deviation of the background signal (233), 
or signal corresponding to zero parasites per well. The mean corresponding to 
the number of parasites per well will be the LOD for that experiment. Table 
12 shows the average number of parasites detected per image field 
(Parasites_No. /Field_Mean) expressed in mean and standard deviation. The 
precision is expressed in terms of percentage coefficient of variation (% CV). 
Fig. 18 shows the graph plots of Avg (Parasites_No. /Field_Mean) against 
number of parasites/well for P. falciparum Dd2 WT and Dd2-GFP in 384-well 
and 96-well plates. Parasite_No. /Field_Mean refer to the number of parasites 
detected over the average number of image fields taken. The number of image 
fields taken for 384-well plate was 5 and 16 for 96-well plate.  
Table 12 (a) and (b) showed that the LOD (mean > 3 × S.D. of 
control) was 80 parasite/well (1.2 > 3 × 0.37) and 240 parasites/well (1.68 > 3 
× 0.25) for both P. falciparum Dd2 WT and Dd2-GFP. However, in Fig. 18 
(a), it was clear that at the calculated LODs, the signals could not be 
distinguished from that of the background (0 parasites/well). From Fig. 18 (a), 
it could be seen that the minimum number of parasites for detection for both 
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Dd2 WT and Dd2-GFP should be 8000 parasites/well. Despite having the 
same parasite densities, the difference in signals between Dd2 WT and Dd2-
GFP could be due to the dilution technique and inherent discrepancies that 
might exist as a result of % parasitemia being an estimate. The LOD 
experiment was repeated with Dd2 WT using 96-well plate and Figure 18 (b) 
have shown that the LOD should be at least 60 000 parasites/well, given that 
the calculated LOD could be between 0.6 to 6000 parasites/well. Although 60 
000 parasites/well is much greater than the 8000 parasites/well required using 
a 384-well plate, this result is plausible as a higher number of parasites would 
be required with increased area of the well.  
Unlike the SYBR® Green I nuclei acid experiment where 0.025% 
hematocrit was used, the MitoTracker® Orange experiments were carried out 
at 4% hematocrit. These experiments were designed with the knowledge that 
the low LOD of 400 parasites/well derived from the SYBR® Green I nuclei 
acid experiment failed to detect resistant mutants in the actual mutant selection 
experiments. The results of the MitoTracker® Orange experiments have shown 
that a lower LOD of 8000 parasites/well would be required in a 384-well plate 
compared to 60 000 parasites/well in a 96-well plate. Previous resistance 
selection experiments using 384-well plates were not successful, as the need 
for regular removal of toxins and metabolites in the media and replenishment 
of blood and nutrients could not be done effectively. Hence, the novel strategy 
that enabled selection of KAF179-resistant mutants was done using 96-well 
plates. Therefore, there would be an additional step of transferring a small 
volume of the culture from a 96-well plate to 384-well plate for detection of 


















Figure 18 Determination of the limit of detection using Opera® high content 
imaging system with MitoTracker®Orange 
Different ranges of parasites/well: (a) 384-well: 0, 80, 240, 400, 800, 2400, 4000, 
8000, 24000, 40000, 80000 and 240000 and (b) 96-well: 0, 0.6, 6, 60, 600, 6000, 
60000, 600000. n=8 replicates per concentration dilution for all experiments.  
Parasite_No. /Field_Mean refer to the number of parasites detected over the average 
number of image fields taken. Number of image fields = 5 and 16 for 384-well and 
96-well experiments respectively. 
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Table 12 Determination of the limit of detection using Opera® high content imaging system with MitoTracker®Orange 
Average number of parasites detected per field (Parasite_No. /Field_Mean) expressed in mean ± s.d. and percentage coefficient of variation (% 







































% CV 173.44 66.39 27.59 27.12 20.68 15.65 7.86 10.27 9.57 7.07 6.34 7.62 
Parasites/ 
well 



























% CV 111.85 78.66 38.23 24.09 14.95 17.89 20.97 14.81 8.36 12.08 5.94 5.92 
Parasites/well 0 0.6 6 60 600 6000 60 000 600 000 
Mean ± S.D. 2.12 ± 0.43 2.77 ± 0.57 2.44 ± 0.43 2.13 ± 0.62 2.19 ± 0.3 2.45 ± 0.43 5.44 ± 0.95 38.51 ± 
4.72 
% CV 20.07 20.56 17.72 29.17 13.8 17.41 17.46 12.26 
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6.2.2 Total fluorescence using SYBR® Green I nucleic acid stain  
Total fluorescence was measured using a microplate reader at 
excitation wavelength of 485 nm and emission wavelength of 528 nm for 
SYBR® Green I nucleic acid stain. This method of detection is used for 
routine drug sensitivity assays and the incubation time is 24 hours. A 30-
minute incubation time point was set up as a comparison to the 24-hour 
incubation.  It is evident from Fig. 19 that an incubation time of 30 minutes 
results in a much lower signal than that of the 24-hour incubation time. The 
total fluorescence readout of the control wells that contain only red blood cells 
(0 p/well) is approximately 15000. The definition of LOD as described in the 
previous section is not applicable here as the mean of any parasite density 
clearly exceeds three times the standard deviation of the control. From Fig. 19, 
it can be deduced that a minimum of 40000 parasites is needed per well.  
 
Figure 19 Total fluorescence readout using SYBR® Green I  
The limit of detection based on a total fluorescence readout using SYBR® 
Green I nucleic acid stain after 30 min (red bars) and 24 hour (green bars) 
incubation time over a range of parasites/well (0 – 75 000 p/well).   
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6.2.3 Quantitative real time PCR (qPCR) platform using 18s rRNA 
primers  
The heat-kill method was employed for the extraction of parasitic 
DNA to determine if this method could be used for large scale DNA extraction 
of putative drug resistant mutants in the 96-well plates. DNA extracted using a 
commercial kit served as a positive control. Primers were designed on P. 
falciparum housekeeping gene, 18s ribosomal RNA (PF3D7_0112300), which 
has at least 5 copies dispersed on separate chromosomes. 
The relative Ct value of the pure DNA obtained using the commercial 
kit was significantly higher than the control, which contained uninfected red 
blood cells and RPMI media (Fig. 20 (b)). The DNA present in the control 
sample could be from the white blood cells that were not removed during 
preparation of host erythrocytes in section 3.1. The relative Ct values of the 
samples derived from the heat-kill method were within 2-folds compared to 
the control (Fig. 20 (b)). This meant that it would be difficult to discern wells 
that contain the putative drug resistant parasites. The limit of detection using 
the heat-kill method for DNA extraction followed by qPCR was at least a 
million parasites. Despite qPCR being a highly sensitive technique for the 
detection of parasites, the presence of impurities from cellular debris 
interfered with the efficiency of PCR. This is also apparent from the melting 
curve analysis where several peaks, rather than a single peak, were present at 
lower temperatures (Fig. 20 (c)). The high LOD required for qPCR is not in 
agreement with the aim of developing an efficient method for throughput 
detection of parasites.  
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Figure 20 Quantitative real time PCR analysis 
(a) Ct values at different parasite densities, (b) Relative Ct values at different 




6.2.4 Flow cytometry platform with Hoechst and dihydroethidium stains 
The detection of putative mutants in microtiter plates was undoubtedly 
the most challenging step in the resistance selection process (Fig. 12). As a 
proof of concept of the novel strategy, the gold standard microscopic 
examination of Giemsa-stained thin blood smears was carried out. However, 
the technique was tedious and requires trained personnel to discern live from 
dead parasites. The use of the impermeable SYBR® Green I nuclei acid stain 
lead to detection of false positives on many occasions. The section on the 
optimization of detection platforms (Fig. 15) has also presented the high limit 
of detection required for some techniques such as qPCR and total fluorescence 
with SYBR® Green I. The high sensitivity and robustness of the tri-colour 
flow cytometry assay (TCM) makes it an attractive detection platform (221). 
This section will present the limit of detection with the tri-colour flow 
cytometry assay.   
Malleret et al has demonstrated that the lower limit of detection for 
TCM is 0.02% parasitemia. The results in Fig. 21 and Table 13 showed that 
the limit of detection is 0.039% parasitemia, which corresponded to 195 
parasites/well. Therefore, a minimum of 782 parasite/well would be required 
to detect parasites with confidence as seen in the dot plot Fig. 22. The use of 
both ethidium and Hoechst allowed different stages of the parasites to be 
distinguished. The low LOD of 782 parasites/well would mean a shorter time 
for the selection of resistant mutants, assuming they grow at the same rate as 
the WT. The LOD of 782 parasites in 40 μL of culture would translate to 
approximately 4000 parasites in a 200 μL culture, the volume in each well. 
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Since replica plating is required, a minimum of 8000 parasites per well is 
needed to ensure detection of parasites.  
An estimation of the time needed before replica plating can be done is 
as follows: (x)n = 8000 where x represents the number of merozoites and n 
represents the number of lifecycles. It is known that each schizont produces at 
least 16 to 32 merozoites per cycle. Taking into consideration the possible 
fitness cost of the mutants, the use of a conservative number of 8 merozoites 
in the calculation, replica plating could be carried out after 4.32 lifecycles, 
approximately 10 days. Another advantage of TCM is that it is also amendable 
for the selection of drug-resistant mutants in P. berghei (221).  
Hence, the detection of putative mutants in microtiter plates with the 



















Figure 21 Determination of limit of detection using flow cytometry 
 
Table 13 Determination of limit of detection using flow cytometry  





No.  of 
parasites/
well 
0 12 49 195 782 3125 12 500 50 000 200 000 800 000 
























Figure 22 Detection of P. falciparum Dd2 parasitemia using TCM 
Ethidium/Hoechst dot plot of parasites obtained from P. falciparum Dd2 
culture at respective parasite density. 0: uninfected red blood cells, 1-9 
(increasing numbers of parasites/well): 12, 49, 195, 782, 3125, 12500, 50000, 
200000.  
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6.3 Determination of time point for replica plating  
Prior to detection of positive wells, where drug-resistant mutants 
reside, a replica plate is prepared by transferring a third to half of the contents 
of a well into the exact same position in another fresh plate (Fig. 12 and 13). 
Replica plating is often a necessary step when the detection method is terminal 
for the parasite; addition of lysis buffer that contains SYBR® Green I nucleic 
acid stain or DNA extraction for qPCR. The novel strategy takes upon the 
assumption that each well contains one parasite or resistant mutant. This 
experiment is set up to determine the minimum time frame required before 
replica plating can be carried out. This experiment also investigates the 
sensitivity of SYBR® Green I nucleic acid stain and 5-(and 6-) carboxy- 
SNARF-1 (c-SNARF-1) dye in comparison to the light microscopy, the 
current gold standard for identification of P. falciparum parasites.   
Lyko et al has described a fluorescence-based assay using c-SNARF-1 
dye for high throughput detection of viable parasites in microplates (235). c-
SNARF-1 is a two-emission wavelength dye that undergoes pH-dependent 
wavelength shift. In vitro parasite cultivation is associated with extracellular 
acidification and the membrane-impermeant nature of the dye allows it to 
detect pH changes in media as a result of metabolic activity of the parasites. 
The dye is non-toxic and replica plating is not required. To facilitate detection 
by c-SNARF-1 dye, normal RPMI media is replaced with HEPES-free media 
2-3 days prior to fluorescence readout.  
 The results of the SYBR® Green I assay (Fig. 23(a)) showed that wells 
that contained an initial number of 32 parasites/well could well be detected by 
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day 9. If each schizont produces 32 merozoites at each lifecycle, the 
approximate number of parasites would be (32)n  × initial number of parasites 
in the well where n refers to the number of lifecycles. By day 13, the wells 
that contained an initial number of 8 parasites/well were well above that of the 
control wells to be detected as positives. By day 16, wells that contained an 
initial number of 1 parasite/well could also be detected. No parasites were 
detected on day 19 for the wells that contained an initial inoculum of 32 p/well 
as parasite overgrowth and competition for nutrients led to the lysis of infected 
red blood cells.  
The c-SNARF-1 assay involves the measurement of fluorescence at 
two emission wavelengths, 590 and 645 nm. The presence of parasites is 
indicated by a ratio of 590/645 nm that is greater than that of the control. The 
results for the fluorescence-based c-SNARF-1 assay were disappointing as the 
ratios of absolute fluorescence at 590/645 nm for all parasite densities were 
indistinguishable from that of the control (Fig. 23 (b)). There was also a lack 
of a discernable pattern in the ratios from wells that contain more parasites and 
fewer parasites. Although the wells that contained an initial inoculum of 16 
and 32 parasites/well did seem to show higher ratios as compared to the 
control wells, this assay failed to demonstrate a reliable readout for wells that 
contained an initial inoculum of 1 parasite/well.  
It was no surprise that the gold standard, Giemsa-stained smears 
prevailed as the most sensitive method of the three. On day 9, parasites were 
detected in wells that contained an initial inoculum of 2 parasites/well as 
compared to 8 parasites/well in the SYBR® Green I assay (Fig. 24). By day 
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13, parasites could be seen on Giemsa-stained smears in wells that contained 
an initial inoculum of 0.5 parasite/well.  
Some of the error bars observed in (Fig. 23) indicated a large standard 
deviation between the 3 replicates. This could be due to the low parasite 
density and possible dilution inaccuracies. For instance, in wells that contain 
0.5 parasite/well, one out of three replicates may not contain any parasite at 
all, resulting in a large standard deviation.  
In summary, Giemsa-stained smears remained the most sensitive 
method compared to SYBR® Green I and c-SNARF-1 assays. Parasites can be 
detected on Giemsa-stained smears from wells with an initial inoculum of 2 
parasites/well on day 9 and on day 16 with SYBR Green I assay. It can be 
deduced that replica plating can be done after day 16. However, this is on the 
pretext that the resistant mutant grows as well as the wild-type strain used in 
this experiment. In cases where the resistant mutant possesses a fitness cost, 
the number of merozoites released per schizont could be less than 32 or the 
lifecycle could be longer than 48 hours. As a result, it might take longer than 












Figure 23 Detection of parasites with (a) SYBR® Green I and (b) c-













Figure 24 Giemsa-stained smears on Day 9, 13, 16 and 19 
1-9 represents number of parasites/well in increasing order: 0, 0.1, 0.5, 1, 2, 4, 













CHARACTERIZATION OF KAF179 -
RESISTANT MUTANTS  
 
7.1 Targeted sequencing of P. falciparum Cyclic Amine 
Resistance Locus (PfCARL) gene 
P. falciparum Cyclic Amine Resistance Locus (PfCARL) 
(PF3D7_0321900) was previously reported to be the putative target of 
KAF179 and imidazolopiperazine class of compounds (170, 178). PfCARL 
gene has seven transmembrane domains and 1283 amino acids (genomic 
sequence: 4969 base pairs). In order to identify the mutations, the entire gene 
was divided into eight smaller fragments with approximately a 1000 
nucleotides each. Eight sets of forward and reverse primers were designed 
with an overlapping region of 100 base pairs between the forward primer of 
the downstream fragment and the reverse primer of the upstream fragment 
(Table 4). PCR reactions were performed using an annealing temperature of 
58.0 oC for all primer sets (Fig. 25). From Fig. 25, it was observed that there 
were multiple bands for primer sets 1, 6 and 8, which indicated non-specific 
binding of the primers. It was relatively difficult to design sequencing primers 
with appropriate Tm as G-C anchors were often absent in the A-T rich genome 
of P. falciparum. Nevertheless, for primer sets 1, 6 and 8, which had multiple 
bands, the gel band that corresponds to the correct fragment size was excised 
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and purified for sequencing. Forward and reverse sequencing was performed 
for each fragment and analyzed using Vector NTI®.   
No mutation was found in any of the KAF179-resistant mutants except 
Mutant H5. On both the forward and reverse sequencing results, there was a 
mutation of cytosine to thymine (CT) on nucleotide number 2593, which 
corresponded to codon 822. This translates into a SNP of proline to leucine on 
codon 822 (P822L) for mutant H5, thereby identifying the first mutant 
targeting PfCARL.  
However, many attempts to sequence the regions covered by primer 
sets 6 and 8 were futile. Attempts to improve coverage include re-designing of 
the primers, change of polymerase enzyme, annealing temperatures and 
sequencing vendor. The regions, which lacked coverage, include nucleotide 
numbers 3418-3765 and 4442-4969. These regions also contain many repeats 
of A-T, which could be difficult to sequence without sequencing errors of 
random insertion and deletion mutations.   
Targeted sequencing of PfCARL revealed KAF179 resistant mutant 
H5 with a SNP at P822L. However, at this point, no genetic information was 
available for the rest of the KAF179 resistant mutants. It was postulated that 
the mutants could potentially have SNPs outside PfCARL, which would allow 
the identification of new target(s) or resistance gene(s) for KAF179 and 
imidazolopiperazine class of compounds. Therefore, whole genome 
sequencing was performed on all 12 KAF179 resistant mutants to identify the 







Figure 25 Electrophoresis gel of PCR products using 8 sets of PfCARL 
sequencing primers 
Electrophoresis of PCR products was carried out to determine appropriate 
annealing temperature. For each set of primers, the temperature range in oC 





7.2 Whole genome sequencing and identification of 
resistance genes  
Whole genome sequencing (WGS) was performed on the parental P. 
falciparum Dd2 strain used for resistance selection and the 12 drug-resistant 
mutants selected with KAF179 using the novel strategy for resistance 
selection. WGS has uncovered three putative candidate genes that are involved 
with KAF179 resistance phenotypes. Of the three, two are novel genes, which 
were not discovered in previous efforts of resistance selection with 
compounds in the same class (170, 178).    
Three out of twelve resistant mutants (Mutant D6, H5 and H8) 
acquired mutations in P. falciparum Cyclic Amine Resistance Locus 
(PfCARL) (PlasmoDB ID: PF3D7_0321900) (Fig. 26 (a)) at two different 
SNPs, corroborating previous work that identified PfCARL as a putative target 
of imidazolopiperazines (170, 178).  Two out of three PfCARL resistant 
mutants (Mutant D6 and H8) bore the same mutation at position 1076, with a 
SNP change in serine to isoleucine (S1076I). The other PfCARL mutant 
(Mutant H5) had a mutation change of proline to leucine at position 822 
(P822L), consistent with the results obtained using targeted sequencing of 
PfCARL. Both proline at codon 822 and serine at codon 1076 could be 
essential for the protein function as they are evolutionarily conserved among 
Plasmodium species at the PfCARL gene locus (Table 14). PfCARL has 
seven transmembrane domains but the exact function of the gene is unknown. 
An analysis of the corresponding yeast deletions strains by Meister et al. 
suggests that the gene plays a role in protein folding within the endoplasmic 
reticulum (236, 237). This critical process could probably explain why 
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PfCARL is expressed in hepatic, asexual and sexual blood stages of 
Plasmodium (170, 178).   
Using the novel strategy for resistance selection, 9 out of 12 resistant 
mutants were found to target two other novel genes that were not identified 
previously, namely the P. falciparum UDP-galactose transporter (PfUGT) 
(PlasmoDB ID: PF3D7_1113300) and P. falciparum Acetyl-CoA transporter 
(PfACT) (PlasmoDB ID: PF3D7_1036800). Of the 12 KAF179-resistant 
mutants, seven mutants (Mutant A3, A9, B6, A2, B5, D8 and E8) acquired the 
same SNP mutation from phenylalanine to valine at position 37 (F37V) of the 
UDP-galactose transporter (Fig. 26 (b)). Phenylalanine is evolutionarily 
conserved at position 37 in all plasmodium species at the PfUGT gene locus 
(Table 14). One resistant mutant (Mutant B3) acquired a detrimental stop-
gained mutation at position 242 (S242*) of the acetyl-CoA transporter (Fig. 
26 (c)). The need for a hydroxyl amino acid is evolutionarily conserved at 
position 242, serine is found in both human and simian plasmodium ACT but 
rodent ACT has a preference for threonine (Table 14). The target for mutant 
D2 was not identified. The prediction of transmembrane domains (Fig. 26) 
was done using TMHMM.  
Both PfUGT and PfACT are evolutionarily conserved genes, with 80-
90% homology between different Plasmodium species (Table 14). UDP-
galactose is a nucleotide-sugar, an activated form of sugar produced by the 
cell as donor precursors for glycosylation reactions in eukaryotic cells (238-
240). Nucleotide-sugar transporters (NSTs) consist of 300- to 400- amino acid 
residues and possess 6 to 10 transmembrane domains (240). PfUGT consists 
of 8 transmembrane domains (Fig. 26). NSTs were shown to be antiporters; 
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the parasite’s UDP-galactose:UMP antiporter facilitates the transport of UDP-
galactose from the cytosol into the Golgi apparatus or endoplasmic reticulum 
lumen in exchange for the corresponding UMP, which is a product of the 
glycosylation reaction (241-243). Specific glycosyltransferase utilize the 
nucleotide sugars to glycosylate proteins and lipids that are transported 
through the secretory pathway (243). Putative P. falciparum NSTs are 
predicted to reside in the secretory pathway; facilitating the translocation of 
membrane proteins to the plasma membrane (243).  
In P. falciparum cell surface proteins, glycosylphosphatidylinositol 
(GPI) anchors represent the major glycoconjugates (244). Some of these GPI-
anchored glycoproteins are essential for parasite invasion and virulence (245). 
However, the presence of orthologues for enzymes involved in biosynthesis of 
sugar nucleotides were not related to GPI anchors in Plasmodium genome 
prompted Sanz et al to quantitate the levels of sugar nucleotides in the 
intraerythrocytic cycle (244). UDP-galactose was found in increasing 
concentrations as the parasite progresses from ring to trophozoite to schizont 
stage (244).  The identification of UDP-galactose was described as puzzling 
by Sanz et al as P. falciparum genome lacks the candidate genes required for 
the production of this sugar. They attributed the production of UDP-galactose 
to either cross activity by UTP-glucose-1-phosphate uridylyltransferase 
enzyme or broad substrate activity by UDP-sugar pyrophosphorylase enzyme 
(244).  Little information is known about the UDP-galactose transporter in 
Plasmodium compared to the extensive studies in Arabidopsis thaliana (240, 
246). Reyes et al has discovered AtUTr1, an UDP-galactose/glucose 
transporter from Arabidopsis thaliana, was involved in protein-folding process 
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in the ER (246). Unlike most NSTs that are reported to localize to the Golgi 
apparatus, AtUTr1 was found on the endoplasmic reticulum. The transporter is 
responsible for the provision of UDP-glucose/galactose to UDP-glucose 
glycoprotein glucosyltransferase (UGGT) for re-monoglucosylation of 
misfolded proteins, thereby facilitating their interaction with lectin chaperone 
calnexin (246). The chaperone retains the glycoprotein in the ER to enhance 
folding efficiency by binding to the monoglycosylated form of the protein. 
AtUTr1 was also upregulated with known ER chaperones such as BiP and 
calnexin in conditions that stimulate the accumulation of misfolded proteins 
that trigger UPR, thereby showing the importance of AtUTr1 in transporting 
nucleotide sugar from the cytosol to the ER lumen (246). The functional 
ortholog of AtUTr1, ScHUT1 protein in Saccharomyces cerevisiae was also 
found to be involved in the protein-folding process at the endoplasmic 
reticulum (247).  
PfACT has 10 transmembrane domains (Fig. 26), the stop-gained 
mutation results in a truncated protein. Given that Plasmodium has a 
minimalistic repertoire of transport proteins, it can be implied that there is 
relatively little redundancy (compared to yeast) and each transporter plays an 
important role in its physiology (243). In fact, the human homolog of the 
acetyl-coA transporter, AT-1 was found to be essential for cell viability (248). 
AT-1 was first reported by Kanamori et al to affect the acetylation of complex 
gangliosides in the secretory pathway (249). Homologs of AT-1 were also 
found in Saccharomyces cerevisiae, Caenorhabditis elegans and Drosophila 
melanogaster (250). Acetyl-CoA transporter facilitates movement of acetyl-
CoA into the ER lumen; where it serves as a donor of acetyl group for the 
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acetylation of lysine residues on ER-transiting and ER-residing proteins (248). 
Acetylation neutralizes the positive charges on the lysine residues, assisting 
the globular domain into a correctly folded state (251). AT-1 appears to 
function as a form of post-translational modification of membrane proteins in 
the secretory pathway (248). As a result, a disruption in the transport of acetyl-
CoA into the ER lumen would cause an impediment in the acetylation of 
nascent proteins (248). Accumulation of unfolded or misfolded proteins in the 
secretory pathway would lead to cellular toxicity, activation of the unfolded 
protein response and ultimately, cell death.  
Literature has shown the possible function of PfUGT and PfACT to be 
the transient post-translational modification of nascent proteins to facilitate 
protein-folding process. PfUGT is likely involved in re-monoglycosylation of 
nascent proteins and regulation of the interaction with lectin chaperon 
calnexin, thereby facilitating the translocation of folded proteins along the 
secretory pathway. PfACT could also behave in a similar pattern, where it 
acetylates positively charged residues to allow effective translocation of the 
nascent protein to the Golgi apparatus and to the cell surface along the 
secretory compartment (251). Both PfUGT and PfACT were reported to 
localize on the ER/Golgi membrane on the Malaria Parasite Metabolic 
Pathways database, thereby suggesting a possible involvement of both 
transporters in the secretory pathway. In the later chapter of this thesis, PfUGT 
was found to be localized to the ER and this could reinforce our hypothesis 
that PfUGT participates in the secretory pathway.  
The concept behind the novel strategy for in vitro resistance selection 
is akin to selecting colonies in bacteriology. This novel strategy selected for 
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mutants that target two novel genes - UDP-galactose transporter and acetyl-
CoA transporter, which were previously not identified in resistant mutants 
selected with the conventional methods (178). The identification of two novel 
targets aside, this method also generated drug-resistant mutants with SNPs in 
the P. falciparum Cyclic Amine Resistance Locus, which is in concordance 
with previous findings (170, 178). Despite the use of a different approach in 
the generation of drug-resistant mutants, SNPs at codons 822 and 1076 were 
also identified in PfCARL (170, 178). This suggests that regions between 
codon positions 821-834 and 1069-1076 of PfCARL might be crucial for the 
putative function of protein folding within the endoplasmic reticulum (170, 
178). These regions are also well conserved among Plasmodium species at the 
PfCARL gene locus (Fig. 26 (a)). 
In spite of the 12 mutants that were generated, only four SNPs were 
identified and mutants that target the UDP-galactose transporter all shared the 
same mutation F37V. It could be contended that F37V is a critical mutation 
for resistance in UDP-galactose transporter or all the mutants could have been 
progenies of a single clone during the selection in the flask prior to 














Figure 26 Single nucleotide polymorphisms of KAF179-resistant mutants 
SNPs found in P. falciparum (a) Cyclic Amine Resistance Locus (1293aa, 
PF3D7_0321900), (b) UDP-galactose transporter (343aa, PF3D7_1113300) 
and (c) Acetyl-CoA transporter (590aa, PF3D7_1036800) 
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Table 14 Amino acid sequence alignment of Plasmodium homologs of P. 
falciparum 
(a) Cyclic Amine Resistance Locus (1293aa, PF3D7_0321900), (b) UDP-
galactose transporter (343aa, PF3D7_1113300) and (c) Acetyl-CoA 
transporter (590aa, PF3D7_1036800)  
 
PF3D7: P. falciparum 3D7 strain, PFIT: P. falciparum IT strain, PCYB: P. 
cynomolgi strain B, PVX: P. vivax Sal-1, PKH: P. knowlesi strain H, PCHAS: 
P. chabaudi chabaudi, PBANKA: P. berghei ANKA, PY17X: P. yoelii yoelii 
17X, PYYM: P. yoelii yoelii YM 
 
 
(a) PfCARL  
 

















(c) PfACT  
 


















7.3 Validation of resistance genes  
The advent of genome-wide association studies has propelled the rapid 
identification of candidate genes and their respective SNVs responsible for 
resistance phenotypes. The confirmation of the actual contributions of these 
SNVs to drug resistance requires efficient tools to genetically modify P. 
falciparum culture in vitro (223). The inefficiency of genomic transfection and 
integration methods coupled with an ineffective RNA interference (RNAi) 
system posed great challenges for genetic manipulation of P. falciparum. The 
latest genome editing technique based on the RNA-guided CRISPR (clustered 
regularly interspaced short palindromic repeats)- Cas (CRISPR-associated 
proteins) system provides a powerful approach for genetic modification of the 
P. falciparum genome (252). Researchers first discovered in the mid-2000s 
that bacteria utilize the CRISPR-Cas systems as a defense against phages and 
foreign DNA. The segments of foreign DNA that were integrated and arrayed 
into the bacterial genome (CRIPSR sequences) were transcribed into short 
guide RNAs (gRNAs) that directed the Cas endonuclease to complementary 
viral DNA sites, creating double-stranded DNA breaks that disabled the viral 
DNA (223).  
CRISPR in P. falciparum requires transfecting two constructs, one 
with Cas9 and the guideRNA, whose expression was driven by a T7 RNA 
polymerase promoter, the other with the modified template (with both the 
desired nucleotide replacement and the Cas9 cut site mutated – the guideRNA 
site was changed to retain amino acid sequence), and T7 RNA polymerase 
itself, into Dd2 parasites which had been synchronized to the ring-stage via 
sorbitol synchronization for electroporation (310kV, 950uF).  The transfected 
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parasites were subsequently selected, cloned and tested for their resistance 
phenotype. 
Previous selections of resistant mutants to imidazolopiperazines have 
identified mutations in codon regions of 821-834 and 1069-1076 of PfCARL. 
Our novel strategy for resistance selection has also selected mutants with 
mutations in PfCARL at S1076I and P822L. While mutations in the UDP-
galactose transporter and the acetyl-CoA transporter were the only identified 
mutations in several of our spontaneous mutants, this alone does not prove that 
mutations in these genes convey resistance to KAF179. In order to provide 
further confirmation of the resistance phenotypes associated with the cyclic 
amine resistance locus, UDP-galactose transporter and acetyl-CoA transporter, 
the specific S1076I, F37V and S242* mutations were introduced using the 
CRISPR/Cas9 system respectively (223).  
The transgenic PfCARL mutant strain that contained a S1076I 
mutation showed a 13-20 fold reduction in susceptibility to KAF179 
compared to the parental Dd2 strain (83 nM vs 5.1 nM) (Table 15). The fold-
change of the transgenic PfCARL mutant strain as compared to the parental 
Dd2 strain were in agreement with that of the PfCARL spontaneous mutants, 
which showed a 20-50 fold reduction in sensitivity to KAF179 (Chapter 8.1 
later).  
 The newly generated UDP-galactose transporter mutant strain, which 
contained a F37V mutation, demonstrated a 111-226 fold reduction in 
sensitivity to KAF179 (Table 15), which was similar, albeit lower than the 
350-540 fold reduction achieved with the PfUGT spontaneous mutants.  
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The transgenic PfACT mutant strain that contained the stop-gained 
mutation S242* demonstrated a 413-1062 fold reduction in sensitivity to 
KAF179, which concurred with the 353 fold reduction achieved with the 
PfACT spontaneous mutant (Table 15). In addition to the PfACT CRISPR 
transgenic strain, the validation of PfACT gene could also be deduced from 
the analogous gene disruption observed both in P. falciparum and P. berghei 
KAF179 mutants (Fig. 28). Noteworthy, the analogous stop-gained mutations 
were located on the same endoplasmic loop of the acetyl-CoA transporter.  
The introduction of S1076I, F37V and S242* SNVs via the 
CRISPR/Cas9 system, and subsequent KAF179 susceptibility testing, 
demonstrated that the identified mutations were sufficient to introduce 
resistance to KAF179. In addition, all the transgenic strains showed similar 
fold reduction in sensitivity to KAF179 as compared to the spontaneous 
mutants selected with the novel protocol (Fig. 27). The level of resistance of 
the KAF179-resistant mutants selected using the novel protocol will be 











Figure 27 Comparison of IC50 values of CRISPR transgenic strains and 
spontaneous mutants 
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Figure 28 Analogous acetyl-CoA transporter gene disruptions in P. falciparum and P. berghei mutants 
(a) P. falciparum stop-gained mutation (S242*) in PfACT was analogous to P, berghei stop-gained mutation (W167*) in PbACT.  
PfACT: PF3D7_1036800 and PbACT: PBANKA_051980 













CHARACTERIZATION OF KAF179 -
RESISTANT MUTANTS  
 
8.1 Level of resistance  
KAF179 exhibits low nanomolar potency (5 to 9 nM) to the laboratory 
adapted multidrug-resistant P.falciparum Dd2 strain (Table 16) using a 72-hr 
SYBR® Green I proliferation assay. All 12 KAF179 drug-resistant mutants 
were equally sensitive to artemisinin as the parental Dd2 WT strain (Table 16 
and Fig. 29), thereby showing no cross-resistance with artemisinin.  
All the IC50 curves on Fig. 29 showed a rightward shift from the 
parental WT Dd2 strain, thereby confirming that these 12 putative mutants 
were indeed true resistant mutants to KAF179. Prior to whole genome 
sequencing, the IC50 values revealed that the 12 KAF179 drug-resistant 
mutants could be grouped into at least 2 distinct clusters. It was also evident 
that three mutants (D6, H5 and H8) demonstrated a much lower level of 
resistance to KAF179 as compared to the other mutants (Table 16 and Fig. 
29). As compared to the parental Dd2 WT, these three mutants exhibited a 
fold-shift in the range of 20-50× whereas the other nine mutants showed a 
much higher level of resistance with a 300-540× fold-shift.  
Whole genome sequencing of the 12 KAF179-resistant mutants 
revealed that the three mutants that exhibited lower levels of resistance were 
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associated with PfCARL. PfCARL mutants (D6, H5 and H8) have a much 
lower level of resistance to KAF179 as compared to the other mutants that 
were associated with either the UDP-galactose transporter (PfUGT) or acetyl-
CoA transporter (PfACT). In addition, mutants D6 and H8 encoding PfCARL-
S1076I were found to have a similar level of resistance (D6: 142 nM and H8: 
186 nM), corresponding to a fold-shift of 22 and 29 times the IC50 
respectively. The seven PfUGT mutants encoding the F37V substitution 
exhibited micromolar potency against KAF179, yielding a drug sensitivity 
shift in the range of 350-540 fold, over 10 times higher than PfCARL mutants. 
Despite acquiring a detrimental stop-gained mutation at position 242 in the 
acetyl-CoA transporter, B3 remains highly resistant to KAF179, with a shift of 
353-fold as compared to the parental Dd2 strain. 
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Table 16 Level of resistance of KAF179-resistant mutants 
  












Dd2 WT - - 10.01 (7.65 to 13.09) NA 6.31 (4.66 to 8.55) NA 
Mutant A3 UDP-galactose transporter F37V 9.86 (7.30 to 13.30) 1.0 2410 (1816 to 3198) 382 
Mutant A9 UDP-galactose transporter F37V 10.62 (8.30 to 13.59) 1.1 3074 (2749 to 3436) 487 
Mutant B6 UDP-galactose transporter F37V 10.88 (8.38 to 14.13) 1.1 3045 (2738 to 3387) 483 
Mutant D6 Cyclic amine resistance locus S1076I 9.25 (6.89 to 12.43) 0.9 141.60 (125.20 to 160.10) 22 
Mutant H5 Cyclic amine resistance locus P822L 6.16 (3.87 to 9.81) 0.6 274.40 (201.70 to 373.30) 43 
Mutant H8 Cyclic amine resistance locus S1076I 10.32 (6.95 to 15.34) 1.0 185.60 (155.80 to 221.20) 29 
Mutant A2 UDP-galactose transporter F37V 8.23 (5.63 to 12.03) 0.8 2858 (1936 to 4219) 453 
Mutant B5 UDP-galactose transporter F37V 7.94 (5.32 to 11.84) 0.8 2660 (2099 to 3371) 422 
Mutant D8 UDP-galactose transporter F37V 10.93 (8.63 to 13.85) 1.1 2210 (1710 to 2855) 350 
Mutant E8 UDP-galactose transporter F37V 8.79 (6.20 to 12.47) 0.9 3402 (2174 to 5324) 539 
Mutant D2 Unknown - 11.84 (9.11 to 15.40) 1.2 2875 (1601 to 5163) 456 
Mutant B3 Acetyl CoA transporter  S242* 7.77 (6.01 to 10.05) 0.8 2230 (1556 to 3196) 353 
IC50  values tabulated from 5 biological experiments with technical duplicates each, n=10.  



























Figure 29 IC50 curves for Dd2 WT strain and twelve KAF179-resistant 
mutants against artemisinin and KAF179.  
Graphs (a and b) artemisinin and (c and d) KAF179. The IC50 values were 
calculated using data from 5 biological experiments (n=5) with duplicates at 
each concentration. 
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8.2 Cross resistance studies  
8.2.1 Standard antimalarial drugs 
As shown earlier in section 8.1, all 12 KAF179-resistant mutants did 
not show any cross-resistance to artemisinin. KAF179-resistant mutants that 
target different SNPs, along with the parental P. falciparum Dd2 strain were 
tested for cross-resistance with standard antimalarial drugs. Notably, mutant 
A9 and B5 which targets PfUGT, mutant D6 which targets PfCARL at 
S1076I, mutant H5 which targets PfCARL at P822L and mutant B3 which 
targets PfACT. The standard antimalarials drugs used in this study belonged to 
the common classes of 4-aminoquinolines (chloroquine), 8-aminoquinolines 
(primaquine, tafenoquine), amino alcohols (lumefantrine, mefloquine), 
antifolates (pyrimethamine, proguanil, trimethoprim) and naphthoquinone 
atovaquone.  
P. falciparum Dd2 strain is resistant to chloroquine, quinine, 
pyrimethamine and sulfadoxine (35). The IC50 curves in (Fig. 30) have shown 
that the antifolates were completely inactive on the parental Dd2 strain and 
KAF179-resistant mutants, which is in agreement with the literature. 
However, chloroquine exhibited high micromolar (5 μM) activity against the 
parental and resistant mutant strains. P. falciparum Dd2 strain remained 
susceptible to the 8-aminoquinolines, amino alcohols and naphthoquinone. 
The IC50 curves of the KAF179-resistant mutants converged with that of the 
parental Dd2 strain for all the standard antimalarial drugs tested. This showed 
that the KAF179-resistant mutants were not cross-resistant to these standard 
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antimalarial drugs (Table 17). This also showed that KAF179 has a 




Figure 30  IC50 curves of Dd2 WT strain and KAF17-resistant mutants against standard antimalarial drugs  
Mutants which target PfUGT (Mut A9 and B5), PfCARL-S1076I (Mut D6), PfCARL-P822L(Mut H5) and PfACT (Mut B3). The IC50 values 
were calculated using data from 3 biological experiments (n=3) with duplicates at each concentration. 
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Table 17 IC50 values of Dd2 WT strain and KAF179-resistant mutants against standard antimalarial drugs 
 
  KAF179-resistant mutants 
Chemical  
Class 


































Primaquine 54.78  
(51.05 to 58.79) 
47.69 
















































Lumefantrine 4.34  
(3.64 to 5.18) 
2.88  
(2.54 to 3.27) 
3.45  
(2.94 to 4.05) 
3.28  
(2.83 to 3.80) 
1.95  
(1.67 to 2.26) 
2.88  
(2.15 to 3.86) 
Naphthoquinone Atovaquone 0.24  
(0.14 to 0.40) 
0.288  
(0.21 to 0.40) 
0.40  
(0.26 to 0.60) 
0.70 
 (0.55 to 0.88) 
0.28  
(0.16 to 0.48) 
0.83  
(0.66 to 1.0) 
Antifolates 
Pyrimethamine >10 000 >10 000 >10 000 >10 000 >10 000 >10 000 
Proguanil 1256  














Trimethoprim >10 000 >10 000 >10 000 >10 000 >10 000 >10 000 
 
Mutants which target PfUGT (Mut A9 and B5), PfCARL-S1076I (Mut D6), PfCARL-P822L(Mut H5) and PfACT (Mut B3).  
The IC50 values were calculated using data from 3 biological experiments (n=3) with duplicates at each concentration. 
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8.2.2 Imidazolopiperazine chemical analogs  
The 12 KAF179-resistant strains were screened for their cross-
resistance against a panel of 62 imidazolopiperazine chemical analogs. These 
analogs incorporate various substitutions at the R1 to R5 positions on the 
imidazolopiperazine core (Fig. 31 (a)). 35/61 compounds were active (< 1 
µM) on the wild-type Dd2 strain. The 26 analogs inactive on the wild-type 
Dd2 strain were also inactive on the PfCARL, PfUGT and PfACT mutants. 
The structure-activity data suggested that a bulky substitution on both R1 and 
R2 generally resulted in inactivity (> 10 µM) against the wild type Dd2 strain 
as well as the resistant mutants (Fig. 31 (b)). Consistent with our findings with 
KAF179, PfCARL mutants (D6, H5 and H8) demonstrated a lower level of 
resistance to the 35 imidazolopiperazine chemical analogs as compared to 
PfUGT and PfACT mutants. Although some variability was observed in the 
level of resistance to the 35 Dd2 active analogs, none could overcome the 
resistance phenotype of the mutants.  
Six compounds (Compounds 12, 18, 20, 23, 24 and 27) with a 
substitution on R1 proved to be more active on PfCARL-S1076I than the 
PfCARL-P822L isolate (Fig. 31 (c)). Likewise compounds (21, 25 and 29) 
with an additional methylation of R2 proved to be more potent against the 
three PfCARL mutants than the PfUGT and PfACT mutants (Fig. 31 (c)). The 
stop-gained (S242*) mutation on the acetyl-CoA transporter has rendered 
mutant B3 highly cross-resistant to all the chemical analogs tested except for 
one analog (Compound 13), which had relatively good activity (0.78 µM) 
against mutant B3. It was also interesting to note that PfACT mutant was 
slightly more sensitive to KAF156 than KAF179, with a lower fold-shift in the 
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10-100× range (Fig. 31 (d)). R-group descriptors such as volume and 
lipophilicity were calculated for the chemical analogs. However, no 
association was observed between R-group descriptors and the IC50 activity 
profiles in the heatmaps (Fig. 31).  
Overall, it was apparent that the KAF179-resistant mutants 
demonstrated similar biological profiles to 62 imidazolopiperazine 
compounds, similar to KAF179 where PfUGT and PfACT mutants showed 























Figure 31 Cross-resistance heatmaps of imidazolopiperazine 
chemical analogs  
Heatmaps of imidazolopiperazine chemical analogs against 
biological activities (pIC50) of KAF179-resistant mutants.  
Repeated measurements for the same mutation were combined 
using median and clustered according to mutation. 
(a) Imidazolopiperazine scaffold for chemical modifications, 
(b) Complete heatmap of all 62 chemical analogs. Color key: 4 
(>10 µM), 5 (10 µM), 6 (1 µM), 7 (100 nM), 8 (10 nM), 9 (1 
nM), (c) Reduced heatmap for compounds active on Dd2 WT 
strain with less than 100 nM (pIC50 above 7). Rows were 
reordered based using a hierarchical clustering of the compound activity profiles.  (d) Heatmap of compounds with IC50 < 100 nM on Dd2 WT 
strain and without modifications on R4 and R5. Biological activities were clustered according to IC50 fold-shift compared to Dd2 WT strain. 




(c)           (d) 
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8.2.3 Non-imidazolopiperazine compounds  
P. falciparum Dd2 WT strain and five KAF179-resistant mutants were 
screened for cross-resistance against a panel of 67 compounds of various 
scaffolds, inclusive of 10 standard antimalarial drugs. The KAF179-resistant 
mutants tested were PfUGT-F37V (Mutant A9 and B5), PfCARL-S1076I 
(Mutant D6), PfCARL-P822L (Mutant H5) and PfACT-S242* (Mutant B3). 
17 out of 69 compounds tested were inactive (>10 µM) on the P. falciparum 
Dd2 WT strain and likewise on the mutants (Table 18). 39 compounds 
demonstrated similar activity profiles on the WT and the KAF179-resistant 
mutants. The screening exercise revealed very interesting activity profiles in 
which compounds with entirely different scaffolds were cross-resistant to the 
KAF179-resistant mutants (Table 18). There were 11 compounds that 
displayed cross-resistance to the mutants and two compounds that were more 
active (< 1× fold-change) on the mutants than on the WT strain (Table 18). 
For some of these compounds, they were cross-resistant to all the mutants and 
in other instances; the compounds were resistant to one or two mutants but not 
the others (Fig. 32 (b)).  
The absolute fold-change in IC50 values compared to the Dd2 WT 
strain can be found on Fig. 32 (a). The compounds highlighted in blue (QA-
92-JW16, ZB-23-VS63, MA-04-ZO97, NA-82-NG33) in Fig. 32 (a) are 
chemical analogs of lerisetron (CA-40-DD07), an antagonist of the 5-
hydroxytryptamine 3 (5-HT3) receptor. Lerisetron (CA-40-DD07) displayed 
the lowest level of resistance among the analogs with a fold-change of 9-25×, 
hence it was also the most active on the KAF179-resistant mutants. The four 
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chemical analogs of lerisetron displayed higher level of resistance with a range 
of fold-change of 20-200×. These compounds did not show cross-resistance 
when tested previously with mutants resistant to KAE609, a spiroindolone and 
KDU691, a phosphoinositol-4 kinase (PI4K) inhibitor (Novartis in-house data 
not shown here). This could suggest that the protein conformations of our 
resistance-associated genes might be similar to 5-HT3 receptor.  
The fold-change of mutant activity relative to wild type were presented 
on Fig. 32 (c). The red box indicates the range in which shift was not 
significant. The criterion for significance was set to be greater than 5-fold. The 
five different activity profiles found on Fig. 32 (c) were presented individually 
on Fig. 32 (d). Activity profile (i) comprised 8 out of the 11 diverse set of 
compounds which showed cross-resistance to the mutants. The compounds in 
this category generally exhibited higher level of resistance to the mutants. 
Activity profile (ii) belonged to RC-90-LV49 (Tyroscherin), a natural product 
that was reported to have anti-tumour activity. This compound showed a 6-
fold increase in activity for PfCARL-S1076I, however, the effect could be 
negligible given that the result was borderline. Profile (iii) showed the activity 
of the compound, IF-52-LE14, which was resistant against all mutants except 
PfCARL at S1076I. It is worthy to note that this compound displayed a similar 
resistance pattern to KAF179. Activity profile (iv) belonged to OA-76-CW76, 
which showed a 40-fold shift for PfUGT and PfCARL-P822L mutants but 
remained potent to PfCARL-S1076I and PfACT mutants. Activity profile (v) 
is different from the four profiles presented prior as it demonstrates increased 
potency and not resistance on the mutants. Both BA-63-MJ54 and DE-30-
GX05 are kinase inhibitors which showed a weak increase in activity on the 
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PfACT mutant. The other two compounds within this class (NE-84-ZY51 and 
VC-44-JG72) did not exhibit the same pattern. As the increase in activity is 
just below our activity threshold, it can be inferred that the effect could be 
negligible.  
Cross resistance of KAF179-resistant mutants with compounds of 
various scaffolds that were markedly different from the imidazolopiperazines 
raised a possibility that the genes identified in whole genome sequencing were 
likely mechanisms of resistance rather than drug targets. In fact, the cross-
resistance screen also showed that PfCARL, PfUGT and PfACT could 



















Table 18 IC50 values of Dd2 WT strain and KAF179-resistant mutants 
against non-imidazolopiperazine scaffolds 
Values (nM) were averaged from three independent experiments with technical duplicates. 














Figure 32 Activity profiles of non-imidazolopiperazine compounds  
Boxed compounds in Table 18 are active on Dd2 WT strain and cross-resistant to 
KAF179 mutants. (a) Absolute values for fold-change in IC50 values compared to WT 
for boxed compounds; grey (<5×), light blue (5-49×), blue (50-99×) and dark blue 
(>100×), (b) Profiles of compounds that show no significant change (less than 5-fold 
compared to WT) are displayed in light grey. The remaining profiles are colored by 
the number of mutants that show a significant shift; red: one mutant, blue: two 
mutants, green: three mutants, purple: all mutants. (c) Fold-change of mutant activity 
relative to wild type. The red box indicates the range in which shift is not significant. 
(d) Five different categories of activity profiles based on (c). All compound codes 

























8.3 Fitness cost  
Resistance to anti-infectives is generally achieved either by altered 
gene expression (often of a transporter) or by mutation(s) which alter protein 
structure to reduce drug-binding efficacy (204). In response to this 
physiological change, natural selection reduces the genetic ‘fitness’ of 
parasites carrying the mutation (204). The cost of fitness of a mutant parasite 
is expressed as a percentage reduction in growth, measured as parasitemia, 
relative to the original non-mutated or wild-type parasite. Fitness costs tend to 
be small in organisms with diploid genome. The haploid genome of P. 
falciparum blood stage parasites make them vulnerable to natural selection or 
antimalarial drugs; the effects of mutations cannot be obscured by the 
presence of another normal gene (204). Fitness can be measured in vitro by 
comparing growth rates and in competitive growth experiments of resistant 
and sensitive strains at a given ratio (205, 206). The following sections will 
present the individual growth kinetics and competitive growth kinetics of 
PfUGT (Mutant A9), PfCARL (Mutant D6) and PfACT (Mutant B3) along 
with the Dd2 WT strain.  
 
8.3.1 Growth kinetics  
It was observed during routine culturing that PfCARL mutants grew as 
well as the Dd2 WT strain but both PfUGT and PfACT mutants grew poorly 
compared to the Dd2 WT strain. An initial experiment designed to investigate 
the growth kinetics of these mutants were done with Giemsa-stained slides. 
The results indeed revealed the trend that was observed during routine 
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culturing. The growth kinetics experiment was repeated using flow cytometry 
as readout. The infected parasites were stained with Hoechst dye, a blue 
fluorescent stain specific for DNA and dihydroethidium (DHE), which 
converts to ethidium in viable cells where it stains both DNA and RNA. 
Details for the optimization of this assay can be found in Malleret et al (221). 
For each data point, 100,000 events were collected and gated for cells stained 
positive for both Hoechst and DHE. Analysis of data was performed using 
FlowJo (Tree Star) software. 
In the absence of drug pressure, PfCARL mutant did not exhibit the 
same fitness as Dd2 WT strain but was nevertheless, the fittest mutant of the 
three (Fig. 34 (a)). The %parasitemia of PfCARL mutant was approximately 
60% to that of the Dd2 WT strain after two lifecycles at 96 hours (Table 19). 
In comparison, PfUGT and PfACT mutants had much slower growth rates. 
The %parasitemia of PfUGT mutant was approximately 45% to that of the 
Dd2 WT strain while PfACT mutant was approximately 57% compared to 
Dd2 WT after two lifecycles at 96 hours (Table 19). However, in the presence 
of KAF179, PfUGT and PfACT mutants exhibited greater loss in fitness (p < 
0.05) as compared to PfCARL mutants (p > 0.05) (Fig. 34). The loss in fitness 
was likely due to the reduced number of merozoites produced rather than a 
delay in progression to next stage of the intraerythrocytic cycle as gathered 
from the dot plot in Fig. 33. It was evident that the parasites progressed to the 
next stage of the intraerythrocytic cycle based on the percentages of the early 
and late stages at each time point.  
There are two important takeaways that can be gathered from the data 
above. Firstly, the higher fitness costs possessed by both the PfUGT and 
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PfACT mutants compared to PfCARL mutants could explain their absence in 
previous resistance selection efforts with imidazolopiperazines. The ‘fitter’ 
PfCARL mutant outcompeted the other two mutants when mutant selection 
was carried in a flask for months (Fig. 13). This reinforces one of the 
advantages of our novel strategy in resistance selection; the ability to select for 
mutants with higher fitness cost (Fig. 12). Secondly, in the absence of the 
KAF179, all three mutants did not grow as well as the Dd2 WT strain. The 
Dd2 strain would likely outgrow the mutants with sufficient generations of the 
parasite, assuming that the mutants do not acquire a compensatory mutation 
that will restore fitness of the mutants. Therefore, there is a lower risk of rapid 





































Figure 33 Hoechst/DHE dot plot   
Dot plot of % parasitemia of parental Dd2 strain and KAF179-resistant 
mutants at respective time points in the (a) absence of KAF179 (n=4)  (b) 
presence of KAF179 (n=2). Percentages of ring stage (left box) and late stages 




















Figure 34 Growth kinetics of Dd2 WT and KAF179-resistant mutants  
Growth of parental Dd2 strain and KAF179-resistant mutants expressed as 
mean %parasitemia in the (a) absence of KAF179 and (b) presence of 
KAF179 at the respective time points.Quadruplicates were performed for 
mutants in the absence of drug pressure (n=4) and replicates were performed 
for mutants in the presence of drug pressure (n=2). (c) %Parasitemia at time = 
96 hours. Paired sample t-tests were performed to compare mean 
%parasitemia at 96 hours for each mutant in the presence and absence of 

























Table 19 Percentage parasitemia of Dd2 WT and KAF179-resistant 
mutants  
Growth of parental Dd2 strain and KAF179 mutants expressed as mean % 
parasitemia. Quadruplicates were performed for mutants in the absence of 
drug pressure (n=4) and replicates were performed for mutants in the presence 
of drug pressure (n=2).  
















8.3.2 Competitive growth kinetics  
While the individual growth kinetics have shown that all three mutants 
grew at a slower rate as compared to the Dd2 WT strain, it would be more 
conclusive to examine the growth kinetics of the mutants in competition with 
the Dd2 WT strain. An outline of the experiment can be found on Fig. 35.  
Briefly, P. falciparum Dd2 WT culture was mixed separately with 
three mutants that target the UDP-galactose transporter (Mutant A9), cyclic 
amine resistance locus (Mutant D6) and acetyl-CoA transporter (Mutant B3) 
in Mutant: WT ratios of 1:10, 1:1 and 10:1. The parasites were passaged in a 1 
in 6 dilution every other day for 10 generations. Genomic DNA was also 
harvested every other day using the QIAamp DNA Blood Mini Kit (Cat. No. 
51106, Qiagen). The genomic DNA was subsequently used for digital PCR to 
amplify an amplicon between 75-150 base pairs within the target of interest 
containing the mutation SNP. The droplet digital PCR data was used to 
analyze the frequencies of WT and mutant strain alleles, which in turn, reflects 
the growth kinetics of the WT and mutant strains. The Taqman probes 
(Integrated DNA Technologies) used to measure the frequencies of WT and 
mutant strain alleles are found within the amplicon and differ only at the 
mutation SNP.  The probes are designed with the WT probe having a 5’ – 
HEX dye (green), the mutant probe having a 5’ – FAM dye (blue) and both 
probes end with a 3' Iowa Black Quencher.  
In droplet digital PCR, the sample is partitioned into many PCR 
reactions. Unlike tradition qPCR, digital PCR provides a linear response to the 
number of copies present to allow for small fold change differences to be 
detected. However, a clear discernment of signals between the WT and mutant 
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probes was a challenge. There were many attempts in redesigning the probes 
to ensure the accurate collection of data. The challenge in optimization of the 
probes can be seen in Fig. 36 (a). The probes for PfACT assay were well 
designed; with a clear distinction between the signals from the WT and mutant 
probes. The probes were also able to accurately detect the varying 
concentrations of WT and mutant DNA in the PfACT assay (Fig. 36 (b)). The 
PfCARL assay fared slightly better and it was possible to distinguish the WT 
probe signal from the mutant probe signal. Several attempts to optimize the 
PfUGT assay were unsuccessful in resolving the issue of accurate 
identification of WT and mutant signals. The optimization results of the 
PfUGT assay demonstrated the difficulty in distinguishing the signal of the 
WT probe from the mutant probe. The close proximity of the signals would 
make the identification of WT and mutant DNA indistinguishable. It was 
perceivable as the probes only differed by one nucleotide, which was the SNP.  
The competitive growth kinetics clearly demonstrated that the parental 
Dd2 strain outgrew both the PfCARL, PfUGT and PfACT mutants in the 
absence of the drugs within a short frame of time (8-14 days). The decreasing 
trend in both PfCARL, PfUGT and PfACT mutant:WT ratios indicated that 
the parental strain outcompeted the mutant strains over time (Fig. 37). It was 
shown in Fig. 37 (a-b) that the PfCARL mutant: WT and PfUGT mutant:WT  
ratios started declining from day 8 as compared to day 14 for PfACT mutant: 
WT ratio (Fig. 37 (c)). This might seem to suggest that PfCARL and PfUGT 
has a greater loss of fitness as compared to PfACT, which was not in 
agreement with the individual growth kinetics data. One explanation for this 
observation could lie in the lower sensitivity of the PfCARL and PfUGT 
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DDPCR assays. As shown in Fig. 36 (a-b), it is highly likely that some mutant 
signals could be misidentified as WT signals. In summary, it can be deduced 
that all mutant strains will be outcompeted by the parental Dd2 strain over 
time. The presence of poor fitness mutants could mean that clinical resistance 
































Figure 36 Optimization of digital PCR probes  
(a) Signals of WT (green) and Mutant (blue) probes for the respective genes 
(PfACT, PfCARL, PfACT), (b) Signals of WT and Mutant probes for varying 















































Figure 37  Competitive growth kinetics of KAF179-resistant mutants  
Analysis of the ratio of (a) PfCARL mutant, (b) PfUGT mutant and (c) PfACT 
mutant and parental Dd2 WT strain over time using DDPCR.  
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8.4 Morphology of KAF179-resistant mutants  
Extensive morphological changes in the late trophozoite to schizont 
stages were observed in all the resistant isolates (Fig. 38). The morphology of 
the ring and early trophozoite stages remained similar to that of the wild-type 
strain. The appearance of these markedly distinct-looking parasites was not 
homogenous in a population of mutant parasites, occurring only in 30-50% of 
the mutant population. The mutant parasites appeared vacuolated and less 
organized in terms of the appearance of the hemazoin and merozoites in the 
schizont stage (Fig. 38). It was also observed that the parasites were arrested 
in the late trophozoite and early schizont stage during the resistance selection 
with KAF179. This observation was in agreement with the intraerythrocytic 
stage of action study where the imidazolopiperazines (KAF156 and KAF179) 






Figure 38 Giemsa-stained morphology of KAF179-resistant mutants 
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8.5 Phenotypic reversion of mutations  
In the absence of the drug, the mutation may revert to that of the WT, 
thereby resulting in a loss of the resistance phenotype. The stability of the 
SNPs observed in the KAF179-resistant mutants were examined by culturing 
the mutants in the absence of KAF179 for four months and subsequently 
tested for their susceptibility using the SYBR® Green I assay.  
PfCARL mutants at two different SNPs, S1076I and P822L, both 
exhibited low micromolar activity to KAF179 (S1076I mutant: 0177 – 0.301 
μM, P822L mutant: 0.295 – 0.398 μM) (Table 20). The PfCARL mutants 
cultured in the absence of the KAF179 also exhibited consistent fold-change 
(20-50×) compared to parental P. falciparum Dd2 strain as presented earlier in 
section 8.1. Mutants associated with PfACT (1.6 – 2.39 μM) and PfUGT (1.56 
– 3.23 μM) exhibited higher micromolar activity to KAF179. The IC50 values 
derived from mutants cultured in the absence of KAF179 were in agreement 
with the values presented earlier in section 8.1.  
The IC50 values of KAF179-resistant mutants cultured in the absence 
of the drug at the 2nd, 3rd and 4th month post drug cessation were all within 
three-fold difference of each other (Table 20). The fact that the resistant 
mutants exhibited the same level of resistance even when grown in the 












Figure 39 IC50 values of KAF179-resistant mutants post drug cessation 
 
Mutant A9 (PfUGT), Mutant D6 (PfCARL-S1076I), Mutant H5 (PfCARL-
P822L) and Mutant B3 (PfACT) 
 
 
Table 20 IC50 values of KAF179-resistant mutants post drug cessation 







8.6 Cellular localization  
The cellular localization of the genes associated with KAF179 
resistance could give an insight to the function of these genes. An analysis of 
the corresponding yeast deletions strains by Meister et al. suggested that the P. 
falciparum cyclic amine resistance locus, a protein with seven transmembrane 
domains, potentially plays a role in protein folding within the endoplasmic 
reticulum (170, 236, 237). In eukaryotic cells, proteins destined for the 
secretory pathway or the extracellular environment, are first translocated into 
the endoplasmic reticulum (225).   
Cellular localization of PfCARL was carried out using PfCARL 
polyclonal antibodies and cytosolic marker HSP70 and cis-Golgi marker 
ERD2. PfCARL antibodies were localized to the darker areas of the images of 
HSP70, thereby showing that PfCARL was not localized in the cytosol (Fig. 
40 (a)). The localization of PfCARL was confirmed by the complete co-
localization of cis-Golgi marker, ERD2 with PfCARL antibodies (Fig. 40 (b)). 
To examine the localization of PfUGT, a transgenic strain expressing a 
fusion of PfUGT with monomeric red fluorescent protein (mRFP) was 
generated (Fig. 41 (a)). The extra copy of mRFP-PfUGT did not affect the 
IC50 value (Fig. 41 (b)). Live cell imaging revealed a perinuclear distribution 
of mRFP-PfUGT characteristic of the endoplasmic reticulum. This 
localization was confirmed by co-transfection of an ER marker, GFP-PfSec12, 
which showed complete co-localization with mRFP-PfUGT (Fig. 41 (c)) 
(225). Unfortunately, the difficulty in the generation of the PfACT transgenic 
strain also hindered the cellular localization of the protein. Hence, the cellular 
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localization of PfACT is currently being investigated and will not be presented 
here.  
The cellular localization of PfCARL to the cis-Golgi and PfUGT to the 
endoplasmic reticulum further suggests their possible involvement in the 









































Figure 40 Localization of PfCARL gene using anti-PfCARL polyclonal 
antibodies 
(a) Overlay of nuclear stain Hoechst, cytosolic marker HSP70 and anti-
PfCARL polyclonal antibodies from ring to schizont stages (top to bottom) 
(b) Overlay of nuclear stain DAPI, cis-Golgi marker ERD2 and anti-PfCARL 
polyclonal antibodies  
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Figure 41 Localization of PfUGT protein  
(a) Transgenic strain expressing a fusion of PfUGT with monomeric RFP 
(mRFP), (b) No shift in IC50  with extra copy of mRFP-PfUGT, 
(c) Live cell imaging of parasites co-expressing mRFP-PfUGT and the ER 
marker GFP-PfSec12. Both proteins were located in a perinuclear pattern 
characteristic of the parasite ER. Nuclei were stained with Hoechst 33342. Bar 

























9 CONCLUSION  
The path to malaria eradication is fraught with challenges; the absence 
of an effective vaccine coupled with increasing resistance to insecticides and 
antimalarial drugs. To this end, discovery and development of new chemical 
entities to combat the rising drug resistance to artemisinin could be the best 
bet to safeguard a cure against malaria. The introduction to this thesis have 
presented the leading clinical candidates in the antimalarial pipeline and an 
extensive discussion on drug resistance, in particular mechanisms of resistance 
of current antimalarial drugs, key concepts pertinent to in vitro selection of 
resistance and conventional methods for selection of drug-resistant mutants. 
This thesis has also discussed in detail the establishment of a novel protocol 
for the selection of drug-resistant mutants and the challenges faced in the 
development of this protocol. The resistance profile of KAF179, a compound 
belonging to the novel class of imidazolopiperazine with a mechanism of 
action unique from current antimalarial drugs, was also presented in this 
thesis.  
 This project was set out to achieve two main objectives: 
I. Target deconvolution and elucidation of mechanisms of resistance 
of imidazolopiperazine class of novel antimalarials using drug-
resistant mutants. 
II. Utilize molecular genetic information to aid medicinal chemistry 
efforts in the design and optimization of novel compounds. 
 
In order to meet the objectives of this project, the utmost priority then 
was to develop a protocol that could enable the selection of multiple drug-
 215 
resistant mutants. Conventional methods such as the single-step and stepwise 
methods were less time- and cost-efficient as only two to four mutants were 
generated for each resistance selection process. To date, there is no 
standardized protocol for the selection of resistant mutants and it varies 
between laboratories. This project has successfully developed a platform for 
the selection of drug-resistant mutants. There were two important steps that 
were crucial for the success of this strategy. Firstly, the use of Percoll 
purification to remove the bulk of the cellular debris. Secondly, the upfront 
dilution of the cultures into 96-well plates. Taken together, these steps 
facilitated the (a) simultaneous selection of multiple drug-resistant mutants, 
(b) discovery of novel genes associated with resistance, (c) identification of 
mutants with resistance-associated fitness cost and (d) reduced duration of 
resistance selection process, thereby minimizing genetic drift. However, the 
strategy is not without limitations. The proof of concept of the current model 
was performed using Giemsa-stained thin smears as a detection method. 
Despite it being the gold standard for identification of malaria parasites, it is 
laborious and requires skilled personnel. Therefore, new detection platforms 
using viability dyes such as MitoTracker® Orange and dihydroethidium have 
been explored and presented in chapter 6 of this thesis. In particular, the high 
sensitivity and specificity of the tri-colour flow cytometry assay makes it a 
promising detection platform for future resistance selection projects.  
With the establishment of an efficient platform for the selection of 
drug-resistant mutants, the project was on track to meet the first objective. The 
imidazolopiperazine class of novel compounds was shown to have activity 
against the liver stage, asexual and sexual blood stage parasites. More 
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importantly, this class of compounds possesses a unique mode of action from 
the current arsenal of antimalarial drugs. A clinical compound of this class, 
currently in Phase IIb clinical trials, KAF156 has the potential to be developed 
as a causal prophylactic and also a transmission-blocking antimalarial drug. 
Identification of the molecular target(s) and deciphering the mechanism of 
resistance of imidazolopiperazines will definitely aid in monitoring of clinical 
resistance and screening of potent compounds against these drug target(s). To 
elucidate the mechanisms of resistance of imidazolopiperazines, KAF179 was 
used for resistance selection.  
The novel protocol described in Chapter 6 enabled the rapid selection 
of 12 KAF179-resistant mutants. The putative mutants were first tested for 
their level of resistance against KAF179 prior to whole genome sequencing. It 
was apparent that the mutants could be clustered into two groups; one with a 
lower level of resistance with 20-50× fold-change compared to the parental 
Dd2 strain and the other with a higher level of resistance with 300-600× fold-
change.  Whole genome sequencing revealed three candidate genes associated 
with the resistance phenotypes. Mutations were found in P. falciparum cyclic 
amine resistance locus (PfCARL), and in two other genes, namely P. 
falciparum UDP-galactose transporter (PfUGT) and acetyl-CoA transporter 
(PfACT). It was the first time that PfUGT and PfACT has been reported to be 
associated with resistance to imidazolopiperazines. No other group has 
managed to identify these two genes in their resistance selection efforts. The 
candidate genes were then matched with their corresponding level of 
resistance and it was found that the mutants associated with PfCARL had a 
lower level of resistance and mutants associated with PfUGT and PfACT 
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showed a higher level of resistance. In a bid to validate the contributions of 
these SNVs to KAF179 resistance, CRISPR/Cas 9 technology was applied to 
generate transgenic strains, which contained the SNPs. All three transgenic 
strains which contained the mutations: S1076I in PfCARL, F37V in PfUGT 
and S242* in PfACT displayed resistance phenotypes similar to that of our 
spontaneous mutants selected with the novel protocol. The fold-change 
compared to the parental Dd2 strain were 13-20× for PfCARL, 111 to 226 for 
PfUGT and 413 to 1062 for PfACT respectively. In addition, validation of 
PfACT could also be deduced from the analogous gene disruption (W167*) 
observed in in vivo P. berghei mutant generated in-house. The analogous stop-
gained mutations were located on the same endoplasmic loop of the acetyl-
CoA transporter.  
Upon validation of the candidate genes associated with KAF179 
resistance, the project was set to move forward to elucidate the mechanisms of 
resistance involved. The KAF179-resistant mutants were first screened against 
10 antimalarial drugs with known mechanisms of action. The absence of 
cross-resistance reinforced published work that KAF179 has a unique mode of 
action from current antimalarials. Next, the mutants were screened against 59 
new chemical entities of different compound classes. The results were very 
interesting as 11 compounds showed cross-resistance to KAF179-resistant 
mutants. It was worthy to note that one compound exhibited a highly similar 
resistance pattern to KAF179. The cross-resistance screen also demonstrated 
that antagonists of the 5-hydroxytryptamine (5-HT3) receptor demonstrated 
high level of resistance (30-200× fold-change vs WT). These compounds did 
not show cross-resistance when tested previously with mutants resistant to 
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spiroindolone KAE609 and KDU691, a PI4-kinase inhibitor. This might 
suggest that the protein conformations of our resistance-associated genes 
could be similar to that of 5-HT3 receptor. The fact that chemical entities of 
different classes showed cross-resistance with KAF179-mutants raised the 
question of whether a global mechanism of resistance, as in the case of 
PfMDR1, is involved. Based on current literature, it can be postulated that all 
three genes associated with KAF179 resistance are involved in the secretory 
pathway, in particular protein-folding process in the endoplasmic reticulum. 
Cellular localization studies have also shown that PfCARL was localized to 
the cis-Golgi and PfUGT was localized to the ER, further supporting our 
postulation.  
Cross-resistance screening of KAF179-resistant mutants with new 
chemical entities answered the second objective of this project. It would aid to 
facilitate go/no-go decisions on a chemical class and designing of new 
chemical entities that has no cross-resistance with existing and potential 
antimalarial candidates (KAF156) in the pipeline.  
In addition to meeting the objectives of the project, the hypotheses of 
were also tested throughout the different segments of this project. It piqued 
our interest when two novel genes, PfUGT and PfACT were discovered to be 
associated with imidazolopiperazine resistance using our strategy. We 
hypothesized that these mutants could likely have a higher fitness cost as 
compared to PfCARL mutants, which could explain why other groups using 
the conventional resistance selection methods never discovered these mutants. 
Individual growth kinetics and competitive growth kinetics experiments have 
unraveled the cost of fitness of PfUGT and PfACT mutants, thereby validating 
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our hypothesis that our strategy allowed mutants with variable fitness-cost to 
thrive. The upfront dilution of cultures facilitated the uptake of nutrients by 
the less fit mutants without competition from fitter mutants.  
Stage-specificity study revealed the predominant intraerythrocytic 
stage of action of the imidazolopiperazines (KAF156 and KAF179) to be the 
schizont stage. Consistent with this data, marked morphological changes were 
observed in the late trophozoite to schizont stages in all the resistant mutants.  
The genes associated with KAF179 resistance were likely expressed in the 
later stages (late trophozoite-schizont) of the intraerythrocytic cycle.  
In summary, the work presented in this thesis has achieved significant 
outcomes. The establishment of a novel platform for the selection of drug-
resistant mutants with unique advantages over existing conventional methods; 
(a) accelerated rate of resistance selection to minimize genetic drift, (b) 
simultaneous selection of multiple mutants, (c) discovery of novel target(s) or 
genes associated with resistance and (d) identification of resistance-associated 
fitness costs. Cross-resistance screening with KAF179-resistant mutants has 
suggested the likelihood of a new global mechanism of resistance involved.  
The mechanism of resistance of imidazolopiperazine is likely associated with 
the parasite secretory pathway. The elucidation of the intraerythrocytic stage 
of action of the Phase IIb clinical drug candidate, KAF156, could aid in the 
selection of a combinatorial partner drug in the future. The tools developed 
and presented for genotypic and phenotypic characterization of the mutants in 
this thesis can be applied to assess the risk of resistance for preclinical 
antimalarial compounds in development. Finally, molecular information 
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obtained from this project will aid in monitoring of clinical drug resistance of 
KAF156 in the future. 
However, the work presented in this thesis is not without limitations. 
The proof of concept of the current model was performed using Giemsa-
stained thin smears as a detection method, which is laborious and requires 
skilled personnel. The current model could be improved to be more labour-
efficient through sorting of spontaneous mutants using flow cytometry prior to 
plating them into 96-well plates. In addition, the current model does not allow 
us to study the frequency of mutation of the drugs. It would be of clinical 
interest to modify the current method to allow the investigation of the 
mutation frequency, which might be an indicator for the rate at which clinical 
resistance might take place. This resistance selection platform could also be 
applied to other kinetoplastid organisms.  
The KAF179-resistant mutants could also be used in cross-resistance 
screens with novel chemical entities to prevent development of compounds 
that share similar mode of action or mechanisms of resistance. In addition, 
these mutants could also be used to screen for partner drugs with synergistic 
activity against the parasite where the partner drug targets ring or trophozoite 
stage. Compensatory mutations may also evolve to restore the fitness of 
PfUGT and PfACT mutants over time. Lastly, it has been proposed that these 
three resistance proteins could be involved in the secretory pathway. 
Biochemical functional assays could be performed to investigate the roles of 
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11 APPENDIX  
Appendix I  
Complete amino acid sequence alignment of P. falciparum (a) Cyclic Amine Resistance 
Locus (1293aa, PF3D7_0321900), (b) UDP-galactose transporter (343aa, 
PF3D7_1113300) and (c) Acetyl-CoA transporter (590aa, PF3D7_1036800) of 
Plasmodium species  
PF3D7: P. falciparum 3D7 strain, PFIT: P. falciparum IT strain, PCYB: P. cynomolgi strain 
B, PVX: P. vivax Sal-1, PKH: P. knowlesi strain H, PCHAS: P. chabaudi chabaudi, 
PBANKA: P. berghei ANKA, PY17X: P. yoelii yoelii 17X, PYYM: P. yoelii yoelii YM 
 
 
(a) PfCARL  
 
                      1                                               50 
PF3D7_0321900     (1) MNRITLYDFIIDEIKGGTHYNRYYSDSDCSEEECKEDE------------ 
 PFIT_0322000     (1) MNRITLYDFIIDEIKGGTHYNRYYSDSDCSEEECKEDE------------ 
  PCYB_082790     (1) MNRITLYDFILDEVRGGRYYDSYLSDGENAEGDVAGAPERKGKKNLSEGN 
   PVX_095140     (1) MNRITLYDFILDEVRGGRYYDSYLSDGENGEGGAAAAAERKGKKNLSEGN 
   PKH_081870     (1) MNRITLYDFILDEVRGGRYYDSYLSDGENAGGGVAGAEERKKKKNLNEVN 
 PCHAS_121730     (1) MNRISLYDFVLDEIKGGRYYEPYQSDNENSERDGNDEKE----------- 
PBANKA_121660     (1) MNRISLYDFVLDEIKGGRYYEPYHSDNENSEENYNGEK------------ 
PY17X_1219800     (1) MNRISLYDFVLDEIKGGRYYEPYQSDNENSEQNGNGEKE----------- 
 PYYM_1219200     (1) MNRISLYDFVLDEIKGGRYYEPYQSDNENSEQNGNGEKE----------- 
    Consensus     (1) MNRITLYDFILDEIKGGRYYE Y SD ENSE    GE E            
                      51                                             100 
PF3D7_0321900    (39) -----NVSKNINDNKEKNINDEYKYDFYKFLDHIFKANSIPDNALDHMLN 
 PFIT_0322000    (39) -----NVSKNINDNKEKNINDEYKYDFYKFLDHIFKANSIPDNALDHMLN 
  PCYB_082790    (51) AAGRGATKTPSNGQVNNPGKDDRQYDFYKFLDTFFKTDSIPENALEHMMN 
   PVX_095140    (51) GPVRGATKAPGTGQANNPGKDDRQYDFYKFLDTFFKTDSIPENALEHMLN 
   PKH_081870    (51) GAVRGATKEPSTGQTNNPGKDEQQYDFYKFLDTFFKTDSIPENALEHMLN 
 PCHAS_121730    (40) --GMGNHLKHMSYSNIHQNTEENKHDFYKFLDDLFKTHTIPDNALEHMIY 
PBANKA_121660    (39) --GMENNLKHMSYSNINQNTEENKHDFYKFLDDLFKTHTIPDNALEHMIY 
PY17X_1219800    (40) --GMGNNLKHMSYSNINQNTEENKHDFYKFLDDLFKTHTIPDNALEHMIY 
 PYYM_1219200    (40) --GMGNNLKHMSYSNINQNTEENKHDFYKFLDDLFKTHTIPDNALEHMIY 
    Consensus    (51)   G GN  K MS Q  NQ  DENKYDFYKFLD LFKT SIPDNALEHMIN 
                      101                                            150 
PF3D7_0321900    (84) VPFFFEKLMSFSFLLCLDNILYDITFMPIQVVRSICLLISLFFKNASRNI 
 PFIT_0322000    (84) VPFFFEKLMSFSFLLCLDNILYDITFMPIQVVRSICLLISLFFKNASRNI 
  PCYB_082790   (101) VPFFLEKIMSFSFLLCLDNILYDITFMPVQVIRSLSILVYRFLRNTGHNF 
   PVX_095140   (101) VPYFLEKIMSFSFLLCLDNILYDITFMPVQVIRSLSILLYTFLRNAARNF 
   PKH_081870   (101) VPYFLEKIMSFSFLLCLDNILYDITFMPVQVIRSLSILLYTFLRNAGHNF 
 PCHAS_121730    (88) VPFCFEKIMSLSFLLCLDNILYDITFMPIQVIRSICILFYILLKNISSNF 
PBANKA_121660    (87) VPIFFEKIMSLSFLLCLDNILYDITFMPIQVIRSICILLYILLKNISNNF 
PY17X_1219800    (88) VPIFFEKIMSLSFLLCLDNILYDITFMPIQVIRSICILLYILLKNISNNF 
 PYYM_1219200    (88) VPIFFEKIMSLSFLLCLDNILYDITFMPIQVIRSICILLYILLKNISNNF 
    Consensus   (101) VPFFFEKIMSFSFLLCLDNILYDITFMPIQVIRSICILLYIFLKN S NF 
                      151                                            200 
PF3D7_0321900   (134) MNIFYNFKNYKFYKYAVNNYKDPKKKYKVRVIKNLN---------KLSYI 
 PFIT_0322000   (134) MNIFYNFKNYKFYKYAVNNYKDPKKKYKVRVIKNLN---------KLSYI 
  PCYB_082790   (151) LIHFCNIKNFKFYKYATTYNHQDLKKYKARMIKSSNKFSPTERR-KRRVL 
   PVX_095140   (151) LRHFCNIKNFKFYKYATTYNYKDLKKYKARMIKSSNKFSPSERRKRRVLK 
   PKH_081870   (151) LRHFCNIKNFKFYKYATTYNHKDLKKYKARIIKSSNKFSPNERRRRRRVL 
 255 
 PCHAS_121730   (138) LNRFIDIKNFKFYKYATTCNFKYLKRYKARVIKNSNKFIDT----EMIRT 
PBANKA_121660   (137) LNRFIDIKNFKFYKYATTCNFKYLKRYKARVIKNSNKFINT----EMIRT 
PY17X_1219800   (138) LNRFIDIKNFKFYKYATTCNFKYLKRYKARVIKNSNKFINT----EMIRT 
 PYYM_1219200   (138) LNRFIDIKNFKFYKYATTCNFKYLKRYKARVIKNSNKFINT----EMIRT 
    Consensus   (151) LN F NIKNFKFYKYATT NFK LKKYKARVIKNSNKF  T    KMI   
                      201                                            250 
PF3D7_0321900   (175) KRKENDHMYESKYIKEKSLDESSILYKKLSRNLFSFHYLNGSRFSMNASH 
 PFIT_0322000   (175) KRKENDHMYESKYIKEKSLDESSILYKKLSRNLFSFHYLNGSRFSMNASH 
  PCYB_082790   (200) KKNKKIKIANQSWKKNSFEDSFILKKNSSKNSFFGQHRVNYFSYNVNYSN 
   PVX_095140   (201) KKNKKIDTDDHSGKKNSLECSFSLKKNSSKNSFFGHPRANCFAYNVNYSN 
   PKH_081870   (201) EKNKNLEIYDQSGRKNSLECSFILKKKSSKNSIFGHHRVNCLSYNVNYSN 
 PCHAS_121730   (184) GKKNKNNDNNDIDNNDLIYDSSYNLKNSTFDKFYGDHDIDGFTYNKNVSN 
PBANKA_121660   (183) GKKIKTNDSNDLNNKNLIYDYSYNLKNYTFDKFYGHHDIDGFTYKNVSIS 
PY17X_1219800   (184) GKKIKTNDTNDLDNKNSIYDYSYNFKNYTFDKFYGHHDIDGFTYNQNVSN 
 PYYM_1219200   (184) GKKIKTNDTNDLDNKNSIYDYSYNFKNYTFDKFYGHHDIDGFTYNQNVSN 
    Consensus   (201)  KK K    N    KNSI D S L KN T   FFGHH INGFTYNVN SN 
                      251                                            300 
PF3D7_0321900   (225) SDDIWVDTH-L---EKRININNNNNNEEEFNKSVEKQENDEHKNNICD-N 
 PFIT_0322000   (225) SDDIWVDTH-L---EKRININNNNNNEEEFNKSVEKQENDEHKNNICD-N 
  PCYB_082790   (250) SDELSFEG------------------VKSISQNNSIDTNAVLSRLRSLNK 
   PVX_095140   (251) SDELSFEG------------------VKSISQNNSIDTNAVLSRLRSLNK 
   PKH_081870   (251) SDEYELSFEG----------------VKSISQNNSIDTNTVLSRLKSLKK 
 PCHAS_121730   (234) SEDIMMFG------DKYFMENNLALMKEGKNCGDELNTTCSHSDNESD-N 
PBANKA_121660   (233) EDVIISGEN-DSINNSMENNLVLMKIKQGKTCGDELNTTCSHSDIENNNT 
PY17X_1219800   (234) SEDVIVSGENDSINNSMENNLVLMKIKEAKTGGDEFNTTCSHSDIENNNT 
 PYYM_1219200   (234) SEDVIVSGENDSINNSMENNLVLMKIKEAKTGGDEFNTTCSHSDIENNNT 
    Consensus   (251) SDDI V G          N        ES S   EINTN  HS I   N  
                      301                                            350 
PF3D7_0321900   (270) ITCS-MKKKNIGKYFLYNRKRKMSSYNKDLK-----------SELLKYGH 
 PFIT_0322000   (270) ITCS-MKKKNIGKYFLYNRKRKMSSYNKDLK-----------SELLKYGH 
  PCYB_082790   (282) LGSS------VDLGSNRDSPATHACSADHTR-----------CADFPIGS 
   PVX_095140   (283) LGSSAVLGSSAVLSGSADLGGNVVISGSADLGANLDRCTIHPCADPPIGS 
   PKH_081870   (285) LGSTTDLGTKCDTCAIHPGCANQDSYENHTR-----------SVEFRFCS 
 PCHAS_121730   (277) SSIDGLDYKNVGSSDEYHSNYSSSFYASRVY-----------YMDSEHSE 
PBANKA_121660   (282) SSLDILDNKNIGSSDEYHSNYSSSFYVPKVY-----------CIDSEYSE 
PY17X_1219800   (284) SSLDILDNKNIGSSDEYHSNYSSSFYAPKLY-----------YVDSEYSE 
 PYYM_1219200   (284) SSLDILDNKNIGSSDEYHSNYSSSFYAPKLY-----------YVDSEYSE 
    Consensus   (301) LS S L  KNIGSS  Y S  S S YA  L             VD  Y   
                      351                                            400 
PF3D7_0321900   (308) KYSVLKSREDVKLLRSKSIMLNCVNNNNDDDEEKGERKKYINNIKYLKNE 
 PFIT_0322000   (308) KYSVLKSREDVKLLRSKSIMLNCVNNNNDDDEEKGERKKYINNIKYLKNE 
  PCYB_082790   (315) SGEYADGKPLQNGESITGVKKDDADHLRDAHFERRKRRAEIKHNKRMLQM 
   PVX_095140   (333) SGEYAGGGPLQNGGSITGAKKDDADHLRDAHLERRKRRAEIKHNKRMLQM 
   PKH_081870   (324) SGEYTDGKALQHGDSITGVNIDNAHHLREAHLERRKRRAEIKYNKRMLQM 
 PCHAS_121730   (316) KIYYKKSIRDALVKKKSLVNFKYTYSRSIGDGNSTEINGNGFGRKRRKKD 
PBANKA_121660   (321) KIYYKKNIRDALVKKNSLVNFNYAYSRSIGDGSSIDINRKGFGRKRKKKK 
PY17X_1219800   (323) KIYYKKSIRDALVKKKSLVNFNYAYSRSIGDGNSFEINRKGFGRKRKKKE 
 PYYM_1219200   (323) KIYYKKSIRDALVKKKSLVNFNYAYSRSIGDGNSFEINRKGFGRKRKKKE 
    Consensus   (351) K  Y KS  D  V K S VN N AY   DGD ER ERRR I   KRMKQE 
                      401                                            450 
PF3D7_0321900   (358) IKLNYYFKYKGNMINDTYYSDNIYDMEKENWTKHKKNKKKINEIYNTTKK 
 PFIT_0322000   (358) IKLNYYFKYKGNMINDTYYSDNIYDMEKENWTKHKKNKKKINEIYNTTKK 
  PCYB_082790   (365) LNKKSIEINSHRRRKTNRLSYLLLFEPIA--------------------- 
   PVX_095140   (383) LNKKSIEKNALRRRKTTRLSRRLLFEPLS--------------------- 
   PKH_081870   (374) LNKKSIERNAHRRRKTNRLSTFLLFEPLA--------------------- 
 PCHAS_121730   (366) KYKFYNINSFDQSVKKNKIYLLIYFLFKP--------------------- 
PBANKA_121660   (371) NFKLYSINSFDKNVKKNRIFILIYFLFKP--------------------- 
PY17X_1219800   (373) NFKLYRISSFDKNVKKNRIFILIYFLFKP--------------------- 
 PYYM_1219200   (373) NFKLYRISSFDKNVKKNRIFILIYFLFKP--------------------- 
    Consensus   (401) L K Y      K VK NRIS LIYFL K                       
                      451                                            500 
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PF3D7_0321900   (408) EKKNFFIHFFIILFCFGKNILQNIKYLMNYIFIKIVYFFHIHKLYTFPIY 
 PFIT_0322000   (408) EKKNFFIHFFIILFCFGKNILQNIKYLMNYIFIKIVYFFHIHKLYTFPIY 
  PCYB_082790   (394) -------FVKRKICYVLKTSTKNVYDVFKRVCIRVLLFFHINRLYSCSIF 
   PVX_095140   (412) -------FAKRKICHVLKSSVKSVYDVFKRVCIRVLLFFHINRLYSCSIF 
   PKH_081870   (403) ------FAKR-IICNVLKSSVNNIYNVFKRIGIRVLLFFHMNRLYSCSIF 
 PCHAS_121730   (395) -----IILIIKLLFNIFKYIVKYFFSFFFIIYMNIIHFFHIKKLYTFNDI 
PBANKA_121660   (400) -----FNFVTKKLFNFFKYIVKYVYSFFLIIYMNIIHFFHIKKLYTFNYI 
PY17X_1219800   (402) -----FNFVTKKLFNFFKYIVKYFYSFFLIIYMNIIHFFHIKKLYTFNDV 
 PYYM_1219200   (402) -----FNFVTKKLFNFFKYIVKYFYSFFLIIYMNIIHFFHIKKLYTFNDV 
    Consensus   (451)      F FV KKLFNF K IVK IY VF  IYIRIIHFFHI KLYTF IF 
                      501                                            550 
PF3D7_0321900   (458) KDERKKKKMYTQSFEMNFHNTRNKQMVDFSDIHNRRGLLKIDYEQGGEIH 
 PFIT_0322000   (458) KDERKKKKMYTQSFEMNFHNTRNKQMVDFSDIHNRRGLLKIDYEQGGEIH 
  PCYB_082790   (437) NVEEKK-KIVTRSFEAKCLGSGKKGGGQAEGERQSDAAKIEERQTGGDQS 
   PVX_095140   (455) NAEEKK-KIVTRSFEAKCLGSGKK---------------GADRAEEGQ-- 
   PKH_081870   (446) KAQEKK-KIVTRSFEAKCLGSGKK---------------GSDTSMMEER- 
 PCHAS_121730   (440) KKDDKT-KITTRSFEIKYLSSKQQ---------------TDNNGQNGE-- 
PBANKA_121660   (445) KKEDKT-KIITRSLEIKYLPSKQQ---------------TGDNVKNEK-- 
PY17X_1219800   (447) KKEDKT-KIITRSLEIKYLSSKQQ---------------TGDNVKNEK-- 
 PYYM_1219200   (447) KKEDKT-KIITRSLEIKYLSSKQQ---------------TGDNVKNEKN- 
    Consensus   (501) K EDKK KIITRSFEIKYL SKQK                 D    GE   
                      551                                            600 
PF3D7_0321900   (508) RLNSVHFEDNEEHISSNLFIKHMYKSNEVDMGKCVNMSNKEKTKQNNKNM 
 PFIT_0322000   (508) RLNSVHFEDNEEHISSNLFIKHMYKSNEVDMGKCVNMSNKEKTKQNNKNM 
  PCYB_082790   (486) KEQLCGDGEAKEQQTGSDQSKEQLCGDGDAKERQTGVDQSKEQLCADGEA 
   PVX_095140   (487) --------------SEAAKTEERKSEAAKTEEGQTCGDPATEQLSRDDQA 
   PKH_081870   (479) --------------QSSDDQAKEQPHDDATVEPPPQTEDQPAVIAQNADV 
 PCHAS_121730   (472) -----------N--DDNDDCVKVYKANLNSSQEMNNLSSQIKSFDRDAQK 
PBANKA_121660   (477) -----N--------NGNDDCVQVYKEHINPTQEMNNVSAQIKACDSDLQK 
PY17X_1219800   (479) -----N--------DDHDDCVQVYKENLNPAQEMNNVSAQIKACDRDLQQ 
 PYYM_1219200   (480) --------------DDHDDCVQVYKENLNPAQEMNNVSAQIKACDRDLQQ 
    Consensus   (551)                  DD   VYK N        NVS Q K    D Q  
                      601                                            650 
PF3D7_0321900   (558) RNLLMCAKR-------------VIGRNNKLCASKNDHIDTNKGENYSNEF 
 PFIT_0322000   (558) RNLLMCAKR-------------VIGRNNKLCASKNDHIDTNKGENYSNEF 
  PCYB_082790   (536) KERQTAGDQAKERQTAGDQSKEQLRADGEAKEQPRDNPTAEQATQQEGEP 
   PVX_095140   (523) EGEPAATSQTGEAR---------KGESPNQASHPTQKKEEPPNESALFLP 
   PKH_081870   (515) RKGEKANQVSHL----------TQMKEDPPKEIPLFLPINNRQ---SRTR 
 PCHAS_121730   (509) TELEKDEKK-------------GKGTNGPISYSNNTQSKSN------VEK 
PBANKA_121660   (514) PEFEKDEKDERK----------GKERNGEISYLENKVHESNVE------- 
PY17X_1219800   (516) SEFEKDGNDEND----------EKDEKDENDENDEKDENDENDEKDENDE 
 PYYM_1219200   (516) SEFEKDGNDEND----------EKDEKDENDENDEKDENDENDEKDENDE 
    Consensus   (601)  E EK G                K                N  E    E  
                      651                                            700 
PF3D7_0321900   (595) VDNKFEASCEQYGKDKDTKMNDPNNNMDNNMENNNDNNNDNHIIMSDVMN 
 PFIT_0322000   (595) VDNKFEASCEQYGKDKDTKMNDPNNNMDNNMENNNDNNNDNHIIMSDVMN 
  PCYB_082790   (586) AGTAQNGQVHKGESPNQASHLTQKKEEPPKDSSLFLPINNRQNSTKNYSQ 
   PVX_095140   (564) ISNRQS-------------------------------------STNNYSQ 
   PKH_081870   (552) SDSKR--------------------------------------------- 
 PCHAS_121730   (540) IKKKE--------------------------------------------- 
PBANKA_121660   (547) -KNQQ--------------------------------------------I 
PY17X_1219800   (556) KDENDEKK------------G----NEKNGEINYSENTVHESNVEKNQQI 
 PYYM_1219200   (556) KDENDEKK----------------GNEKNGEINYSENTVHESNVEKNQQI 
    Consensus   (651)  D K                                               
                      701                                            750 
PF3D7_0321900   (645) NASYCTTEKHNNCDLLNMKANDNMFN-ACSHNNDDDKIIKKGCHDLKYKK 
 PFIT_0322000   (645) NASYCTTEKHNNCDLLNMKANDNMFN-ACSHNNDDDKIIKKGCHDLKYKK 
  PCYB_082790   (636) KGSLQQNGDDIISDFSNHSDYTTDGSDLSCSSNPTDICDVFDGVLFLDGQ 
   PVX_095140   (577) QGNPPPNGDDQVSDSSNQSVYTTDGSDLSCSSNPSDICEVFDGVLFLDGQ 
   PKH_081870   (557) -GSYQQNVDDLISDFSNQSAYTTDGSDLSCSTNPTDICEVFDGVLFLDGQ 
 PCHAS_121730   (545) -TGKITNESGKTVNFTNLRNVVNKYI-NKKSNKKYNLKKKKDENDVNCKD 
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PBANKA_121660   (552) ETEHTTNENEKAVNFTNIRNVANKYISNKKLNEKHNFKKRKEENDANCKD 
PY17X_1219800   (590) ETENTTNESGKAVNFTDIRNVVNKYISNKKLNEKHNLKKRKEENDVNCKD 
 PYYM_1219200   (590) ETENTTNESGKAVNFTDIRNVVNKYISNKKLNEKHNLKKRKEENDVNCKD 
    Consensus   (701)  G   TNE     DFTNIR   N Y      NN  DI  KKD  DV  K  
                      751                                            800 
PF3D7_0321900   (694) DNQNCNSFMVNEKNDDKFINDTNKCNPFLVKSFYKDEKYKKSNDDFTKLN 
 PFIT_0322000   (694) DNQNCNSFMVNEKNDDKFINDTNKCNPFLVKSFYKDEKYKKSNDDFTKLN 
  PCYB_082790   (686) SNPDEENDPSDSYGQNQNDQLNPLFMTQ--KRNSENCVYYKLNEGYTKRR 
   PVX_095140   (627) SNPDEENNPSDPYGQNQSGQLDPLFMTQ--KRNSENCVYYKLNEGFTKRR 
   PKH_081870   (606) SNLEEENDPSDSYGQNQSCHLNPLFMTQ--KRNSENYLYYKLNEGFAKRK 
 PCHAS_121730   (593) KNVIHEKNNENTRIDDEIRNEGFTMN----EQNGDSYFYYTYNDQYSEKK 
PBANKA_121660   (602) KNIIYEKSQENTKINNETKNEGFTMN----EQNDDSYFYYTCNEHYSEKK 
PY17X_1219800   (640) KNIIYEKNQENKKINNEAKNEGFTMN----GQNDNNYFYYTCNEQYSEKK 
 PYYM_1219200   (640) KNIIYEKNQENKKINNEAKNEGFTMN----GQNDNNYFYYTCNEQYSEKK 
    Consensus   (751)  NI  E    N K NN   NE    N    K N ENY YYK NE YSKKK 
                      801                                            850 
PF3D7_0321900   (744) ENNKKDSKNMKNKKNINNLQNMNKIKDMKKKLFKEHLNSLKLSFPEYSGI 
 PFIT_0322000   (744) ENNKKDSKNMKNKKNINNLQNMNKIKDMKKKLFKEHLNSLKLSFPEYSGI 
  PCYB_082790   (734) SIMKN----------------ISKVKEMKRKLLRQHLNSLKLSFPEYSGL 
   PVX_095140   (675) SIIKN----------------ISKVKEMKRKLLKQHLNSLKLSFPEYSGL 
   PKH_081870   (654) SIMKN----------------ISKVKEMKRKLLRQHLNSLKLSFPEYSGL 
 PCHAS_121730   (639) KKN------------------VKKVKHMKKKLLKDHIKFLNLSFPEYSGL 
PBANKA_121660   (648) KKN------------------VKNVKYMKKKLLKDHINFLNLSFPEYSGL 
PY17X_1219800   (686) KKK-----------------NVKNVKYMKKKLLKDHINFLNLSFPEYSGL 
 PYYM_1219200   (686) KKK-----------------NVKNVKYMKKKLLKDHINFLNLSFPEYSGL 
    Consensus   (801)    K                 V KVKEMKKKLLKDHLNSLKLSFPEYSGL 
                      851                                            900 
PF3D7_0321900   (794) IRLSLILICIYIFSFVDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
 PFIT_0322000   (794) IRLSLILICIYIFSFVDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
  PCYB_082790   (768) IRMSLILICIYIFSFVDTSRIYHYIRAQPFMKLYVVLNMLEIVERLLRSL 
   PVX_095140   (709) IRMSLILICIYIFSFVDTSRIYHYIRAQPFMKLYVVLNMLEIVERLLRSL 
   PKH_081870   (688) IRMSLILICIYIFSFVDTSRIYHYIRAQPFMKLYVVLNMLEIVERLLRSL 
 PCHAS_121730   (671) IRTSLILICIYIFSFLDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
PBANKA_121660   (680) IRTSLILICIYIFSFLDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
PY17X_1219800   (719) IRASLILICIYIFSFLDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
 PYYM_1219200   (719) IRASLILICIYIFSFLDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
    Consensus   (851) IRMSLILICIYIFSFVDTSRIYHYIRAQPFMKLYVVLNMLEILERLLRSL 
                      901                                            950 
PF3D7_0321900   (844) GKDLIDNMIRTFIRIINLRSYICIIRNNYNEKSSINSNSNYINYVHNDNY 
 PFIT_0322000   (844) GKDLIDNMIRTFIRIINLRSYICIIRNNYNEKSSINSNSNYINYVHNDNY 
  PCYB_082790   (818) GKDLIDNMIRTFIRIINLRSYVYIVRNHYTSKENEQREAGGMPGMSEQTP 
   PVX_095140   (759) GKDLIDNMIRTFIRIINLRSYVYIVRNHYTSKEGEREAGGVPGMAEHGSG 
   PKH_081870   (738) GKDLIDDMIRTFIRIINLRSYVYIVRNHYTSKENERETGATPGMSEHNPS 
 PCHAS_121730   (721) GKDLIDNMIRTFIRIINLRSYIYIVRKHYNNMTNDDIHFSNTSLE----- 
PBANKA_121660   (730) GKDLIDNMIRTFIRIINLRSYIYIIRNHYNNMTNDDENFSNESLE----- 
PY17X_1219800   (769) GKDLIDNMIRTFIRIINLRSYIYIIRNHYNNMTNDDENFSNESLE----- 
 PYYM_1219200   (769) GKDLIDNMIRTFIRIINLRSYIYIIRNHYNNMTNDDENFSNESLE----- 
    Consensus   (901) GKDLIDNMIRTFIRIINLRSYIYIIRNHYN KTND EN S   L       
                      951                                           1000 
PF3D7_0321900   (894) GV------------------------NSYIYKNKDNNNELITFDNTRHIN 
 PFIT_0322000   (894) GV------------------------NSYIYKNEDNNNELITFDNTRHIN 
  PCYB_082790   (868) SGASQGRKKATFPAASPTTAMNGMTTTAATTTTTTTTDMTATPAATSGGS 
   PVX_095140   (809) GVPSGGVS-----------PGGALQGGKKATFPAASPTTTTNGATTGGPS 
   PKH_081870   (788) GVPQGRKK-------TTFPASSPTTTTTATTTATTGTTATITTAATSGGS 
 PCHAS_121730   (766) -------------------------------------------------- 
PBANKA_121660   (775) -------------------------------------------------- 
PY17X_1219800   (814) -------------------------------------------------- 
 PYYM_1219200   (814) -------------------------------------------------- 
    Consensus   (951)                                              T     
                      1001                                          1050 
PF3D7_0321900   (920) VFTNKNKDNLLNNNNNNMNYMNYMYKDSVIKNKHEYENGYVTNMDKDIFS 
 258 
 PFIT_0322000   (920) VFTNKNKDNLLNNNN--MNYMNYMYKDSVIKNKHEYKNGYVTNMDKDIFS 
  PCYB_082790   (918) AIQADHSPENKSPTQKHPTPCEDPPNDHQATNKPTDICPIGNGTQDAEKC 
   PVX_095140   (848) TQAEHYPETNATPTREHPNQGEAPPSDDQAASKPAGICPVGNDAQDVEMC 
   PKH_081870   (831) WTQGEHCSENKLPTPKHLNPFEITPNDDQPKNKPTDICQISHATQESEKG 
 PCHAS_121730   (766) ---GRRKKNYIINKN------NILHEEGNIKKKNEKVKFSENSTKECRKI 
PBANKA_121660   (775) ---GRRKEKYIINNN---S-NNILQEEGNGKKKNEKIKFSEIFTKEYRTN 
PY17X_1219800   (814) ---GRRKKTYIINNS------NILHEEGNGKKKNEKIKFSEIFTKEYRKN 
 PYYM_1219200   (814) ---GRRKKTYIINNS------NILHEEGNGKKKNEKIKFSEIFTKEYRKN 
    Consensus  (1001)    GR K   IINNN      NILH D NGK K E I      T E  K  
                      1051                                          1100 
PF3D7_0321900   (970) NNFYMNNIRHHADSFYYQNE---------------------------LNS 
 PFIT_0322000   (968) NNFYMNNIRHHADSFYYQNE---------------------------LNS 
  PCYB_082790   (968) RNKIATTPRHNQKQSQNQNPNQNQNHSQNQLSSNQLSPNQLSQNQLSSNQ 
   PVX_095140   (898) RSEVSSAPRHNHIPSQNQNQNQNANQNQN------------------PNQ 
   PKH_081870   (881) RNKITTTPRHNQNHQMKQN------------------------------Q 
 PCHAS_121730   (807) SNLYLNYKRVNFKK----------------------------------NN 
PBANKA_121660   (818) SDIYINYKGINFKKNNKNN-----------------------------DN 
PY17X_1219800   (855) SDIYINYKGINLKKNNKNN-----------------------------VN 
 PYYM_1219200   (855) SDIYINYKGINLKKNNKNN-----------------------------VN 
    Consensus  (1051)  N YIN  RHN K  N QN                             NN 
                      1101                                          1150 
PF3D7_0321900   (993) FNLNKNKENNVRFFNNE----------NDKKKNNKSKISILFPFYSVVLK 
 PFIT_0322000   (991) FNLNKNKENNVRFFNNE----------NDKKKNNKSKISILFPFYSVVLK 
  PCYB_082790  (1018) LSPNEREKNKIDCLKNN----------KDDQMNKKFKIPIFYPFYSILIK 
   PVX_095140   (930) LSPNEREKNKIDCLKNNKDKDKDKDKDKDDQTNKKFKIPIFYPFYSILIK 
   PKH_081870   (901) LSPNEREKNKIDGLKNN----------KEDQMNKKFKIPIFYPFYSILIK 
 PCHAS_121730   (823) EDPYFNKEKNVFAFLKN----------NDEMAAN-FKLPIFFPFLSILIK 
PBANKA_121660   (839) TNPYFNKEKNMFSFLKN----------NNEMPAN-FKLPIFYPFLSILIK 
PY17X_1219800   (876) TNPYFNKEKNMFSFLKN----------NNEMAAN-FKLPIFYPFLSILIK 
 PYYM_1219200   (876) TNPYFNKEKNMFSFLKN----------NNEMAAN-FKLPIFYPFLSILIK 
    Consensus  (1101)  NPN NKENNI  F NN          NDE  NNKFKIPIFYPFYSILIK 
                      1151                                          1200 
PF3D7_0321900  (1033) FTIQYIFVLAYILIHAFMHLVRFLSLNIAINSSESTMFLILVMSNFTEIK 
 PFIT_0322000  (1031) FTIQYIFVLAYILIHAFMHLVRFLSLNIAINSSESTMFLILVMSNFTEIK 
  PCYB_082790  (1058) FIVQYIFVLTYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
   PVX_095140   (980) FIVQYIFVLTYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
   PKH_081870   (941) FIVQYIFVLTYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
 PCHAS_121730   (862) FILQYIFVLAYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
PBANKA_121660   (878) FILQYIFVLIYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
PY17X_1219800   (915) FILQYICVLIYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
 PYYM_1219200   (915) FILQYICVLIYILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
    Consensus  (1151) FILQYIFVL YILTHAFAHLIRFLSLNIAINSSESTMFLILVMSNFTEIK 
                      1201                                          1250 
PF3D7_0321900  (1083) STVFKKFTKISLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFFSI 
 PFIT_0322000  (1081) STVFKKFTKISLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFFSI 
  PCYB_082790  (1108) STVFKKFSKTSLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFFSI 
   PVX_095140  (1030) STVFKKFSKTSLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFFSI 
   PKH_081870   (991) STVFKKFSKTSLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFFSI 
 PCHAS_121730   (912) STVFKKFNKISLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFLSI 
PBANKA_121660   (928) STVFKKFTKISLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFLSI 
PY17X_1219800   (965) STVFKKFTKISLFTIVASDSVERFYLFIDAFLVLLKMSTAYRTQNSFLSI 
 PYYM_1219200   (965) STVFKKFTKISLFTIVASDSVERFYLFIDAFLVLLKMSTAYRTQNSFLSI 
    Consensus  (1201) STVFKKFTKISLFTIVASDAVERFYLFIDAFLVLLKMSTAYRTQNSFFSI 
                      1251                                          1300 
PF3D7_0321900  (1133) SSWLIIILLLEVGVDWCKHSYLLKYNKLDSESLNKYFHTLLADVLISRTP 
 PFIT_0322000  (1131) SSWLIIILLLEVGVDWCKHSYLLKYNKLDSESLNKYFHTLLADVLISRTP 
  PCYB_082790  (1158) SSWLIIILLLEVGVDWCKHSYLLKYNKLDSESLNKYFHTLLADVLISRTP 
   PVX_095140  (1080) SSWLIIILLLEVGVDWCKHSYLLKYNKLDSDSLNKYFHTLLADVLISRTP 
   PKH_081870  (1041) SSWLIIILLLEVGVDWCKHSYLLKYNKLDSDSLNKYFHTLLADVLISRTP 
 PCHAS_121730   (962) TSWLIIILLLEVGVDWCKHSYLLKYNKLKSESLIRYFQTLLADVLISRTT 
PBANKA_121660   (978) TSWLVIILLLEVGVDWCKHSYLLKYNKLKSESLIRYFQTLLADVLISRTR 
 259 
PY17X_1219800  (1015) TSWLIIILLLEVGVDWCKHSYLLKYNKLKSESLIRYFQTLLADVLISRTT 
 PYYM_1219200  (1015) TSWLIIILLLEVGVDWCKHSYLLKYNKLKSESLIRYFQTLLADVLISRTT 
    Consensus  (1251) SSWLIIILLLEVGVDWCKHSYLLKYNKLDSESLNKYFHTLLADVLISRTP 
                      1301                                          1350 
PF3D7_0321900  (1183) NKNIYYM-KDSFAVPCKNIFSFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
 PFIT_0322000  (1181) NKNIYYM-KDSFAVPCKNIFSFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
  PCYB_082790  (1208) NNNIYYMNTSSFEVPCKNIFCFAHIPTRRLGYMSMP-------------- 
   PVX_095140  (1130) NNNIYYMNTSSFEVPCKNIFCFAHIPTRRLGYMSMPVVTLIVCSLPRLNY 
   PKH_081870  (1091) NNNIYYMNTSSFEVPCKNIFCFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
 PCHAS_121730  (1012) NNNIYYMNTVSFEVPCKNIFSFPHIPTRRLGYMSMPVVTLIVCSLPRLNY 
PBANKA_121660  (1028) NNNIYYMNTLSFEVPCKNIFSFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
PY17X_1219800  (1065) NNNIYYMNTLSFEVPCKNIFSFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
 PYYM_1219200  (1065) NNNIYYMNTLSFEVPCKNIFSFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
    Consensus  (1301) NNNIYYMNT SFEVPCKNIFSFSHIPTRRLGYMSMPVVTLIVCSLPRLNY 
                      1351                                          1400 
PF3D7_0321900  (1232) LSNISLFSFALSIWICLFLFKIILSIMIVSYTISEKKQLKNLKKPYDDIS 
 PFIT_0322000  (1230) LSNISLFSFALSIWICLFLFKIILSIMIVSYTISEKKQLKNLKKPYDDIS 
  PCYB_082790  (1244) --------------------VIILSVMIVSYTISEKKHLKNLGKPYDDIS 
   PVX_095140  (1180) LYNISHFSFALSIWVCLFLFKIILSVMIVSYTISEKKHLKNLGKPYDDIS 
   PKH_081870  (1141) LYNISHLSFALSIWVCLFLFKITLSVMIVSYTISQKKHLKNLGKPYDDIS 
 PCHAS_121730  (1062) LSNISLLSFALSIWICLFLFKIILSIMIVSYTISEKHQLKNLKKPYDDIS 
PBANKA_121660  (1078) LSNISLLSFALSIWICLFLFKIILSIMIVSYTISEKHQLKNLKKPYDDIS 
PY17X_1219800  (1115) LSNISLLSFALSIWICLFLFKIILSIMIVSYTISEKHQLKNLKKPYDDIS 
 PYYM_1219200  (1115) LSNISLLSFALSIWICLFLFKIILSIMIVSYTISEKHQLKNLKKPYDDIS 
    Consensus  (1351) LSNISLLSFALSIWICLFLFKIILSIMIVSYTISEKKQLKNLKKPYDDIS 
                      1401 
PF3D7_0321900  (1282) AL 
 PFIT_0322000  (1280) AL 
  PCYB_082790  (1274) AM 
   PVX_095140  (1230) AM 
   PKH_081870  (1191) AM 
 PCHAS_121730  (1112) AL 
PBANKA_121660  (1128) AL 
PY17X_1219800  (1165) AL 
 PYYM_1219200  (1165) AL 

















(b) PfUGT  
                     1                                               50 
PF3D7_1113300    (1) ---MVKIQKSSGMFWKRNS-ESSNLYNFLNGLFCIGGIYFFFIIFGYYQE 
 PFIT_1114100    (1) ---MVKIQKSSGMFWKRNS-ESSNLYNFLNGLFCIGGIYFFFIIFGYYQE 
  PCYB_091960    (1) ---MAKLKKNSLFWKRDSS-EASYFYNMLNGLICVSGIYFFFLIFGYYQE 
   PKH_091050    (1) ---MAKLKKNSMMFWKRDSNEMSYFYNMLNGLICISGIYFFFLIFGYYQE 
   PVX_091310    (1) ---MAKLKKNSMMFWKRDSHEVSYFYNMLNGLICVSGIYFFFLIFGYYQE 
 PCHAS_091000    (1) MMGVGKSQKGKFAFLKKGLKEGSSLYNFLNGLFCVSGIYIFFLIFGYYQE 
PBANKA_093430    (1) MMGVGKSQKGKFSFLKKDLEEGSSLYNFLNGLFCISGIYIFFLIFGYYQE 
PY17X_0936300    (1) MMGVGKSQKGKFSFFKKGLKEGSGLYNFLNGLFCVSGIYIFFLIFGYYQE 
 PYYM_0935700    (1) MMGVGKSQKGKFSFFKKGLKEGSGLYNFLNGLFCVSGIYIFFLIFGYYQE 
    Consensus    (1)    MGKLQK S  FWKK S EGS LYNFLNGLFCVSGIYFFFLIFGYYQE 
                     51                                             100 
PF3D7_1113300   (47) KLPQLGRGSDRFYYNIFLICVLCLSNSLCSLSAIFFKSRLNNENVMSSLK 
 PFIT_1114100   (47) KLPQLGRGSDRFYYNIFLICVLCLSNSLCSLSAIFFKSRLNNENVMSSLK 
  PCYB_091960   (47) KLPNLGKGKDKFYYNIFLICILCFSNSVCSLTAVFIKSKLNNEQFLQDLK 
   PKH_091050   (48) KLPNLGKGKDKFYYNIFLICILCFSNSVCSLTAVFIKSKLNNEKFLQDLK 
   PVX_091310   (48) KLPNLGKGKDKFYYNIFLICILCFSNSVCSLTAVFIKSKLNNEPFLHDLK 
 PCHAS_091000   (51) KIPTLGSGRDKFYYNIFLICILCLSNSLGSLLSIFTKSTLNNEKFLRNMK 
PBANKA_093430   (51) KIPTLGKGKDKFYYNIFLICILCLSNSLGSLLSIFTKSMLNNEKFLRSMK 
PY17X_0936300   (51) KIPTLGKGKDKFYYNIFLICILCLSNSLGSLLSIFTKSMLNNEKFLRSMK 
 PYYM_0935700   (51) KIPTLGKGKDKFYYNIFLICILCLSNSLGSLLSIFTKSMLNNEKFLRSMK 
    Consensus   (51) KLPNLGKGKDKFYYNIFLICILCLSNSLCSLTAIF KSKLNNEKFL SLK 
                     101                                            150 
PF3D7_1113300   (97) KNVDKYFIKQIMLISITYSIAMIATNYSLSHVNFPTQVLVKSGKMIPIVV 
 PFIT_1114100   (97) KNVDKYFIKQIMLISITYSIAMIATNYSLSHVNFPTQVLVKSGKMIPIVV 
  PCYB_091960   (97) KNVDKYFIKQIMLISVTYSIAMIATNYSLSHVNFPTQVLVKSGKMIPIVV 
   PKH_091050   (98) KNVDKYFLKQIMLISVTYSIAMIATNYSLSHVNFPTQVLVKSGKMIPIVV 
   PVX_091310   (98) KNVDKYFIKQIMLISVTYSIAMIATNYSLSHVNFPTQVLVKSGKMIPIVV 
 PCHAS_091000  (101) KNIDKYFLTQIMLISITYSIAMIATNYSLRHVNFPTQVLVKSGKMIPIIV 
PBANKA_093430  (101) KNIDKYFITQIMLISITYSIAMIATNYSLRHVNFPTQVLVKSGKMIPIIV 
PY17X_0936300  (101) KNIDKYFITQIMLISITYSIAMIATNYSLRHVNFPTQVLVKSGKMIPIIV 
 PYYM_0935700  (101) KNIDKYFITQIMLISITYSIAMIATNYSLRHVNFPTQVLVKSGKMIPIIV 
    Consensus  (101) KNVDKYFIKQIMLISITYSIAMIATNYSLSHVNFPTQVLVKSGKMIPIVV 
                     151                                            200 
PF3D7_1113300  (147) GGYFFFGKKYPYYDYISVFLITSSLVLFNLLRTKSSKEVHQTTFGILLLC 
 PFIT_1114100  (147) GGYFFFGKKYPYYDYISVFLITSSLVLFNLLRTKSSKEVHQTTFGILLLC 
  PCYB_091960  (147) GGYCFFGKKYPYYDYISVFLITSSLVIFNLLRTKSSKEVQQTTFGLLLLC 
   PKH_091050  (148) GGYFFFGKKYPYYDYISVFLITSSLVIFNLLRTKSSKEVHQTTFGLLLLC 
   PVX_091310  (148) GGYCFFGKKYPYYDYISVFLITSSLVIFNLLRTKSSKEVHQTTFGLLLLC 
 PCHAS_091000  (151) GGYFFFGKKYPYYDYVSVFLITTSLIIFNLLKAKTAKEMHQTTFGILLLC 
PBANKA_093430  (151) GGYLFFGKKYPYYDYISVFLITTSLIIFNLLKTNTTKEMHQTTFGILLLC 
PY17X_0936300  (151) GGYLFFGKKYPYYDYISVFLITTSLIIFNLLKTNTTKEMHQTTFGILLLC 
 PYYM_0935700  (151) GGYLFFGKKYPYYDYISVFLITTSLIIFNLLKTNTTKEMHQTTFGILLLC 
    Consensus  (151) GGY FFGKKYPYYDYISVFLITSSLVIFNLLRTKSSKEVHQTTFGILLLC 
                     201                                            250 
PF3D7_1113300  (197) ISLLCDGLTGPRQDKLLSKYNVDSVNLMFYVNIFAFIFNLLASLIIEGNK 
 PFIT_1114100  (197) ISLLCDGLTGPRQDKLLSKYNVDSVNLMFYVNIFAFIFNLLASLIIEGNK 
  PCYB_091960  (197) LSLICDGLTGPRQDKLLSKYNVNSINLMFYVNIFAFFFNLLASLLIEGGK 
   PKH_091050  (198) LSLMCDGLTGPRQDKLLSKYNVNSINLMFYVNIFAFFFNLLASLIIEGAK 
   PVX_091310  (198) LSLICDGLTGPRQDKLLSKYNVNSINLMFYVNIFAFCFNLVASLIIEGAK 
 PCHAS_091000  (201) VSLVCDGLTGPRQDKLLSKYNVNSFNLMFYVNIFAFFFNLVASLLIEGAK 
PBANKA_093430  (201) ISLVCDGLTGPRQDKLLSKYNVNSFNLMFYVNIFAFFFNLVASLLIEGAK 
PY17X_0936300  (201) ISLVCDGLTGPRQDKLLSKYNVNSFNLMFYVNIFAFFFNLVASLLIEGAK 
 PYYM_0935700  (201) ISLVCDGLTGPRQDKLLSKYNVNSFNLMFYVNIFAFFFNLVASLLIEGAK 
    Consensus  (201) ISLVCDGLTGPRQDKLLSKYNVNSINLMFYVNIFAFFFNLVASLLIEGAK 
                     251                                            300 
PF3D7_1113300  (247) PYIFLQKYTTSYYYILAFSVSGTLGQFFVFYSLRVYGSLYTSLFTTLRKA 
 PFIT_1114100  (247) PYIFLQKYTTSYYYILAFSVSGTLGQFFVFYSLRVYGSLYTSLFTTLRKA 
  PCYB_091960  (247) PYNFLSKYPNSYYYIIAFSISGTLGQFFVFYSLKVYGSLYTSLFTTLRKA 
 261 
   PKH_091050  (248) PYNFLSKYSNSYYYILAFSISGTLGQFFVFYSLKVYGSLYTSLFTTLRKA 
   PVX_091310  (248) PYNFLSKYTNSYYYILAFSISGTLGQFFVFYSLKVYGSLYTSLFTTLRKA 
 PCHAS_091000  (251) PYAFLAKYPSSYYYILGFSISGTLGQFFIFYSLKVYGSLYTSLFTTLRKA 
PBANKA_093430  (251) PYAFLAKYPNSYYYILGFSISGTLGQFFIFYSLKVYGSLYTSLFTTLRKA 
PY17X_0936300  (251) PYAFLAKYPSSYYYILGFSISGTLGQFFIFYSLKVYGSLYTSLFTTLRKA 
 PYYM_0935700  (251) PYAFLAKYPSSYYYILGFSISGTLGQFFIFYSLKVYGSLYTSLFTTLRKA 
    Consensus  (251) PY FLAKYPSSYYYILAFSISGTLGQFFVFYSLKVYGSLYTSLFTTLRKA 
                     301                                         347 
PF3D7_1113300  (297) LSTVVSVYLFGHVLKPLQWICIGVIFSTLIVQSYLKKQSKKVQSKNK 
 PFIT_1114100  (297) LSTVVSVYLFGHVLKPLQWICIGVIFSTLIVQSYLKKQSKKVQSKNK 
  PCYB_091960  (297) LSTVVSVYLFGHVLKPLQWGCIAVIFSTLIIQNYLKQQAKK------ 
   PKH_091050  (298) LSTVVSVYLFGHVLKPLQWVCIAVIFSTLIIQNYLKQQAKKVHSKTK 
   PVX_091310  (298) LSTVVSVYLFGHVLKPLQWGCIAVIFSTLIIQNYLKQQAKKVHSKTK 
 PCHAS_091000  (301) LSTVVSVYMFGHVLKPLQWICIIVIFSTLIIQNYLKKNDKKHHKKLI 
PBANKA_093430  (301) LSTVVSVYLFGHVLKPLQWICIIVIFSTLIIQNYLKKNTKKNHKKNM 
PY17X_0936300  (301) LSTVVSVYLFGHVLKPLQWICIIVIFSTLIIQNYLKKNTKKHHKKNM 
 PYYM_0935700  (301) LSTVVSVYLFGHVLKPLQWICIIVIFSTLIIQNYLKKNTKKHHKKNM 


















                     1                                               50 
PF3D7_1036800    (1) MFNRLFENFEYNFFIKRKKLKYDTKD-------GQYVKQNISKRNKDYYN 
 PFIT_1036000    (1) MFNRLFENFEYNFFIKRKKLKYDTKD-------GQYVKQNISKRNKDYYN 
  PCYB_063040    (1) MTKTVHDKTDANVLKERKQKHGAVKDGGSYCKDEEKVKVKVPTKGHDFYN 
   PVX_110920    (1) MTKIVNDKTDANVLKERKQKHGAVKDG--GSYCKDEGKVKVPTKGHDFYN 
   PKH_062100    (1) MSKIVHDKTEANVLKERKQKHGAVKDG--ASYCQDEGNVKVATRGHDFYN 
 PCHAS_052000    (1) MNKSSHGNTNTNLMKERKPKQKTDDE-------KDYSKEKISNNNSDFYN 
PBANKA_051980    (1) MTKSSHGNTNTNLMKERRPKQKTDDE-------KDYSKEKISKNNTDFYN 
PY17X_0520900    (1) MTKSSHGNTNTNLMKERRPKQKTDDE-------KDYSKEKISKNNTDFYN 
 PYYM_0520300    (1) MTKSSHGNTNTNLMKERRPKQKTDDE-------KDYSKEKISKNNTDFYN 
    Consensus    (1) MTKSVHDNTE NLMKERK K    KD       KDY K KISKRN DFYN 
                     51                                             100 
PF3D7_1036800   (44) IIFLLSLYTIQGVPIGVSSVVPLIIQDKVSYSQLSILSLVSIPFSIKLLW 
 PFIT_1036000   (44) IIFLLSLYTIQGVPIGVSSVVPLIIQDKVSYSQLSILSLVSIPFSIKLLW 
  PCYB_063040   (51) IIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSILSLVSIPFSLKLLW 
   PVX_110920   (49) IIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSILSLVSIPFSLKLLW 
   PKH_062100   (49) IIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSILSLVSIPFSLKLLW 
 PCHAS_052000   (44) VIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSMLSLISIPFSLKLLW 
PBANKA_051980   (44) VIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSMLSLISIPFSLKLLW 
PY17X_0520900   (44) VIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSMLSLISIPFSLKLLW 
 PYYM_0520300   (44) VIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSMLSLISIPFSLKLLW 
    Consensus   (51) IIFLLLLYTIQGVPIGVSSVVPLIIQDKVSYSQLSILSLVSIPFSLKLLW 
                     101                                            150 
PF3D7_1036800   (94) APIVDSVYNKRIGRRKSWIIPLQLFCSFTMIYFSNHVSIWLGEKDNIPNL 
 PFIT_1036000   (94) APIVDSVYNKRIGRRKSWIIPLQLFCSFTMIYFSNHVSIWLGEKDNIPNL 
  PCYB_063040  (101) APLVDSVYHKKIGRRKSWIIPLQLICSFSMICCGKYVSVWLGERGNITNL 
   PVX_110920   (99) APLVDSVYHKKIGRRKSWIIPLQLICSFSMICCGNHVSVWLGERGHMANL 
   PKH_062100   (99) APLVDSVYHKKIGRRKSWIIPLQLICSFSMIFCGNHVSVWLGERGNIANL 
 PCHAS_052000   (94) APIVDAVYIKKFGRRKSWIIPLQLICSLLMILYSLRVSTWLGERNDPINL 
PBANKA_051980   (94) APIIDAVYIKKFGRRKSWIIPLQLICSLLMIFYSLRVSTWLGERNGSINL 
PY17X_0520900   (94) APIIDAIYIKRFGRRKSWIIPLQLICSLLMIFYSLRVSTWLGERNGSINL 
 PYYM_0520300   (94) APIIDAIYIKRFGRRKSWIIPLQLICSLLMIFYSLRVSTWLGERNGSINL 
    Consensus  (101) APIVDSVY KKIGRRKSWIIPLQLICSFSMIFYS HVSVWLGER  I NL 
                     151                                            200 
PF3D7_1036800  (144) FFLTLFFFLLFFLMATQDIAVDGWALTMLSEENKKAASTCNILGQNIGYC 
 PFIT_1036000  (144) FFLTLFFFLLFFLMATQDIAVDGWALTMLSEENKKAASTCNILGQNIGYC 
  PCYB_063040  (151) YFLATFFFVLFFLMATQDIAVDGWALTMLSEENKGLASTCNILGQNIGYC 
   PVX_110920  (149) YFLTAFFFVLFFLMATQDIAVDGWALTMLSEENKGLASTCNILGQNIGYC 
   PKH_062100  (149) YFLTSFFFVLFFLMATQDIAVDGWALTMLSEENKGLASTCNILGQNIGYC 
 PCHAS_052000  (144) YYLTSFFFILFFLMATQDIAVDGWALTMLSEKNKGLASICNILGQNIGYC 
PBANKA_051980  (144) YSLTSFFFVLFFLMATQDIAVDGWALTMLSEKNKGLASICNILGQNIGYC 
PY17X_0520900  (144) YSLTSFFFVLFFLMATQDIAVDGWALTMLSEKNKGLASICNILGQNIGYC 
 PYYM_0520300  (144) YSLTSFFFVLFFLMATQDIAVDGWALTMLSEKNKGLASICNILGQNIGYC 
    Consensus  (151) YFLTSFFFVLFFLMATQDIAVDGWALTMLSEENKGLASTCNILGQNIGYC 
                     201                                            250 
PF3D7_1036800  (194) LSQLSFLTLNNKNICFYIFKKYIKFMYLIFNKSTYYRNVYEKLDLLYPSF 
 PFIT_1036000  (194) LSQLSFLTLNNKNICFYIFKKYIKFMYLIFNKSTYYRNVYEKLDLLYPSF 
  PCYB_063040  (201) VSQLSFLTLNNKNICFYIFRKYIQCMHSMFNQSSHYRHLHESMDVIYPSF 
   PVX_110920  (199) VSQLSFLTLNNKNVCFYIFRKYIQCMHSMFNQSSHYRQLHENMDVIYPSF 
   PKH_062100  (199) VSQLSFLTLNNKNICFYIFRKYIECMHSMFNHSSHYRHLHETMDMIYPSF 
 PCHAS_052000  (194) VSQLSFLTLNNKKICFYLFKRYVKIMHSIFHNSEYYKMLNDNLKLIYHTF 
PBANKA_051980  (194) VSQLSFLTLNNKKICFYLLKKYAKIMHLVFYKSEYYKMLNTNLDLIYPTF 
PY17X_0520900  (194) ASQLSFLTLNNKKICFYLLKKYAKIMHLIFYKSEYYKMLNTNLDLIYPTF 
 PYYM_0520300  (194) ASQLSFLTLNNKKICFYLLKKYAKIMHLIFYKSEYYKMLNTNLDLIYPTF 
    Consensus  (201) VSQLSFLTLNNKNICFYIFKKYIK MHLIFNKSSYYR LHENLDLIYPSF 
                     251                                            300 
PF3D7_1036800  (244) QPFVDMKKFLKFWGTFILMLTIFTCFKKEMSDQNEEKNKLKNSNEMDNYN 
 PFIT_1036000  (244) QPFVDMKKFLKFWGTFILMLTIFTCFKKEMSDQNEEKNKLKNSNEMDNYN 
  PCYB_063040  (251) QPFVDMNIFLKFWGVFILALTILTCFKKEMMEDNGKEKN--------DGE 
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   PVX_110920  (249) QPFVDMNIFLKFWGVFILALTILTCFKKEMMDENGKEKS---------DG 
   PKH_062100  (249) QPFVDMNIFLKFWGVFILALTILTCFKKEMMDDNGKEKN-------DNGV 
 PCHAS_052000  (244) LPFVDMNVFLKFWGVFILLLTILTFFKKETSNNKENENT----------K 
PBANKA_051980  (244) QPFVDMNVFLKFWGIFILILTIFTFFKKETSNNKEKENK----------K 
PY17X_0520900  (244) QPFVDMNVFLKFWGIFILLLTILTFFKKETSNNKEKENK----------K 
 PYYM_0520300  (244) QPFVDMNVFLKFWGIFILLLTILTFFKKETSNNKEKENK----------K 
    Consensus  (251) QPFVDMNVFLKFWGVFILLLTILTCFKKEMSDNNEKENK            
                     301                                            350 
PF3D7_1036800  (294) ISEAQKCDDKMNNAKMNYPKKINNQIRTNEHIKINDIKQTNIQKQSSEIN 
 PFIT_1036000  (294) ISEAQKCDDKMNNAKMNYPKKINNQIRTNEHIKINDIKQTNIQKQSSEIN 
  PCYB_063040  (293) VKSALVKKGNQHPSEAKHPNEAKHPSEAKHPSEAKHPSEAKHPNE--SSN 
   PVX_110920  (290) AVVNAPSKKNLQPSGANHHKE--------------------------GSN 
   PKH_062100  (292) GSSTPSKKYNKYPSVRDEHNE--------------------------NSN 
 PCHAS_052000  (284) IIEEEQEQKNKSQSISNAPKK--------------------------DGN 
PBANKA_051980  (284) MTEQEKEQNNKSQNISNAPKK--------------------------EEN 
PY17X_0520900  (284) ITEQEKEQNNKSQNISNVPKK--------------------------EEN 
 PYYM_0520300  (284) ITEQEKEQNNKSQNISNVPKK--------------------------EEN 
    Consensus  (301) ISE  K   NK QSISN PKK                          E N 
                     351                                            400 
PF3D7_1036800  (344) EFANAKDTYKTLYELLFLPPMKIFIILFLINRLPFASVEVGTNFKMLKRG 
 PFIT_1036000  (344) EFANAKDTYKTLYELLFLPPMKIFIILFLINRLPFASVEVGTNFKMLKRG 
  PCYB_063040  (341) EFANSKDTYKNLYQLLFLPPMKIFIFIFLLNRFPFASVEVGTNFKMLKKG 
   PVX_110920  (314) EFANSKDTYKNLYQLLFLPPMKIFIFIFLLNRFPFASVEVGTNFKMLKKG 
   PKH_062100  (316) EFANSKDTYKNLYQLIFLPPMKIFIFIFLMIRVPFASVEVGTNFKMLKKG 
 PCHAS_052000  (308) EFRNAKETYKNLYELLFLPPMKIFIILFLINRLPFASVEVATNFKMLKKG 
PBANKA_051980  (308) KFRNAKETYKNLYELLFLPPMKIFIILFLINRLPFASVEVATNFKMLKKG 
PY17X_0520900  (308) EFRNAKETYKNLYELLFLPPMKIFIILFLINRLPFASVEVATNFKMLKKG 
 PYYM_0520300  (308) EFRNAKETYKNLYELLFLPPMKIFIILFLINRLPFASVEVATNFKMLKKG 
    Consensus  (351) EFANAKDTYKNLYELLFLPPMKIFIILFLINRLPFASVEVGTNFKMLKKG 
                     401                                            450 
PF3D7_1036800  (394) ITKEEFAIFNPLYIPVSIISPAIIGKIIQKLKPLDVYYFGYVLRYFSNII 
 PFIT_1036000  (394) ITKEEFAIFNPLYIPVSIISPAIIGKIIQKLKPLDVYYFGYVLRYFSNII 
  PCYB_063040  (391) ITKEEFAIFNPFFIPISIISSAIIGKIIKNIKPLSIYYYGYLLRYLSNII 
   PVX_110920  (364) ITKEEFAIFNPFFIPISIISSAIIGKITQNIKPLSIYYYGYLLRYFSNII 
   PKH_062100  (366) ISKEEFAIFNPFFIPISIISSAIIGKITKNVKPLNIYYYGYLLRYLSNII 
 PCHAS_052000  (358) ITKEEFAIFNPFFIPISIISPAIIGKIIQNTNPLNVYYYGYMLRYISNIV 
PBANKA_051980  (358) ITKEEFAIFNPFFIPVSIISPAIIGKIIQNTNPLNVYYYGYILRYISNIV 
PY17X_0520900  (358) ITKEEFAIFNPFFIPISIISPAIIGKIIQNTNPLNVYYYGYILRYISNIV 
 PYYM_0520300  (358) ITKEEFAIFNPFFIPISIISPAIIGKIIQNTNPLNVYYYGYILRYISNIV 
    Consensus  (401) ITKEEFAIFNPFFIPISIISPAIIGKIIQNIKPLNVYYYGYILRYISNII 
                     451                                            500 
PF3D7_1036800  (444) LSTLLPITKYMYSNKTQSTNMKFYFYYMYIYMAQVFNHFSIDLMTVSSMS 
 PFIT_1036000  (444) LSTLLPITKYMYSNKIQSTNMKFYFYYMYIYMAQVFNHFSIDLMTVSSMS 
  PCYB_063040  (441) LSTLLPLTEYIYSNKSELPQVYLYSYYLYIFVAQVFNHFCIDLMTVSSMS 
   PVX_110920  (414) LSTLLPLTEYIYSRKSDLPQIYFYSYYLYIFVAQVFNHFCIDLMTVSSMS 
   PKH_062100  (416) LSTLLPLTEYIYSNKTHLPQAYLYSYYLYIFIAQVFNHFCIDLMTVSSMS 
 PCHAS_052000  (408) LSTLLPLTEYMYSNKTHAPQILFYMYYLYIFGAQIFNNLCIDLMTVSSMG 
PBANKA_051980  (408) LSTLLPLTEYMYSNKTHISQIFFYIYYLYIFGAQIFNNLCIDLMTLSSMG 
PY17X_0520900  (408) LSTLLPLTGYMYSNKTHISQIFFYIYYLYIFGAQIFNNMCIDLMTVSSMG 
 PYYM_0520300  (408) LSTLLPLTGYMYSNKTHISQIFFYIYYLYIFGAQIFNNMCIDLMTVSSMG 
    Consensus  (451) LSTLLPLTEYMYSNKTHISQIFFY YYLYIFMAQVFNHFCIDLMTVSSMS 
                     501                                            550 
PF3D7_1036800  (494) FQNIISDPKIGGTYMTFLNTVNNLGSHWSTIFLWLLDYTDKEFCYK---- 
 PFIT_1036000  (494) FQNIISDPKIGGTYMTFLNTVNNLGSHWSTIFLWLLDYTDKEFCYK---- 
  PCYB_063040  (491) FQNIISDPEIGGTYMTFLNTVNNMGSHWSTIFLWLLDYTDRTVCYGGLVL 
   PVX_110920  (464) FQNIISDPEIGGTYMTFLNTVNNMGSHWSTIFLWLLDYTDRTVCYG---- 
   PKH_062100  (466) FQNIISDPEIGGTYMTFLNTVNNMGSHWSTIFLWLLDYTDRTVCYG---- 
 PCHAS_052000  (458) FQNVISDPQIGGTYMTFLNTINNMGSHWSTIFLWLLDYTDMTICYG---- 
PBANKA_051980  (458) FQNVISDPQIGGTYMTFLNTINNMGSHWSTIFLWLLDYTDMTICYG---- 
PY17X_0520900  (458) FQNVISDPQIGGTYMTFLNTINNMGSHWSTIFLWLLDYTDMTICYG---- 
 PYYM_0520300  (458) FQNVISDPQIGGTYMTFLNTINNMGSHWSTIFLWLLDYTDMTICYG---- 
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    Consensus  (501) FQNIISDP IGGTYMTFLNTVNNMGSHWSTIFLWLLDYTDRTICYG     
                     551                                            600 
PF3D7_1036800  (540) -------------------------------GKCVLVDGFYIQMILSFIV 
 PFIT_1036000  (540) -------------------------------GKCVLVDGFYIQMILSFIV 
  PCYB_063040  (541) FLAKWPLQFATHTYTQYTWNYLPKICLLFLSGKCLLIDGYYTQMVFSFII 
   PVX_110920  (510) -------------------------------GKCLLIDGYYTQMVFSFII 
   PKH_062100  (512) -------------------------------GKCLLIDGYYTQMVFSFIV 
 PCHAS_052000  (504) -------------------------------GRCIFIDGFYTQMICSFLI 
PBANKA_051980  (504) -------------------------------GNCIYFDGFYTQMICSFLV 
PY17X_0520900  (504) -------------------------------EKCIFFDGFYTQMICSFLV 
 PYYM_0520300  (504) -------------------------------EKCIFFDGFYTQMICSFLV 
    Consensus  (551)                                GKCILIDGFYTQMI SFIV 
                     601                             635 
PF3D7_1036800  (559) GIIINKYILSFTRKLQAFPLEDWRTKYIGKEF--- 
 PFIT_1036000  (559) GIIINKYILSFTRKLQAFPLEDWRTKYIGKEF--- 
  PCYB_063040  (591) GILINKYITKCITKLQVGLTNN------------- 
   PVX_110920  (529) GILINKYITRCITKLQAFPIEDWRTKNGGGEKKTK 
   PKH_062100  (531) GILINKYITRCITKLQAFPIEDWRTNSSSSEKKIK 
 PCHAS_052000  (523) GILINSFVLKCIKKLQNFPIEDWRTYSDSITKKNN 
PBANKA_051980  (523) GLLINNFVLKCIKKLQNFPIEDWRTYSDSITKKNN 
PY17X_0520900  (523) GLLINNFVLKCIKKLQNFPIEDWRTYSDSITKKNN 
 PYYM_0520300  (523) GLLINNFVLKCIKKLQNFPIEDWRTYSDSITKKNN 
    Consensus  (601) GILINKYILKCIKKLQ FPIEDWRT S S  KK   
 
